Updated on 2024/12/30

Information

 

写真a

 
UCHIDA MAYAKO
 
Organization
Kyushu University Hospital Pharmacy Professor
Title
Professor

Research Areas

  • Life Science / Clinical pharmacy

Research History

  • 九州大学病院 薬剤部 教授・薬剤部長

    2024.10 - Present

      More details

    Country:Japan

  • 同志社女子大学 薬学部 臨床薬学教育研究センター 教授

    2021.4 - Present

  • Osaka University of Pharmaceutical Sciences Lecturer

    2016.4 - 2021.3

  • Kyushu University

    2001.4 - 2016.3

Awards

  • 優秀演題発表賞

    2023.6   日本医療薬学会 第6回フレッシャーズ・カンファランス   急性骨髄性白血病患者に対するIDR+AraC寛解導入療法の服薬指導シートの評価

    望月絵梨香, 石田茂, 小澤奈々, 米滿紘子, 落合秀樹, 中村花絵, 川尻雄大, 江頭伸昭, 家入一郎, 内田まやこ

  • The 74th FIP World Congress of Pharmacy and Pharmaceutical Sciences 2014

    2014.9   Efficacy and safety of aprepitant in Japanese patients receiving high-dose chemotherapy followed by allogeneic hematopoietic stem cell transplantation

    Ikesue H, Uchida M, Suetsugu K, Nagata K, Egashira N, Masuda S

  • 優秀論文賞

    2010.1   第2回 西日本ファーマシューティカルケア研究会   副作用の発現予測に基づく服薬指導シートを使用したがん化学療法への薬剤師の関わり

    内田まやこ

  • 学術奨励賞

    2009.12   平成22年度 日本病院薬剤師会   アントラサイクリン系抗がん剤の投与時間の短縮による血管外漏出の減少

    伊藤美代, 池末裕明, 末次王卓, 内田まやこ, 三嶋一登, 佐々木智啓, 森山智彦, 江頭伸昭, 大石了三

Papers

  • Impact of tumor-treating fields on the survival of Japanese patients with newly diagnosed glioblastoma: A multicenter, retrospective cohort study

    Kanamori, M; Tsuzuki, S; Shibahara, I; Saito, K; Shimoda, Y; Tanaka, K; Yamaguchi, S; Natsumeda, M; Matsutani, T; Hanihara, M; Nakada, M; Kuroda, JI; Matsuda, M; Yoshimoto, K; Yonezawa, U; Sonoda, Y; Takano, K; Yonezawa, H; Otani, Y; Nakahara, Y; Uchida, M; Nonaka, M; Mineharu, Y; Kitamura, Y; Yamashita, S; Yamauchi, T; Miyake, Y; Deguchi, S; Beppu, T; Tamura, K; Koizumi, S; Hirose, Y; Asano, K; Hiruta, R; Kinoshita, M; Miyake, K; Nakayama, N; Inoue, A; Ono, T; Sasaki, T; Akiyama, Y; Fukami, S; Yoshino, A; Kawanishi, Y; Asanome, T; Yamaguchi, T; Takahashi, M; Yamasaki, F; Arakawa, Y; Narita, Y

    NEURO-ONCOLOGY ADVANCES   6 ( 1 )   vdae176   2024.12   eISSN:2632-2498

     More details

  • Disproportionality analysis of cardiac adverse events associated with lenvatinib using the Japanese Adverse Drug Event Report database. International journal

    Yuko Kanbayashi, Sakura Kobayashi, Asuka Kojima, Haruka Wakabayashi, Tadashi Shimizu, Mayako Uchida

    British journal of clinical pharmacology   2024.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    AIMS: This study was conducted to examine disproportionality, times to onset, incidence rates and outcomes of lenvatinib-associated cardiac adverse events (AEs) using the Japanese Adverse Drug Event Report database. METHODS: We analysed data for the period between April 2004 and May 2023. Data on cardiac AEs were extracted and the relative disproportionality of AEs was estimated using reporting odds ratios (RORs). Furthermore, Weibull distribution parameters were calculated. RESULTS: Of the 2 230 863 reports analysed, we identified 7684 reports of AEs associated with lenvatinib, including 317 cardiac AEs. Signals were detected for eight cardiac AEs: hypertension, cardiac failure, myocarditis, myocardial infarction, immune-mediated myocarditis, cardiomyopathy, angina unstable and cardiotoxicity. Among these, fatal outcomes were observed for cardiac failure, myocarditis and myocardial infarction. Histograms of median times to onset for the eight detected cardiac AE signals showed that AEs occurred at a median of 3.5-134.5 days after lenvatinib administration. The Weibull distributions showed that cardiac failure occurred early after administration (early failure type), myocarditis occurred in a dose-dependent manner (wearout failure type), and myocardial infarction occurred constantly throughout the exposure period (random failure type). CONCLUSIONS: We focused on cardiac AEs associated with lenvatinib as post-marketing AEs. Serious outcomes can arise after lenvatinib administration. Patients should be monitored for signs of onset of these AEs not only at the start of administration, but also over an extended period.

    DOI: 10.1111/bcp.16237

    PubMed

  • Pharmacists' Behavioral Changes after Attending a Multi-Prefectural Palliative Care Education Program. International journal

    Masahiro Yamada, Mayako Uchida, Masao Hada, Haruka Wakabayashi, Daigo Inma, Shunji Ariyoshi, Hidetoshi Kamimura, Tohru Haraguchi

    Pharmacy (Basel, Switzerland)   12 ( 3 )   2024.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Central to the pharmacist's role in palliative care is symptom management through direct participation in patient care and the provision of optimal pharmacotherapy to support patient outcomes. Consequently, palliative care requires extensive knowledge and action for patients with cancer. Therefore, this study aimed to evaluate how pharmacists' behavior changed after attending a palliative care educational program. We conducted a web-based questionnaire survey examining the behavior of pharmacists regarding palliative care before participating in the program, two months after participating in the program, and eight months after participating in the program to determine their behavior and changes over time. For all questions, scores were higher at two and eight months after attending the program than before attending the program (p < 0.05). In addition, no significant difference was observed between two and eight months after attending the program for any question (p = 0.504-1.000). The knowledge gained from the educational program was used to repeatedly intervene with patients with cancer in order to address the various symptoms they experienced and maintain their behavior. The proven effectiveness of this program serves as a stepping stone for nationwide rollout across Japan's 47 prefectures.

    DOI: 10.3390/pharmacy12030087

    PubMed

  • Evaluation of time-to-onset and outcome of cardiac adverse events related to pembrolizumab using post-marketing surveillance in Japanese patients. International journal

    Yuko Kanbayashi, Eren Tsuchiya, Tadashi Shimizu, Mayako Uchida

    Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences   32 ( 1 )   279 - 287   2024.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Pembrolizumab has been widely used in patients since its release, but information on cardiac Adverse Events (AEs) related to pembrolizumab remains lacking, particularly in Japanese populations. OBJECTIVES: This study aims to evaluate time to onset, incidence rates, and outcomes for pembrolizumab-induced cardiac AEs in patients with cancer using the Japanese Adverse Drug Event Report database. METHODS: We analysed data for the period from April 2004 to March 2022. Data on cardiac AEs were extracted and relative risks of AEs were estimated using the reporting odds ratio. RESULTS: We analysed 2,021,907 reports and identified 15,306 reports of AEs caused by pembrolizumab. Of these, 399 cardiac AEs were associated with pembrolizumab. Signals were detected for six cardiac AEs: myocarditis, immune-mediated myocarditis, pericardial effusion, cardiac tamponade, pericarditis, and pericarditis malignant. A histogram of median times to onset showed occurrence from 33 (21-97) days for immune-mediated myocarditis to 138 (67-168) days for pericarditis malignant, but some cases occurred even more than 1 year after the start of administration. Among these, myocarditis was the most frequently reported (27.1%), with fatal cases also reported. CONCLUSION: This study focused on cardiac AEs caused by pembrolizumab as post-marketing AEs. Patients should be monitored not only at the time of administration, but also over time for signs of these AEs, especially myocarditis, as some patients may have serious outcomes.

    DOI: 10.1007/s40199-024-00516-z

    PubMed

  • Eye-tracking-based analysis of pharmacists' thought processes in the dispensing work: research related to the efficiency in dispensing based on right-brain thinking. International journal

    Toshikazu Tsuji, Kenichiro Nagata, Masayuki Tanaka, Shigeru Hasebe, Takashi Yukita, Mayako Uchida, Kimitaka Suetsugu, Takeshi Hirota, Ichiro Ieiri

    Journal of pharmaceutical health care and sciences   10 ( 1 )   21 - 21   2024.5   ISSN:2055-0294

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Pharmacists should be aware of their thought processes in dispensing work, including differences in the dispensing complexities owing to different drug positions in the left, center, and right areas. Dispensing errors associated with "same-name drugs (a pair of drugs with the same name but a different ingredient quantity)" are prevalent and often negatively affect patients. In this study, using five pairs of comparative models, the gaze movements of pharmacists in dispensing work were analyzed using an eye-tracking method to elucidate their thought processes. METHODS: We prepared verification slides and displayed them on a prescription monitor and three drug rack monitors. The dispensing information (drug name, drug usage, location display, and total amount) was displayed on a prescription monitor. A total of 180 drugs including five target drugs were displayed on the three drug rack monitors. Total gaze points in the prescription area, those in the drug rack area, total vertical movements between the two areas, and time required to dispense drugs were measured as the four classifications Gaze 1, Gaze 2, Passage, and Time, respectively. First, we defined the two types of location displays as "numeral combination" and "color/symbol combination." Next, we defined two pairs of models A1-A2 (numerals) and B1-B2 (color/symbol) to compare differences between the left and right areas. Moreover, three pairs of models C1-C2 (left), D1-D2 (center), and E1-E2 (right) were established to compare differences between "numeral combination" and "color/symbol combination." RESULTS: Significant differences in the complexities of dispensing work were observed in Gaze 2, Passage, and Time between the models A1-A2 (A1<A2), in Gaze 2 between the models B1-B2 (B1>B2), and in Gaze 2 and Time between the models C1-C2, D1-D2, and E1-E2 (C1>C2, D1>D2, and E1>E2, respectively). CONCLUSIONS: Using the current dispensing rules, pharmacists are not good at dispensing drugs located in the right area. An effective measure for reducing the dispensing complexity is to introduce visual information in the prescription content; the utilization of the right brain facilitates reducing the complexity in the right dispensing area.

    DOI: 10.1186/s40780-024-00341-1

    Web of Science

    Scopus

    PubMed

  • Eye-tracking-based analysis of pharmacists' thought processes in the dispensing work: research related to the efficiency in dispensing based on right-brain thinking(タイトル和訳中)

    Tsuji Toshikazu, Nagata Kenichiro, Tanaka Masayuki, Hasebe Shigeru, Yukita Takashi, Uchida Mayako, Suetsugu Kimitaka, Hirota Takeshi, Ieiri Ichiro

    Journal of Pharmaceutical Health Care and Sciences   10   s40780 - 024   2024.5

     More details

    Language:English   Publisher:(一社)日本医療薬学会  

  • 糖尿病患者への新規服薬フォローアップ支援シートに対する薬局薬剤師の評価

    矢原 恵美[堀田], 一丸 智司, 井上 良祐, 津田 賢蔵, 清水 忠, 内田 まやこ, 木下 淳

    医療薬学   50 ( 5 )   248 - 257   2024.5   ISSN:1346-342X

     More details

    Language:Japanese   Publisher:(一社)日本医療薬学会  

    薬局薬剤師22名を対象として、服薬フォローアップを支援するためのシート(支援シート)を使用した糖尿病患者に対する服薬フォローアップについてアンケート調査を行った。対象者の薬剤師が約3ヵ月間支援シートを使用した後、服薬フォローアップの必要性の有無を判断する観点の抽出や服薬フォローアップを実施した期間を調査した。その結果、「薬剤変更(用法用量の変更を含む)」「薬剤追加」「自身の判断」の3項目が服薬フォローアップ実施の判断に必要な内容であることが示唆され、実施のタイミングは過半数が7日目前後であり、実施の手段はすべて「電話」であった。薬剤師の約4割は支援シートの適用に対して比較的肯定的であり、半数から支援シート改善に前向きな意見が得られた。本研究で作成した支援シートは、糖尿病患者を対象とした服薬フォローアップを支援することが示唆された。

  • Medical Economic Effect of Pharmaceutical Interventions by Board-Certified Pharmacists in Palliative Pharmacy for Patients with Cancer Using Medical Narcotics in Japan: A Multicenter, Retrospective Study

    Kawashiri Takehiro, Sugawara Hideki, Makihara Katsuya, Ohno Rintaro, Miyamoto Yoshihiro, Hidaka Noriaki, Uchida Mayako, Takase Hisamitsu

    Journal of Nippon Medical School   91 ( 1 )   59 - 65   2024.2   ISSN:13454676 eISSN:13473409

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:The Medical Association of Nippon Medical School  

    <p><b>Background: </b>The Japanese Society for Pharmaceutical Palliative Care and Sciences specializes in pharmacology in the field of palliative medicine. More than 700 board-certified pharmacists in palliative pharmacy (BCPPP) are actively involved in palliative pharmacotherapy at various hospitals and pharmacies. The purpose of this study was to determine the economic effect of pharmaceutical interventions by BCPPPs. <b>Methods: </b>This multicenter retrospective study included 27 medical centers and analyzed the medical economic effect of interventions by BCPPPs (17 pharmacists) and non-BCPPPs (24 pharmacists) on patients using medical narcotics for cancer pain in September 2021. <b>Results: </b>The percentage of patients who received a pharmaceutical intervention and whose drug costs were reduced by pharmacist intervention was significantly higher in the BCPPP group than in the non-BCPPP group. Although there was no significant difference between the two groups in drug cost reduction per patient per month (BCPPP group: $0.89 [−$64.91 to $106.76] vs. non-BCPPP group $0.00 [−$1,828.95 to $25.82]; <i>P</i> = 0.730), the medical economic benefit of pharmacist intervention in avoiding or reducing adverse drug reactions was higher in the BCPPP group ($103.18 [$0.00 to $628.03]) than in the non-BCPPP group ($0.00 [$0.00 to $628.03]) (<i>P</i> = 0.070). The total medical economic benefit-the sum of these-was significantly higher in the BCPPP group ($88.82 [−$14.62 to $705.37]) than in the non-BCPPP group ($0.66 [−$1,200.93 to $269.61]) (<i>P</i> = 0.006). <b>Conclusion: </b>Pharmacological intervention for patients with cancer using medical narcotics may have a greater medical economic benefit when managed by BCPPPs than by non-certified pharmacists in Japan.</p>

    DOI: 10.1272/jnms.jnms.2024_91-105

    Web of Science

    Scopus

    PubMed

    CiNii Research

  • 医療用麻薬を使用する日本のがん患者に対する緩和薬物療法認定薬剤師による薬物介入の医療経済効果 多施設共同後ろ向き研究(Medical Economic Effect of Pharmaceutical Interventions by Board-Certified Pharmacists in Palliative Pharmacy for Patients with Cancer Using Medical Narcotics in Japan: A Multicenter, Retrospective Study)

    Kawashiri Takehiro, Sugawara Hideki, Makihara Katsuya, Ohno Rintaro, Miyamoto Yoshihiro, Hidaka Noriaki, Uchida Mayako, Takase Hisamitsu

    Journal of Nippon Medical School   91 ( 1 )   59 - 65   2024.2   ISSN:1345-4676

     More details

    Language:English   Publisher:日本医科大学医学会  

    がん性疼痛に対して医療用麻薬を使用したがん患者に対する緩和薬物療法認定薬剤師(BCPPP)による薬学的介入の経済的効果を明らかにした。本研究は27施設が参加した多施設共同後ろ向き研究であり、BCPPP 17名(経験年数中央値17年)と非BCPPP 24名(同10年)が参加した。薬剤師の介入によって薬剤費が削減された患者の割合は、BCPPP群が20.0%、非BCPPP群が5.3%で有意差が認められた。患者1人の1ヵ月間の薬剤費削減額は両群間で有意差はなかったが、薬剤師の介入による副作用の回避・削減による医療経済的便益はBCPPP群が非BCPPP群よりも高かった。医療経済的便益の合計は、BCPPP群が非BCPPP群よりも有意に高かった。

  • Disproportionality Analysis of Stomatitis Associated with Anticancer Drugs Using the Japanese Adverse Drug Event Report Database

    Kousuke Hosonaka, Kenta Yamaoka, Naoe Ikeda, Mayako Uchida, Yoshihiro Uesawa, Kazushige Takahashi, Tadashi Shimizu

    Oncology   1 - 8   2024.1   ISSN:0030-2414 eISSN:1423-0232

     More details

    Publishing type:Research paper (scientific journal)   Publisher:S. Karger AG  

    &lt;b&gt;&lt;i&gt;Introduction:&lt;/i&gt;&lt;/b&gt; Anticancer drug-induced stomatitis can affect a patient’s quality of life and the continuation of drug treatment. Although there have been reports of the occurrence of stomatitis associated with anticancer agents in clinical trials, few Japanese participants have been enrolled in clinical trials and have not been sufficiently investigated. In addition, there has been little attention on research on anticancer drugs associated with stomatitis by patient stratification with different carcinogenic sites. Therefore, the aim of this study was to determine the disproportionality associated with stomatitis for various types of anticancer drugs in different types of cancer patients using the Japanese Adverse Drug Event Report (JADER) database. &lt;b&gt;&lt;i&gt;Methods:&lt;/i&gt;&lt;/b&gt; The aim of this study was to identify the disproportionality of stomatitis by analyzing the type of anticancer drug and cancer patients using the Japanese Pharmacovigilance Database. Data obtained from spontaneous reports of adverse events with more than 10 stomatitis outbreaks reported in the JADER database between April 2004 and March 2023 were analyzed. The safety signal for an adverse event was defined as the lower limit of the 95% confidence interval of the reported odds ratio of &amp;gt;1. &lt;b&gt;&lt;i&gt;Results:&lt;/i&gt;&lt;/b&gt; There were 6,178 reports of drugs associated with stomatitis. Among these, 41 drugs were suggested to be associated with stomatitis, and 41 drugs were detected as signals. These drugs were classified based on their efficacy: antipyrimidines (six drugs), folate metabolism antagonists (three drugs), alkylating agents (four drugs), platinum (three drugs), topoisomerase inhibitors (three drugs), microtubule inhibitors (three drugs), mammalian target of rapamycin (mTOR) inhibitors (two drugs), kinase inhibitors (seven drugs), anti-growth factor antibodies (five drugs) immune checkpoint inhibitors (one drug), and others (four drugs). &lt;b&gt;&lt;i&gt;Conclusion:&lt;/i&gt;&lt;/b&gt; The drugs that may be associated with stomatitis were cell cycle-dependent drugs, epidermal growth factor receptor-tyrosine kinase inhibitors, and mTOR inhibitors. Moreover, this study suggested that anti-growth factor antibodies and immune checkpoint inhibitors may be associated with stomatitis development.

    DOI: 10.1159/000535331

  • Risk Factor for Rash in Patients Receiving Cytarabine and Idarubicin Induction Therapy for Acute Myeloid Leukemia. International journal

    Mayako Uchida, Shigeru Ishida, Erika Mochizuki, Nana Ozawa, Hiroko Yonemitsu, Hideki Ochiai, Hanae Nakamura, Takehiro Kawashiri, Hiroyuki Watanabe, Toshikazu Tsuji, Kimitaka Suetsugu, Koji Kato, Nobuaki Egashira, Koichi Akashi, Ichiro Ieiri

    Cancer diagnosis & prognosis   4 ( 5 )   617 - 622   2024

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND/AIM: Rash is a common adverse event (AE) observed during cytarabine and idarubicin induction therapy in patients with acute myeloid leukemia (AML). Previous studies have highlighted the challenge in predicting the onset and duration of rash. This study aimed to determine the factors that affect the onset of rash in patients receiving induction therapy for AML. PATIENTS AND METHODS: This retrospective study involved 97 patients with AML who received induction chemotherapy with cytarabine and idarubicin at the Department of Hematology, Kyushu University Hospital between January 2008 and June 2022. The factors associated with rash were identified through a multivariate stepwise logistic regression analysis. Subsequently, the patient's characteristics were compared between those with risk factors and those without risk factors using a matched pair analysis. RESULTS: Pre-existing leukopenia [odds ratio (OR)=3.294; 95% confidence interval (CI)=1.272-8.531] and good performance status (PS=0) (OR=2.717; 95%CI=1.087-6.792) were significant risk factors for rash development. Conversely, the matched pair analysis indicated that patients with pre-existing leukopenia, excluding those with a PS score of 0, exhibited a significantly (p=0.015) higher incidence of rash than those without it. CONCLUSION: Both multivariate logistic regression analysis and matched pair analysis identified pre-existing leukopenia as a primary risk factor for rash development associated with cytarabine and idarubicin chemotherapy.

    DOI: 10.21873/cdp.10372

    Scopus

    PubMed

  • 血中のAGEsに対する赤ワインの効果(Effect of red wine on AGEs in blood)

    Sugiura Shinichi, Iwata Yumeno, Hirano Sae, Nagano Momoka, Shimada Saki, Uchida Mayako, Asano Mika, Akita Hirotaka

    Glycative Stress Research   10 ( 4 )   164 - 170   2023.12   ISSN:2188-3602

     More details

    Language:English   Publisher:(一社)糖化ストレス研究会  

    ブドウの品種、産地、醸造方法の違いにより抗糖化作用が強いワインを選出し、そのワインを摂取することでヒト血中終末糖化産物(AGEs)蓄積抑制作用に影響がみられるか調べた。本研究では、アルコール摂取が可能な20歳以上65歳未満の男女48名を対象とする前向きクロスオーバー非盲検無作為化比較試験を行った。基礎研究では、ヒト血清アルブミン(HSA)-グルコース糖化モデルに各種ワインを添加し、蛍光AGEs産生量を測定することで糖化抑制効果を評価した。参加者には、基礎研究で抗糖化作用が強かったワインまたはミネラルウォーターのどちらか1種類を週6日、1日125mLずつ4週間継続して摂取させた。摂取前と摂取後の計4回、体内のAGEs蓄積レベルとストレス値を測定した。AGEs蓄積に影響する生活に関するアンケート調査を実施した。アンケート結果の回答率が50%未満の9名および測定会に1回以上欠席した6名を除外した。ワイン摂取群ではAGEs値の低下が見られ、ミネラルウォーター摂取群ではAGEsの上昇が見られたが、有意差はなかった。第2週~5週群(6月上旬~7月中旬)と第8週~11週群(7月下旬~9月上旬)の比較では、ワイン摂取前後のAGEs値は強い減少傾向がみられた。女性はワイン摂取後のAGEsが低下する傾向がみられた。第8週~11週群の女性ではワインを摂取群のAGEsが有意に低下した。

  • 緩和薬物療法認定薬剤師と非認定薬剤師による服薬指導に関する日本全国で行った比較研究(Japanese Nationwide Comparative Survey of Medication Guidance Provided by Certified and Uncertified Palliative Care Pharmacists)

    Tanaka Rei, Satoh Yumi, Suga Yukio, Nakagawa Junichi, Miyazaki Masayuki, Hagiwara Ryoichi, Uchida Mayako, Takase Hisamitsu

    Journal of Nippon Medical School   90 ( 6 )   449 - 459   2023.12   ISSN:1345-4676

     More details

    Language:English   Publisher:日本医科大学医学会  

    日本緩和医療薬学会に所属する薬剤師を対象に、2022年2~3月にオンラインアンケート調査を行い、緩和薬物療法を受ける患者の身体症状や精神症状に対する服薬指導の状況を調査した。また、緩和薬物療法認定薬剤師と非認定薬剤師の服薬指導の実態を比較した。3854名に調査を依頼し、緩和薬物療法認定薬剤師(認定群)123名(58.9%)と非認定薬剤師(非認定群)86名(41.1%)の計209名の回答を分析した。認定群は非認定群よりも病院所属率、薬剤師経験年数、緩和ケアチームへの所属率が有意に高かった。疼痛緩和に関する4項目、疼痛以外の症状緩和に関する全項目、精神症状緩和に関する項目については、認定群の方が服薬指導を行う頻度が高かった。患者のQOLの向上につながる緩和薬物療法への関与については、認定群が非認定群よりも高い評価を得ていた。緩和薬物療法認定薬剤師は、非認定薬剤師と比較して、より積極的に介入し、より幅広い緩和薬物療法を提供していることが示された。

  • 日本の副作用データベースで報告された非がん患者のオピオイド関連呼吸抑制(Opioid-Related Respiratory Depression in Non-Cancer Patients, as Reported in the Japanese Adverse Drug Event Report Database)

    Sugawara Hideki, Uchida Mayako, Suzuki Shinya, Suga Yukio, Uesawa Yoshihiro, Nakagawa Takayuki, Takase Hisamitsu

    Journal of Nippon Medical School   90 ( 6 )   439 - 448   2023.12   ISSN:1345-4676

     More details

    Language:English   Publisher:日本医科大学医学会  

    大規模副作用データベースであるJapanese Adverse Drug Event Report(JADER)を用いて、日本の非がん患者におけるオピオイド関連呼吸抑制(RD)を調査した。2004年4月~2020年2月にJADERに記録されたデータを解析した。2020年2月までに日本で承認された20種のオピオイドについてRDのオッズ比を算出した。さらに、非がん性慢性疼痛(CNCP)に対するオピオイドの1日投与量と作用発現時間を解析した。1639417症例のうち、非がん患者でRDが報告された薬剤は1883剤であった。20種のオピオイドのうち、12種のオピオイドで非がん患者のRDが報告された。RDが報告された22通りのオピオイドと投与経路の組み合わせのうち、ブプレノルフィン経皮投与とトラマドール/アセトアミノフェン経口投与はCNCPに対して承認されており、高齢患者で報告例が多い傾向があった。この2剤の1日投与量中央値は、それぞれ経口モルヒネ換算で10.0mgおよび22.5mg、RD出現までの期間中央値はそれぞれ6.5日および4.0日であり、症例の75%は投与開始後20~40日以内に報告された。

  • Improvement of Medication Guidance Sheet for Total Body Irradiation/Cyclophosphamide Followed by Allogeneic Hematopoietic Stem Cell Transplantation Based on Real Monitoring Data. Reviewed International journal

    Mayako Uchida, Shigeru Ishida, Erika Mochizuki, Nana Ozawa, Hiroko Yonemitsu, Hideki Ochiai, Hanae Nakamura, Takehiro Kawashiri, Koji Kato, Nobuaki Egashira, Koichi Akashi, Ichiro Ieiri

    Anticancer research   43 ( 9 )   4067 - 4075   2023.9   ISSN:0250-7005 eISSN:1791-7530

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND/AIM: Adverse events (AEs) must be managed during cancer therapy. We had previously developed a medication guidance sheet (MGS) to monitor AEs after conditioning therapy with allogeneic hematopoietic stem cell transplantation (HSCT). However, it remains unclear whether this sheet can accurately predict the type, onset, and duration of AEs in clinical practice. In this study, we evaluated the clinical utility of the original MGS in patients receiving total body irradiation (TBI) and cyclophosphamide (CY). PATIENTS AND METHODS: Fifty-eight patients who underwent TBI/CY were included. The types, onsets, and durations of AEs observed during real monitoring were compared with those listed in the original MGS. RESULTS: A total of 361 subjective AE symptoms were observed, all of which were predictive, as listed in the MGS. However, the durations of several AEs were longer than expected. Thus, the prediction accuracy for all AEs was 67.0%. The accuracy rate was the lowest for anorexia (6.7%), followed by diarrhea (42.6%), and nausea/vomiting (55.6%). Acute graft versus host disease (GVHD) most likely caused the prolongation of AEs. Subsequently, the original MGS was revised to account for the possible occurrence of acute GVHD. CONCLUSION: When monitoring AEs in patients receiving a TBI/CY conditioning regimen for HSCT, the involvement of acute GVHD-associated AEs should be considered. In this respect, the present modified MGS is particularly useful for rapid and accurate monitoring of AEs.

    DOI: 10.21873/anticanres.16596

    Web of Science

    Scopus

    PubMed

  • Evaluation of time to onset and outcome of cardiac adverse events associated with nilotinib using post-marketing surveillance. Reviewed International journal

    Yuko Kanbayashi, Asuka Kojima, Haruka Wakabayashi, Tadashi Shimizu, Mayako Uchida

    Oncology   2023.8

     More details

    Authorship:Last author   Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Cardiac adverse events (CAEs) have become a concern as serious adverse events of nilotinib administration. No reports have described the incidence of CAEs associated with nilotinib in Japanese patients. OBJECTIVES: Thus, we conducted this study to evaluate the risk of nilotinib-induced CAEs, time to onset, incidence rates, and post hoc outcomes using the Japanese Adverse Drug Event Report database. METHOD: We analysed data for the period between April 2004 and March 2022. Data on CAEs were extracted, and relative risk of adverse events (AEs) was estimated using the reporting odds ratio (ROR). RESULTS: We analysed 2,021,907 reports and identified 3,545 reports of AEs caused by nilotinib. Of these, 511 reports involved CAEs. Signals were detected for 19 CAEs. Of these, electrocardiogram QT prolonged was the most frequently reported (30.9%). Fatal outcomes were observed in eight AEs: cardiac failure, atrial fibrillation, acute myocardial infarction, pericardial effusion, myocardial infarction, cardiac arrest, pericarditis, and cardiac tamponade. Of these, acute myocardial infarction, myocardial infarction, pericarditis, and cardiac tamponade exhibited mortality rates >10%. A histogram of median times to onset showed nilotinib-associated AEs occurring 3-485 days after nilotinib administration. CONCLUSIONS: We focused on CAEs caused by nilotinib as post-marketing AEs. Some cases resulted in serious outcomes. Patients should be monitored for signs of onset of these AEs not only at the start of administration, but for a long period of time.

    DOI: 10.1159/000533325

    PubMed

  • Evaluation of time to onset and outcome of lung adverse events related to pembrolizumab using marketing surveillance. Reviewed International journal

    Yuko Kanbayashi, Momoko Kobayashi, Miku Anzai, Tadashi Shimizu, Mayako Uchida

    Oncology   2023.8

     More details

    Authorship:Last author   Language:English  

    Background Pembrolizumab has been widely used in patients since its release, but detailed information on lung-specific adverse events (AEs) from post-marketing monitoring has not been reported. Objectives This study was undertaken to determine the risk of pembrolizumab-induced lung AEs, time to onset, and post hoc outcomes using the Japanese Adverse Drug Event Report database. Method We analyzed data for the period between April 2004 and March 2022. Data on lung AEs were extracted and the relative risks of AEs were estimated using reporting odds ratios. Results We analyzed 2,021,907 reports and identified 15,306 reports of AEs caused by pembrolizumab, including 3,004 lung AEs. Signals were detected for 14 lung AEs. Interstitial lung disease was the most frequently reported (62.3%) and included fatal cases. A histogram of median time to onset showed occurrence from 2 to 73 days, but some cases of interstitial lung disease occurred even more than 2 years after the start of administration. The AEs showing the highest fatality rates were interstitial lung disease, respiratory failure, and pneumonia aspiration. Conclusions This study focused on lung AEs caused by pembrolizumab as post-marketing AEs. Some cases could potentially involve serious outcomes, so patients should be monitored for signs of AE onset not only at the start of administration, but also over an extended period, especially for interstitial lung disease.

    DOI: 10.1159/000533302

    PubMed

  • 癌悪液質マウスモデルにおけるシスチンとテアニンの改善効果(Ameliorating effects of cystine and theanine in a cancer cachexia mouse model)

    Kudamatsu Hibiki, Kawashiri Takehiro, Mine Keisuke, Mori Kohei, Inoue Mizuki, Ishida Haruna, Uchida Mayako, Tsuchiya Takashi, Kobayashi Daisuke, Shimazoe Takao

    Journal of Pharmacological Sciences   152 ( 3 )   163 - 166   2023.7   ISSN:1347-8613

     More details

    Language:English   Publisher:(公社)日本薬理学会  

    癌悪液質(CC)マウスモデルを用いて、シスチンとテアニンの併用(CT)がCCに及ぼす改善効果を、アナモレリン(AM)と比較した。結腸癌細胞株C-26担癌マウスモデルにて、CT群、AM群、無処置対照群のいずれでも体重増加が抑制され、精巣上体脂肪などの内部脂肪とヒラメ筋などの下肢筋肉の両者が減少した。CTの反復投与によるCT群では、対照群に比べて体重減少、内部脂肪減少、下肢筋肉減少、血清IL-6増加が有意に抑制され、その効果はAM群と同程度であった。

  • Development of Real-world Data-based Medication Instruction Sheet for Acute Myeloid Leukemia Patients Receiving High-dose Cytarabine Consolidation Therapy. Reviewed International journal

    Mayako Uchida, Shigeru Ishida, Erika Mochizuki, Nana Ozawa, Hiroko Yonemitsu, Hideki Ochiai, Hanae Nakamura, Takehiro Kawashiri, Koji Kato, Nobuaki Egashira, Koichi Akashi, Ichiro Ieiri

    Anticancer research   43 ( 7 )   3321 - 3329   2023.7   ISSN:0250-7005 eISSN:1791-7530

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND/AIM: For quick and accurate monitoring of potential adverse events (AEs) during concurrent chemotherapy, we had previously developed innovative medication instruction sheets (MIS) for a variety of chemotherapy regimens. However, it is still unclear whether these sheets correctly predict the type and time course of the onset and recovery of AEs. Therefore, we monitored AEs in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine (HD-AraC) using the original MIS. PATIENTS AND METHODS: Patients who received HD-AraC following remission induction chemotherapy were included in this study. Data obtained from AE monitoring were evaluated, and the original MIS was modified as appropriate. RESULTS: Among 41 patients, a total of 203 AEs (139 non-hematological and 64 hematological) were observed after chemotherapy. By contrast, all but one patient (97.6%) experienced 102 AEs (43 non-hematological and 59 hematological) before chemotherapy. The AEs that appeared after chemotherapy were all predicted items described in the original MIS; however, their onset and duration were not consistent with the predicted data, in which the prediction accuracy was 69.1% for non-hematological AEs and 1.6% for hematological events. Based on these monitoring data, the original MIS was revised, which led to an increase in the prediction accuracy to 94.2% for nonhematological events and 100% for hematological events. CONCLUSION: Preexisting AEs should be considered when preparing MIS for consolidation therapy with HD-AraC. The modified MIS based on AE monitoring exhibited a sufficiently high prediction accuracy.

    DOI: 10.21873/anticanres.16508

    Web of Science

    Scopus

    PubMed

  • Ameliorating effects of cystine and theanine in a cancer cachexia mouse model. Reviewed

    Hibiki Kudamatsu, Takehiro Kawashiri, Keisuke Mine, Kohei Mori, Mizuki Inoue, Haruna Ishida, Mayako Uchida, Takashi Tsuchiya, Daisuke Kobayashi, Takao Shimazoe

    Journal of pharmacological sciences   152 ( 3 )   163 - 166   2023.7   ISSN:1347-8613 eISSN:1347-8648

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Cachexia is a common cancer complication and is associated with weight loss and anorexia. In this study, we investigated the ameliorating effects of cystine and theanine on cancer cachexia using a mouse model. In mice carrying the colon cancer cell line C-26, there was a suppression of body weight increase and reduction in both internal fat and lower limb muscles. Repeated cystine and theanine administration significantly prevented weight loss, internal fat loss, lower limb muscle loss, and serum IL-6 increase in the cachexia model. These results suggested that cystine and theanine may be effective in ameliorating cancer cachexia.

    DOI: 10.1016/j.jphs.2023.04.008

    Web of Science

    Scopus

    PubMed

  • Adverse Event Profile of Azacitidine: Analysis by Route of Administration using Japanese Pharmacovigilance Database. Reviewed International journal

    Kenta Yamaoka, Masaki Fujiwara, Mayako Uchida, Yoshihiro Uesawa, Nobuyuki Muroi, Tadashi Shimizu

    Oncology   101 ( 10 )   664 - 674   2023.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    UNLABELLED: Intoroduction: Azacitidine is a useful drug for myelodysplastic syndromes and acute myeloid leukemia. In clinical trials, hematologic toxicity, infection have been observed as adverse events (AEs) of this drug. However, information on the time to onset of high-risk AEs and subsequent outcomes, as well as differences in the frequency of AEs due to the route of administration is lacking. In this study, we investigated azacitidine-induced AEs comprehensively using the Japanese Adverse Event Reporting Database (JADER) published by the Pharmaceuticals and Medical Devices Agency, with disproportionate analysis of AE incidence trends, time to onset, and subsequent outcomes. In addition, we analyzed the differences in AEs by route of administration and the number of days until the occurrence of AEs and generated hypotheses. METHODS: The study used JADER data reported from April 2004 to June 2022. Risk estimation was conducted using reported odds ratio (ROR). A signal was detected when the lower limit of the 95% confidence interval of the calculated ROR was ≥ 1. RESULTS: A total of 34 signals were detected as AEs due to azacitidine. Among them, 15 were hematologic toxicities, and 10 were infections, which demonstrated a particularly high rate of death. Signals of AEs such as tumor lysis syndrome (TLS) and cardiac failure, which have been described in case reports, were also detected, and the rate of death after onset was high. In addition, more AEs generally occurred within the first month of treatment. DISCUSSION/CONCLUSION: The results of this study suggest that more attention should be paid to cardiac failure, hematologic toxicity, infection, and TLS. Because in clinical trials have discontinued treatment due to serious AEs before the therapeutic effect became apparent, appropriate supportive care, dose reduction, and drug withdrawal are important for the continuation of treatment.

    DOI: 10.1159/000531390

    PubMed

  • がん患者におけるオピオイド誘発性便秘症の危険因子 単一施設における後方視的研究

    神林 祐子, 清水 真弓, 石塚 友一, 澤 昇平, 矢部 勝茂, 内田 まやこ

    Palliative Care Research   18 ( Suppl. )   S270 - S270   2023.6   eISSN:1880-5302

     More details

    Language:Japanese   Publisher:(NPO)日本緩和医療学会  

  • Evaluation of lung adverse events with nivolumab using the spontaneous reporting system in Japan. Reviewed International journal

    Yuko Kanbayashi, Tadashi Shimizu, Asuka Kojima, Miku Anzai, Rika Kawai, Mayako Uchida

    Scientific reports   13 ( 1 )   8819 - 8819   2023.5

     More details

    Authorship:Last author   Language:English   Publishing type:Research paper (scientific journal)  

    This study was conducted to examine times to onset, incidence rates, and outcomes of nivolumab-induced lung adverse events (AEs), using the Japanese Adverse Drug Event Report database. We analysed data for the period between April 2004 and March 2021. Data on lung AEs were extracted, and relative risks of AEs were estimated using the reporting odds ratio. We analysed 5,273,115 reports and found 18,721 reports of nivolumab-related AEs, including 3084 lung AEs. Signals were detected for nine lung AEs: interstitial lung disease; pneumonitis; lung disorder; organising pneumonia; pleural effusion; pneumonia aspiration; pneumonia bacterial; radiation pneumonitis; and infectious pleural effusion. Among these, interstitial lung disease was the most frequently reported (68.7%) and included some fatal cases. A histogram of median times to onset showed AEs occurring from 34 to 79 days after the first dose, but some cases occurred even more than one year after starting administration. In conclusion, we focused on lung AEs caused by nivolumab as post-marketing AEs. Some cases could potentially involve serious outcomes, particularly in interstitial lung disease. Patients should be monitored for signs of the development of these AEs not only at the start of administration, but also over an extended time.

    DOI: 10.1038/s41598-023-35602-w

    PubMed

  • Usefulness of a Medication Instruction Sheet for Patients Receiving Cytarabine and Idarubicin Induction Therapy for Acute Myeloid Leukemia. Reviewed International journal

    Mayako Uchida, Erika Mochizuki, Shigeru Ishida, Nana Ozawa, Hiroko Yonemitsu, Hideki Ochiai, Hanae Nakamura, Takehiro Kawashiri, Koji Kato, Nobuaki Egashira, Koichi Akashi, Ichiro Ieiri

    In vivo (Athens, Greece)   37 ( 2 )   924 - 932   2023.3   ISSN:0258-851X eISSN:1791-7549

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND/AIM: To monitor adverse events rapidly and accurately during combination chemotherapy, we established an innovative medication instruction sheet (MIS) including cytarabine and idarubicin induction therapy. However, it is unclear whether this MIS allows for the accurate prediction of adverse events and their onset timing in a clinically significant manner. We therefore evaluated the clinical usefulness of our MIS for monitoring adverse events. PATIENTS AND METHODS: Patients who received cytarabine and idarubicin induction therapy for acute myeloid leukemia (AML) at the Department of Hematology, Kyushu University Hospital between January 2013 and February 2022 were included. The real-world clinical data were compared to the MIS to determine the accuracy of the MIS for predicting the onset and duration of adverse events in patients with AML during induction chemotherapy. RESULTS: Thirty-nine patients with AML were included in this study. Overall, 294 adverse events were noted, all of which were predicted items in the MIS. Among the 192 non-hematological adverse events, 131 (68.2%) occurred during a similar period as that listed in the MIS, whereas among the 102 hematological adverse events, 98 (96.1%) appeared earlier than expected. For the non-hematological events, the onset and duration of elevated aspartate aminotransferase levels and nausea/vomiting coincided well with those listed in the MIS, whereas the predictive accuracy for rashes was the lowest. CONCLUSION: Hematological toxicity was not predicted because of the bone marrow failure associated with AML. Our MIS was useful for rapidly monitoring non-hematological adverse events in patients with AML receiving cytarabine and idarubicin induction therapy.

    DOI: 10.21873/invivo.13164

    Web of Science

    Scopus

    PubMed

  • Evaluation of Cardiac Adverse Events with Nivolumab Using a Japanese Real-World Database. Reviewed International journal

    Yuko Kanbayashi, Tadashi Shimizu, Miku Anzai, Rika Kawai, Mayako Uchida

    Clinical drug investigation   43 ( 3 )   177 - 184   2023.2

     More details

    Authorship:Last author   Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Nivolumab has been used for the treatment of various types of cancers and has achieved improvements in overall survival. However, nivolumab can cause a variety of adverse events (AEs). Among these, cardiac-specific AEs have received little attention in clinical trials, despite their life-threatening potential. OBJECTIVE: The present study aimed to determine the risk of nivolumab-induced cardiac AEs, time to onset, incidence rates, and post hoc outcomes using the Japanese Adverse Drug Event Report database. METHODS: We analyzed data for the period between April 2004 and March 2021. Data on cardiac AEs were extracted and relative risk of AEs was estimated using the reporting odds ratio (ROR). RESULTS: We analyzed 1,772,494 reports and identified 18,721 reports of AEs caused by nivolumab. Of these, 409 reports involved cardiac AEs. Signals were detected for four cardiac AEs: myocarditis; pericardial effusion; pericarditis; and immune-mediated myocarditis. Among these, myocarditis was the most frequently reported (35.0%) and included fatal cases. A histogram of times to onset showed nivolumab-associated AEs occurring 41-127 days after starting administration, with outlier cases of myocarditis or pericardial effusion occurring after more than one year, both with catastrophic consequences. CONCLUSION: This study focused on cardiac AEs caused by nivolumab as post-marketing AEs. Myocarditis and pericardial effusion have been associated with some fatal cases after administration of nivolumab. Patients should be monitored for signs of onset for these AEs, not only at the start of administration, but also over an extended period after nivolumab administration.

    DOI: 10.1007/s40261-023-01246-x

    PubMed

  • Efficacy and safety of mycophenolate mofetil in treating immune-related hepatitis induced by immune checkpoint inhibitor use: A retrospective study. Reviewed International journal

    Yukio Kadokawa, Satoko Inoue, Akitoshi Tatsumi, Mayako Uchida, Keiko Fujita, Mari Takagi, Takako Inoue, Shuichi Ohe, Yasutomo Nakai, Tomoyuki Otsuka, Yutaro Abe, Tasuku Nakabori, Taiki Isei, Toru Kumagai, Kazuo Nishimura, Kazuyoshi Ohkawa

    JGH open : an open access journal of gastroenterology and hepatology   7 ( 2 )   87 - 97   2023.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND AND AIM: To investigate the outcomes in eight Japanese patients with cancer treated with mycophenolate mofetil (MMF) and corticosteroids for immune checkpoint inhibitor treatment-induced severe immune-related hepatitis (ir-hepatitis) and the efficacy and safety of MMF. METHODS: We retrospectively examined patient background, treatment course, as well as examination and imaging data using electronic medical records. RESULTS: The ratio of male to female patients was 7:1, and the median age was 60 years (27-72 years). There were five and two cases of kidney cancer and malignant melanoma, respectively, and one case of lung cancer. The median number of days until MMF administration in addition to systemic corticosteroid therapy after the onset of ir-hepatitis was 14.5 (2-42). The patients were categorized as four "good responders" who showed an improvement in the liver function tests following MMF treatment and four "poor responders" who did not. Furthermore, the time from the onset of ir-hepatitis to initial MMF administration was significantly shorter in good responders (median 3 days, range 2-15 days) than in poor responders (median 25.5 days, range 14-42 days) (P = 0.042). No significant intergroup difference was observed in other clinical factors. No serious adverse events caused by MMF were observed in any case. CONCLUSIONS: According to these findings, early recognition of corticosteroid refractoriness and the use of MMF may be beneficial in patients with ir-hepatitis.

    DOI: 10.1002/jgh3.12868

    PubMed

  • Assessment of Time-to-onset and Outcome of Lung Adverse Events With Pomalidomide from a Pharmacovigilance Study. Reviewed International journal

    Yuka Kawahara, Saeko Murata, Tadashi Shimizu, Yoshihiro Uesawa, Mayako Uchida

    In vivo (Athens, Greece)   37 ( 2 )   955 - 961   2023

     More details

    Authorship:Last author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND/AIM: Pomalidomide is an immunomodulatory drug that is used to treat multiple myeloma. We examined the time-to-onset and outcome of lung adverse events (LAEs) related to pomalidomide in Japanese patients based on information obtained from the spontaneous reporting system of the Japanese Adverse Drug Event Report database (JADER) of the Pharmaceuticals and Medical Devices Agency. PATIENTS AND METHODS: We analyzed adverse events (AEs) reports recorded between April 2004 and March 2021 from JADER. Data on LAEs were extracted, and the relative risk of AEs was estimated using the reporting odds ratio and 95% confidence interval. We analyzed 1,772,494 reports and identified 2,918 reports of AEs caused by pomalidomide. Of these, 253 LAEs were reportedly associated with pomalidomide. RESULTS: Signals were detected for five LAEs: pneumonia, pneumocystis jirovecii pneumonia, bronchitis, pneumonia bacterial, and pneumonia pneumococcal. Pneumonia was the most frequently mentioned condition (68.8%). The median time-to-onset of pneumonia was 66 days, but some cases of pneumonia occurred as late as 20 months after the start of administration. Fatal outcomes were observed in two of the five AEs wherein signals were detected and were due to pneumonia and bacterial pneumonia. CONCLUSION: Serious outcomes can occur after pomalidomide administration. It has been suggested that these LAEs occur relatively early after pomalidomide administration. Since some situations can result in fatal consequences, patients should be monitored for the emergence of these AEs over a prolonged period of time, especially for pneumonia.

    DOI: 10.21873/invivo.13168

    PubMed

  • The Influence of the Rapid Increase in the Number of Adverse Event Reports for COVID-19 Vaccine on the Disproportionality Analysis Using JADER. Reviewed International journal

    Kenta Yamaoka, Masaki Fujiwara, Mayako Uchida, Yoshihiro Uesawa, Tadashi Shimizu

    In vivo (Athens, Greece)   37 ( 1 )   345 - 356   2023

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND/AIM: The COVID-19 prophylactic vaccine for the prevention of coronavirus infection was approved in Japan on February 14, 2021. Adverse event reports for the vaccine were collected from the Japan Adverse Drug Event Relief (JADER) database, similar to those for drugs. Reported odds ratios (RORs) and proportional reporting ratios (PRRs) are commonly used in disproportionality analysis to detect safety signals. Therefore, adverse event reports from the vaccinated population may affect the detection of safety signals for the registered drugs. This study determined the impact of adverse event reports on the detection of safety signals for a COVID-19 prophylactic vaccine by analyzing the JADER database using disproportionality analysis. PATIENTS AND METHODS: We extracted data from the JADER dataset, in which the COVID-19 vaccine was reported as a suspected drug, and selected the top 10 adverse events in terms of the number of reports. We then extracted the top 30 drugs by the amount of information in the selected 10 adverse events and compared the changes in the number of signal detections with and without the COVID-19 vaccine report data. RESULTS: The total number of adverse events reported in the JADER database during the study period was 2,002,564. Of the total number of reports, 85,489 (4.3%) reported adverse events related to the COVID-19 vaccine. Of the top 30 drugs reported in the 10 selected adverse events, the ROR and PRR were found to be lower with the inclusion of COVID-19 vaccine data than without. Detection by ROR excluded 23 out of 245 drugs, and detection by PRR excluded 34 out of 204 drugs. CONCLUSION: The rapid increase in the number of adverse event reports for the COVID-19 vaccine in JADER may affect the detection of safety signals by disproportionality analysis.

    DOI: 10.21873/invivo.13085

    PubMed

  • Pharmacist interventions for adverse drug reactions in palliative care: A multicentre pilot study. Reviewed

    Eiji Kose, Sari Nakagawa, Kazuyuki Niki, Junya Hashizume, Tetsushi Kawazoe, Norifumi Suzuki, Mayako Uchida, Takase Hisamitsu

    Pharmazie.   78 ( 8 )   141 - 149   2023

  • Opioid-Related Respiratory Depression in Non-Cancer Patients, as Reported in the Japanese Adverse Drug Event Report Database. Reviewed

    Hideki Sugawara, Mayako Uchida, Shinya Suzuki, Yukio Suga, Yoshihiro Uesawa, Takayuki Nakagawa, Hisamitsu Takase

    Journal of Nippon Medical School = Nippon Ika Daigaku zasshi   90 ( 6 )   439 - 448   2023

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Opioid-induced respiratory depression (RD) is a potentially life-threatening adverse drug event. This study used the Japanese Adverse Drug Event Report (JADER) database to investigate the profile of opioid-related RD in non-cancer patients. METHODS: We analyzed data recorded in the JADER database between April 2004 and February 2020, which were downloaded from the Pharmaceutical and Medical Devices Agency website. Reporting odds ratios for RD were calculated for the 20 opioids approved in Japan, and daily dose and onset time were further analyzed for opioids used in chronic non-cancer pain (CNCP). RESULTS: Among the opioids, RD adverse event signals were detected for 22 combinations of opioids and administration routes in non-cancer patients. Of these combinations, transdermal buprenorphine and oral tramadol/acetaminophen were approved for CNCP and tended to be reported more frequently in elderly patients. The median daily doses of transdermal buprenorphine and oral tramadol/acetaminophen were 10.0 and 22.5 mg of daily oral morphine equivalent doses, respectively, which are within the standard range for starting dosage. The median time-to-onset of transdermal buprenorphine and oral tramadol/acetaminophen was 6.5 and 4.0 days, respectively, and 75% of cases were reported within 20 to 40 days after the start of treatment. The hazard type for both opioids was classified as early failure. CONCLUSIONS: Our findings suggest that elderly CNCP patients should be closely monitored after the start of opioid treatment, especially during the first week and, if possible, for 1 month, even if starting doses are within ranges recommended by the manufacturer and guidelines.

    DOI: 10.1272/jnms.JNMS.2023_90-612

    PubMed

  • Multicenter prospective observational study on hospital pharmacist interventions to reduce inappropriate medications. Reviewed International journal

    Shinya Suzuki, Mayako Uchida, Hideki Sugawara, Yukio Suga, Takayuki Nakagawa, Hisamitsu Takase

    Frontiers in pharmacology   14   1195732 - 1195732   2023

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

    Background: In Japan, the involvement of hospital pharmacists in inappropriate medications (IMs) practices has not been sufficiently reported. Therefore, this prospective study described the interventions of hospital pharmacists in discontinuing inappropriate drugs or reducing drug doses. Methods: We conducted a prospective, multicenter, observational study to investigate the intervention of hospital pharmacists in inappropriate prescriptions for inpatients in September 2018. Fifty pharmacists from 45 hospitals in Japan participated in this study. IMs were defined as medications that pharmacists deemed inappropriate for patient treatment. The subjects of the study were patients who interacted with the participating pharmacists. Results: During the study period, the median number of beds in hospitals where the 50 participating pharmacists worked was 380, and the average number of beds for which the pharmacists were responsible was 49. The enrolled hospital pharmacists recommended that doctors discontinue or reduce the doses of their regular drugs for 347 out of 1,415 (24.5%) patients. Among the 391 pharmacists' recommendations to reduce IMs for 347 patients, physicians accepted 368 (94.1%) recommendations, and 523 drugs were discontinued as a result. Pharmacist intervention also led to improvements in hypnotic sedation, delirium, and hypotension. The most common reasons for IMs identified by pharmacists were "long-term administration of irresponsible or aimless medications" (44.5%), "adverse effects caused by medications" (31.5%), and "medications-mediated duplication of the pharmacological effect" (15.3%). Approximately 90% of pharmacists' suggestions to reduce medications were accepted for each reason. The average number of regular medications used by patients involved in drug reduction was 8.2, and the average number of medications reduced was 1.7. A sub-analysis showed that patients using opioids tended to take more medications, and these patients were able to reduce the amount of medications taken. Interventions by pharmacists certified in palliative pharmacies tended to reduce adverse drug events. Conclusion: This was the first multicenter prospective observational study conducted in Japan to demonstrate hospital pharmacist intervention's effectiveness in promoting appropriate prescription and, consequently, a reduction in the number of medications in use and polypharmacy.

    DOI: 10.3389/fphar.2023.1195732

    PubMed

  • Evaluation of the Time to Onset and Outcome of Lenalidomide-induced Thrombosis and Embolism Using Spontaneous Reporting Database. Reviewed International journal

    Junya Sato, Naru Yamamoto, Yuka Kawahara, Tadashi Shimizu, Mayako Uchida

    In vivo (Athens, Greece)   37 ( 3 )   1246 - 1252   2023

     More details

    Authorship:Last author   Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND/AIM: Lenalidomide (LND) is an oral antineoplastic agent used in the treatment of various malignant hematologic diseases, including multiple myeloma. Major adverse events of LND include myelosuppression, pneumonia, and thromboembolism. Thromboembolism is an adverse drug reaction (ADR) associated with poor outcomes, therefore anticoagulants are administered prophylactically. However, LND-induced thromboembolism has not been clearly characterized from clinical trials. The purpose of this study was to evaluate the incidence, timing, and outcome details of thromboembolism caused by LND using the JADER (Japanese Adverse Drug Event Report) database. PATIENTS AND METHODS: ADRs due to LND reported from April 2004 to March 2021 were selected. Data on thromboembolic adverse events were analyzed and relative risks were estimated using reported odds ratios (RORs) and 95% confidence intervals (CIs). In addition, the time of onset and outcome of thromboembolism were analyzed. RESULTS: There were 11,681 adverse events attributed to LND. Of these, 306 were thromboembolisms. The most frequently reported thrombosis with the highest ROR was deep vein thrombosis (DVT) (165 cases, ROR=7.12, 95%CI=6.09-8.33). The median onset of DVT (quartiles, 25-75%) was 80 (28-155) days. The parameter value (β) was 0.87 (0.76-0.99), suggesting the onset of DVT early in treatment. The prognosis of DVT due to LND was recovery and remission in 34% and 43% of patients, respectively, but 7.9% did not recover. CONCLUSION: DVT is the most frequent thromboembolism in LND, and early treatment is important.

    DOI: 10.21873/invivo.13201

    PubMed

  • Evaluation of Cardiac Adverse Events with Ponatinib Using a Spontaneous Reporting Database. Reviewed International journal

    Yuko Kanbayashi, Mayako Uchida, Kana Nakano, Haruka Wakabayashi, Tadashi Shimizu

    Oncology   101 ( 6 )   397 - 405   2023

     More details

    Authorship:Last author   Language:English   Publishing type:Research paper (scientific journal)  

    INTRODUCTION: The efficacy of ponatinib was demonstrated in patients resistant or intolerant to prior BCR-ABL tyrosine kinase inhibitors. However, cardiac adverse events (CAEs) have become a concern as a serious side effect of ponatinib administration. No reports have described the incidence of CAEs associated with ponatinib in Japanese patients. Thus, this study aimed to determine the risk of ponatinib-induced CAEs, time to onset, and post hoc outcomes using the Japanese Adverse Drug Event Report database. METHODS: We analyzed data for the period between April 2004 and March 2021. Data on CAEs were extracted, and relative risk of AEs was estimated using the reporting odds ratio. RESULTS: We analyzed 1,772,494 reports and identified 1,152 reports of AEs caused by ponatinib. Of these, 163 CAEs were reportedly associated with ponatinib. Signals were detected for thirteen CAEs: hypertension, cardiac failure, acute cardiac failure, atrial fibrillation, increased blood pressure, coronary artery stenosis, myocardial infarction, angina pectoris, pulmonary hypertension, prolonged QT on electrocardiography, cardiomyopathy, cardiac dysfunction, and acute myocardial infarction. Among these, hypertension was the most frequently reported AE (27.6%). A histogram of times to onset showed occurrence from 4.5 to 150.5 days. DISCUSSION/CONCLUSION: Hypertension, cardiac failure, coronary artery stenosis, and myocardial infarction could potentially result in serious outcomes and some cases occurred earlier or even more than 1 year after starting administration. Patients should be monitored for signs of the onset of these AEs not only at the start of ponatinib administration but also over the longer term.

    DOI: 10.1159/000529768

    PubMed

  • Cardiac Adverse Events Associated with Multiple Myeloma Patients Treated with Proteasome Inhibitors. Reviewed International journal

    Masaki Fujiwara, Mayako Uchida, Mirai Endo, Makoto Goto, Tadashi Shimizu

    Oncology   101 ( 5 )   343 - 348   2023

     More details

    Language:English  

    BACKGROUND: Proteasome inhibitors (PIs) are standard treatments for multiple myeloma (MM). The risk of cardiac adverse events (CAEs) with PIs has been documented with bortezomib and carfilzomib; however, only a few studies have been reported on ixazomib. Furthermore, the effects of concomitant medications including dexamethasone and lenalidomide remain unclear. OBJECTIVES: This study aimed to determine the safety signals of adverse events related to CAEs, the effect of concomitant medications, the time to the occurrence of CAEs, and the incidence of fatal clinical outcomes after the occurrence of CAEs for three PIs using the US Pharmacovigilance database. METHODS: We examined 1,567,240 cases of 231 drugs registered as anticancer drugs in the US Food and Drug Administration Adverse Event Reporting System (FAERS) database from January 1997 to March 2021. We compared the odds of developing CAEs between patients who received PIs and those who received non-PI anticancer drugs. RESULTS: Bortezomib treatment resulted in significantly higher reporting odds ratios (RORs) for cardiac failure, cardiac failure congestive, and atrial fibrillation. Carfilzomib treatment resulted in significantly higher RORs for cardiac failure, congestive cardiac failure, atrial fibrillation, and QT prolonged. However, no adverse event CAE signals were observed with ixazomib treatment. A signal was detected for the safety of cardiac failure with bortezomib or carfilzomib, regardless of the presence or absence of concomitant medications. Safety signals for cardiac failure congestive with bortezomib and for cardiac failure congestive, atrial fibrillation, and QT prolonged with carfilzomib were observed only with dexamethasone combination therapy. Co-administration of lenalidomide and its derivatives did not affect the safety of bortezomib and carfilzomib. CONCLUSION: We identified CAE safety signals for bortezomib and carfilzomib exposure when compared with 231 other anticancer agents. The safety signal for developing cardiac failure for both the drugs did not differ between patients with and without concomitantly administered medications.

    DOI: 10.1159/000529341

    PubMed

  • Japanese Nationwide Comparative Survey of Medication Guidance Provided by Certified and Uncertified Palliative Care Pharmacists. Reviewed

    Rei Tanaka, Yumi Satoh, Yukio Suga, Junichi Nakagawa, Masayuki Miyazaki, Ryoichi Hagiwara, Mayako Uchida, Hisamitsu Takase

    Journal of Nippon Medical School = Nippon Ika Daigaku zasshi   90 ( 6 )   449 - 459   2023

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: As members of a medical team, pharmacists are expected to provide optimal patient-centered, evidence-based pharmacotherapy. In Japan, in consideration of the importance of palliative care, a system was initiated for certifying palliative care pharmacists in 2010. However, no studies have evaluated the usefulness of board certification in palliative pharmacy. Therefore, we surveyed the status of medication guidance for the physical and psychological symptoms of patients receiving palliative care and compared the medication guidance provided by certified and uncertified pharmacists. METHODS: The survey was conducted in February and March 2022. Pharmacists registered as members of the Japanese Society of Pharmaceutical Palliative Care and Sciences were surveyed by using a web-based questionnaire and 209 pharmacists responded: the certified pharmacist group comprised 123 (58.9%) pharmacists and the uncertified pharmacist group comprised 86 (41.1%) pharmacists. RESULTS: The certified pharmacist group provided better and more frequent medication guidance, according to responses to four of the six items related to pain relief. Three items were related to non-pain symptom relief, and one of the four items was related to psychiatric symptom relief (P < 0.05). The study showed that the certified pharmacist group received a better rating than the uncertified pharmacist group for involvement in palliative pharmacotherapy leading to improvement of patient quality of life (P < 0.05). CONCLUSION: As compared with uncertified pharmacists, certified pharmacists intervened more proactively and provided a broader range of palliative care.

    DOI: 10.1272/jnms.JNMS.2023_90-613

    PubMed

  • Evaluation of Lung Toxicity With Lenalidomide Using the Pharmacovigilance Database. Reviewed International journal

    Junya Sato, Tsuchiya Eren, Saeko Murata, Tadashi Shimizu, Mayako Uchida

    Anticancer research   42 ( 12 )   5917 - 5925   2022.12

     More details

    Authorship:Last author   Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND/AIM: Lenalidomide (LND) is an oral anticancer drug used to treat various malignant hematologic diseases, including multiple myeloma. The most common adverse events with LND are myelosuppression, thrombosis and pneumonia. Myelosuppression is reversible, and thrombosis can be treated with prophylactic administration of antithrombotic drugs. Pneumonia is less common and its incidence profile in clinical studies is unclear. This study aimed to evaluate the incidence and onset timing of LND-related lung toxicity and outcome details using the Japanese Adverse Drug Event Report (JADER) database. PATIENTS AND METHODS: Adverse events with LND reported between April 2004 and March 2021 were selected. Data on lung adverse drug reactions (ADRs) were analyzed, and safety signals were estimated using reported odds ratios (RORs) and 95% confidence intervals (CIs). We also estimated the timing of onset of lung toxic signs. RESULTS: A total of 10,929 ADRs were attributed to LND. Of these, 908 were lung toxicities. The most frequently reported ADRs with significantly high RORs were pneumonia (559 cases, ROR=3.89, 95% CI=3.57-4.24) and bacterial pneumonia (38 cases, ROR=2.02, 95% CI=1.46-2.78). Median onset of pneumonia and bacterial pneumonia were 84 and 74 days, respectively. Prognoses of patients who received LND and had pneumonia and bacterial pneumonia were poor, with 10-20% non-recovery and deaths. CONCLUSION: The findings indicate that pneumonia and bacterial pneumonia, among all LND-related lung toxicities, may be associated with immunosuppression, suggesting the importance of monitoring respiratory symptoms within the first 3 months of treatment.

    DOI: 10.21873/anticanres.16101

    PubMed

  • Inhibitory Effect of α1 Receptor Antagonists on Paclitaxel-Induced Peripheral Neuropathy in a Rodent Model and Clinical Database. Reviewed International journal

    Kohei Mori, Takehiro Kawashiri, Keisuke Mine, Mizuki Inoue, Hibiki Kudamatsu, Mayako Uchida, Nobuaki Egashira, Daisuke Kobayashi, Takao Shimazoe

    Toxics   10 ( 11 )   2022.11   eISSN:2305-6304

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    The anticancer drug, paclitaxel, is widely used for ovarian, breast, non-small cell lung, and gastric cancers; however, it induces peripheral neuropathy as a side effect. There is insufficient evidence-based prophylaxis, and new prophylaxis and treatment methods are required. We examined the effect of α1-receptor antagonists on paclitaxel-induced peripheral neuropathy using Sprague-Dawley rats and a large adverse event database. The repeated administration of doxazosin or tamsulosin significantly reduced the response threshold to paclitaxel administration in animal models. In the sciatic nerve tissue, axonal degeneration and myelopathy were significantly suppressed. Furthermore, an analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS) database suggested that the group using α1 inhibitors showed a lower reporting rate for paclitaxel-related peripheral neuropathy than the group that did not use these inhibitors (odds ratio (95% confidence interval): tamsulosin 0.21 (0.08-0.56), p &lt; 0.01, doxazosin 0.41 (0.10-1.65), p = 0.195; any α1 receptor antagonist 0.54 (0.38-0.76), p &lt; 0.01). Thus, doxazosin and tamsulosin may inhibit the development of paclitaxel-induced peripheral neuropathy by suppressing neurodegeneration, particularly axonal degeneration and myelopathy.

    DOI: 10.3390/toxics10110669

    Web of Science

    Scopus

    PubMed

  • Evaluation of lung adverse events with trastuzumab using the Japanese pharmacovigilance database. Reviewed International journal

    Yuko Kanbayashi, Mayako Uchida, Misui Kashiwagi, Hitomi Akiba, Tadashi Shimizu

    Medical oncology (Northwood, London, England)   39 ( 12 )   219 - 219   2022.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    The present study aimed to determine the risk of trastuzumab-induced lung toxicity, time to onset, and post hoc outcomes using the Japanese Adverse Drug Event Report database. We analyzed data for the period between April 2004 and March 2021. Data on lung toxicities were extracted, and relative risk of adverse events (AEs) was estimated using the reporting odds ratio. We analyzed 1,772,494 reports and identified 4362 reports of AEs caused by trastuzumab. Of these, 693 lung toxicities were reportedly associated with trastuzumab. Signals were detected for seven lung toxicities: interstitial lung disease, pulmonary edema, pleural effusion, lung disorder, acute pulmonary edema, pulmonary fibrosis, and radiation pneumonitis. Among these, interstitial lung disease was the most frequently reported (61.8%). A histogram of times to onset showed occurrence from 1 to 105 days, but some cases of interstitial lung disease occurred even more than one year after the start of administration. The AEs showing the highest fatality rates were interstitial lung disease, pulmonary fibrosis, and radiation pneumonitis. This study focused on lung toxicities caused by trastuzumab as post-marketing AEs. Some cases could potentially involve serious outcomes; therefore, patients should be monitored for signs of the onset of these AEs not only at the start of administration, but also over an extended period, especially for interstitial lung disease.

    DOI: 10.1007/s12032-022-01805-w

    PubMed

  • Evaluation of lung toxicity with bevacizumab using the spontaneous reporting database. Reviewed International journal

    Yuko Kanbayashi, Mayako Uchida, Misui Kashiwagi, Hitomi Akiba, Tadashi Shimizu

    Scientific reports   12 ( 1 )   15619 - 15619   2022.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    This study was undertaken to determine the risk of bevacizumab-induced lung toxicity, time to onset, and post hoc outcomes using the Japanese Adverse Drug Event Report database. We analysed data for the period between April 2004 and March 2021. Data on lung toxicities were extracted, and relative risk of adverse events (AEs) was estimated using the reporting odds ratio. We analysed 5,273,115 reports and identified 20,399 reports of AEs caused by bevacizumab. Of these, 1679 lung toxicities were reportedly associated with bevacizumab. Signals were detected for nine lung toxicities. A histogram of times to onset showed occurrence from 35 to 238 days, but some cases occurred even more than one year after the start of administration. Approximately 20% of AEs were thromboembolic events. Among these, pulmonary embolism was the most frequently reported and fatal cases were also reported. The AEs showing the highest fatality rates were pulmonary haemorrhage, pulmonary infarction, and pulmonary thrombosis. In conclusion, we focused on lung toxicities caused by bevacizumab as post-marketing AEs. Some cases could potentially result in serious outcomes, patients should be monitored for signs of onset of AEs not only at the start of administration, but also over a longer period of time.

    DOI: 10.1038/s41598-022-19887-x

    PubMed

  • Current Status of Adverse Event Profile of Cyclosporine in Kidney, Stem Cell, and Heart Transplantations Using the Japanese Pharmacovigilance Database. Reviewed International journal

    Iku Niinomi, Saki Oyama, Ayaka Inada, Tomohito Wakabayashi, Tatsuya Iida, Hiroko Kambara, Mayako Uchida, Yukako Sano, Keiko Hosohata

    Cureus   14 ( 9 )   e29383   2022.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Cyclosporine is widely used to prevent allograft rejection after transplantation. The purpose of this study was to clarify the adverse events profiles associated with cyclosporine in transplant patients using a spontaneous reporting system database. METHODS: Retrospective pharmacovigilance disproportionality analysis was conducted using the Japanese Adverse Drug Event Report (JADER) database, with the reporting odds ratio (ROR) and 95% confidence interval (CI) for each adverse event. RESULTS: The database comprised 3,327, 958, and 956 reports associated with cyclosporine in the kidney, stem cell, and heart transplant patients, respectively. Infectious and renal disorders were commonly detected in these transplant patients. The signal scores of cyclosporine for toxic nephropathy were noteworthy in the kidney (ROR: 15.1, 95% CI: 11-20.8) and stem cell (ROR, 216; 95% CI, 29.3-1593) transplantation. Cyclosporine in heart transplantation was strongly associated with gastric cancer (ROR, 39.4; 95% CI, 16.7-93.2), but not kidney or stem cell transplantation. CONCLUSION: It was suggested that there is a diversity in the strength of the association between cyclosporine and adverse events in the kidney, stem cell, and heart transplantation. Our results may provide useful information for treatment with cyclosporine, although further research with more data is needed.

    DOI: 10.7759/cureus.29383

    PubMed

  • Effectiveness of educational program on systematic and extensive palliative care in cancer patients for pharmacists. Reviewed International journal

    Mayako Uchida, Masahiro Yamada, Masao Hada, Daigo Inma, Shunji Ariyoshi, Hidetoshi Kamimura, Tohru Haraguchi

    Currents in pharmacy teaching & learning   14 ( 9 )   1199 - 1205   2022.9

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND AND PURPOSE: Continuing education is essential for pharmacists to acquire latest knowledge. Our previously established educational program for pharmacists on the systematic and extensive palliative care of cancer patients was evaluated for its educational effectiveness in one urban prefecture. However, whether the same learning effect can be achieved when a program is expanded from one urban prefecture to multiple rural prefectures is unclear. In this study, we examined whether the continuing education program would be useful to pharmacists, even if the scale was expanded. EDUCATIONAL ACTIVITY AND SETTING: With the aim of correcting educational disparities in the region, pharmacists living in nine prefectures in the Kyushu area underwent a systematic and extensive palliative care educational program for six days (with 24 topics in total). They were administered a questionnaire before and after each topic to evaluate their level of understanding. FINDINGS: The level of understanding of the 24 topics in the program that palliative care pharmacists underwent, from "basic knowledge" to "clinical application," significantly improved (P < .01). SUMMARY: The educational program for pharmacists is useful even when implemented on a larger scale. We believe that our efforts are important for improving community-based care.

    DOI: 10.1016/j.cptl.2022.07.034

    PubMed

  • Comprehensive Analysis of Adverse Events Induced by PARP Inhibitors Using JADER and Time to Onset. Reviewed International journal

    Kenta Yamaoka, Masaki Fujiwara, Mayako Uchida, Yoshihiro Uesawa, Nobuyuki Muroi, Tadashi Shimizu

    Life (Basel, Switzerland)   12 ( 9 )   2022.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Poly (ADP-ribose) polymerase (PARP) inhibitors are effective against breast cancer susceptibility gene (BRCA) mutations. Clinical trials have reported hematologic toxicity and gastrointestinal symptoms as class effects of PARP inhibitors. However, information on adverse events (AEs) in a Japanese clinical cohort is currently lacking. In this study, we conducted a comprehensive survey of the AEs of two PARP inhibitors, olaparib and niraparib, using the Japanese Adverse Reaction Reporting (JADER) database provided by the Pharmaceuticals and Medical Devices Agency (PMDA). Moreover, we also analyzed the course and time to the onset of AEs. Signals were detected for 15 and 11 AEs for olaparib and niraparib, respectively. Most occurred within the first month of treatment with either agent. These results may indicate the importance of early response and monitoring after beginning PARP inhibitor therapy. The results of this study may be useful for managing side effects and suggesting supportive care for patients using PARP inhibitors in the future.

    DOI: 10.3390/life12091355

    PubMed

  • Adverse event profiles of drugs used for treatment of juvenile idiopathic arthritis according to spontaneous reporting system database. Reviewed International journal

    Iku Niinomi, Saki Oyama, Ayaka Inada, Tomohito Wakabayashi, Toshinori Hirai, Hiroko Kambara, Tatsuya Iida, Mayako Uchida, Yukako Sano, Keiko Hosohata

    International journal of clinical pharmacology and therapeutics   60 ( 9 )   402 - 407   2022.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Juvenile idiopathic arthritis (JIA) is a systemic inflammatory disease of childhood onset. The purpose of this study was to clarify the frequency of adverse events caused by drugs used in JIA treatment and characterize their safety profiles using a spontaneous reporting system database. We performed a retrospective pharmacovigilance disproportionality analysis using the Japanese Adverse Drug Event Report (JADER) database. Adverse event reports on drugs used for the treatment of JIA and which were submitted to the Pharmaceuticals and Medical Devices Agency were analyzed, and the reporting odds ratio (ROR) and 95% confidence interval (CI) for reports on each adverse event were calculated. A total of 5,748 reports were identified in the treatment of JIA, in which 35 different drugs were involved. Adverse events by drugs in JIA were frequently reported in females (64.3%) and in those younger than 10 (61.2%). Among the most frequently reported drugs, prednisolone (36.8%) and tocilizumab (36.0%) were predominant. Prednisolone was significantly correlated with hematophagic histiocytosis (ROR, 1.37; 95% CI, 1.18 - 1.61). Tocilizumab was associated with a high ROR for pneumonia (ROR, 8.61: 95% CI, 5.81 - 12.7), a decreased neutrophil count (ROR, 6.1; 95% CI, 4.07 - 9.16), and lymphadenitis (ROR, 8.34; 95% CI, 4.2 - 16.6). Our results revealed the safety profile of drugs for the treatment of JIA patients. It was suggested that there is a diversity in drugs and their strength of association with adverse events in JIA patients. Our results may provide useful information for the treatment of JIA patients, although further research with more data is needed.

    DOI: 10.5414/CP204255

    PubMed

  • Omeprazole Suppresses Oxaliplatin-Induced Peripheral Neuropathy in a Rodent Model and Clinical Database. Reviewed International journal

    Keisuke Mine, Takehiro Kawashiri, Mizuki Inoue, Daisuke Kobayashi, Kohei Mori, Shiori Hiromoto, Hibiki Kudamatsu, Mayako Uchida, Nobuaki Egashira, Satoru Koyanagi, Shigehiro Ohdo, Takao Shimazoe

    International journal of molecular sciences   23 ( 16 )   2022.8   ISSN:16616596 eISSN:1422-0067

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    (1) Background: Oxaliplatin is used as first-line chemotherapy not only for colorectal cancer but also for gastric and pancreatic cancers. However, it induces peripheral neuropathy with high frequency as an adverse event, and there is no effective preventive or therapeutic method. (2) Methods: The effects of omeprazole, a proton pump inhibitor (PPI), on oxaliplatin-induced peripheral neuropathy (OIPN) was investigated using an in vivo model and a real-world database. (3) Results: In a rat model, oxaliplatin (4 mg/kg, i.p., twice a week for 4 weeks) caused mechanical hypersensitivity accompanied by sciatic nerve axonal degeneration and myelin sheath disorder. Repeated injection of omeprazole (5-20 mg/kg, i.p., five times per week for 4 weeks) ameliorated these behavioral and pathological abnormalities. Moreover, omeprazole did not affect the tumor growth inhibition of oxaliplatin in tumor bearing mice. Furthermore, clinical database analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS) suggests that the group using omeprazole has a lower reporting rate of peripheral neuropathy of oxaliplatin-treated patients than the group not using (3.06% vs. 6.48%, p &lt; 0.001, reporting odds ratio 0.44, 95% confidence interval 0.32-0.61). (4) Conclusions: These results show the preventing effect of omeprazole on OIPN.

    DOI: 10.3390/ijms23168859

    Web of Science

    Scopus

    PubMed

  • 日本のCOVID-19パンデミックにおける基礎的臨床腫瘍学を学ぶ薬剤師ためのオンラインセミナーの評価(Evaluation of a Webinar for Pharmacists Learning Basic Clinical-Oncology during COVID-19 Pandemic in Japan)

    Terazono Hideyuki, Tsuchiya Masami, Maki Yosuke, Yoshikawa Naoki, Kawahara Yosuke, Nishimura Keiko, Shinohara Keisuke, Ogawa Daisuke, Mori Riho, Iwamoto Yoshihiro, Itagaki Fumio, Masuko Hiroyuki, Yonemura Masahito, Uchida Mayako

    Biological & Pharmaceutical Bulletin   45 ( 7 )   856 - 862   2022.7   ISSN:0918-6158

     More details

    Language:English   Publisher:(公社)日本薬学会  

    日本臨床腫瘍学会では進行癌に対する医学を習得するための対面でのセミナーを毎年実施していた。しかしCOVID-19パンデミックにより、今年はウエブによるセミナーを開催せざるを得なくなった。腫瘍領域に対する初心者と中等度の技術の薬剤師に、オンラインセミナー(Web)がどのように影響したかを調べる質問票調査を行った。1756名のWeb参加者のうち1661名がWeb前に、1586名がWeb後に回答した。すべての7単元でWeb後の知識スコアの中央値は、Web前のスコアよりも有意に高かった。7単元の知識の程度に関する主成分分析では、スコア改善群は年齢が若く、薬剤師としての経験が浅く、非学会員で、過去の学会のセミナーの経験が少ないことを示していた。Webは都会や田舎の在住に関係なく、均一の学習効果を発揮した。

  • Evaluation of Durvalumab-induced Lung Toxicity Using a Spontaneous Reporting Database. International journal

    Junya Sato, Kana Nakano, Tadashi Shimizu, Mayako Uchida

    Anticancer research   42 ( 7 )   3575 - 3582   2022.7

     More details

    Authorship:Last author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND/AIM: Durvalumab is a human monoclonal antibody targeting programmed cell death ligand 1. It is classified as an immune checkpoint inhibitor and has shown high efficacy as maintenance therapy after chemoradiation for stage III non-small-cell lung cancer and as the primary treatment for small-cell carcinoma. Interstitial lung disease is the most common adverse event leading to durvalumab discontinuation. Hence, this study was aimed at assessing the incidence and timing of durvalumab-induced lung toxicity by using the Japanese Adverse Drug Event Report (JADER) database. PATIENTS AND METHODS: Adverse Adverse events (AEs) of durvalumab reported from August 2018 to March 2021 were extracted. Data on lung AEs were analysed to estimate relative risk using reporting odds ratios (RORs) and 95% confidence interval (CIs). Furthermore, the times of onset of signs of lung toxicity were also estimated. RESULTS: Overall, 2,162 AEs attributable to durvalumab were obtained. Of these, 1,239 were lung toxicities, the most common among which were pneumonia, interstitial lung disease, and radiation-associated pneumonitis. The corresponding RORs (95% CIs) for these signs were 271.50 (244.79-301.11), 5.96 (5.29-6.72), and 713.21 (595.04-854.85), respectively. The median (interquartile range) times of onset were 32.5 (28.5-35.5), 31.5 (28.5-41.5), and 28.5 (28.5-30.5) days, respectively. CONCLUSION: Among the AEs of durvalumab, pneumonia, interstitial lung disease, and radiation-induced pneumonitis were associated with high RORs, suggesting a strong causal relationship with durvalumab. Interstitial lung disease and radiation-induced pneumonitis most often occurred approximately 30 days after treatment initiation, suggesting that monitoring for adverse events during this period is important.

    DOI: 10.21873/anticanres.15844

    PubMed

  • Risk factors for opioid-induced constipation in cancer patients: a single-institution, retrospective analysis. International journal

    Yuko Kanbayashi, Yuichi Ishizuka, Mayumi Shimizu, Shohei Sawa, Katsushige Yabe, Mayako Uchida

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer   30 ( 7 )   5831 - 5836   2022.7

     More details

    Authorship:Last author   Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: To identify risk factors for opioid-induced constipation (OIC). METHODS: This study retrospectively analyzed 175 advanced cancer patients who were receiving pain treatment with opioids and were newly prescribed laxatives for OIC at Seirei Hamamatsu General Hospital between November 2016 and June 2021. For the regression analysis of factors associated with OIC, variables were extracted manually from clinical records. The effect of newly prescribed laxatives for OIC was evaluated as "effective" in cases where the number of spontaneous bowel movements increased at least once in the first 3 days. The OIC was defined based on Rome IV diagnostic criteria. Multivariate logistic regression analysis was performed to identify risk factors for OIC. Optimal cutoff thresholds were determined using receiver operating characteristic analysis. Values of P < 0.05 (two-tailed) were considered significant. RESULTS: Significant factors identified included body mass index (BMI) (odds ratio [OR] = 0.141, 95% confidence interval [CI] = 0.027-0.733; P = 0.020), chemotherapy with taxane within 1 month of evaluation of laxative effect (OR = 0.255, 95% CI = 0.068-0.958; P = 0.043), use of naldemedine (OR = 2.791, 95% CI = 1.220-6.385; P = 0.015), and addition or switching due to insufficient prior laxatives (OR = 0.339, 95% CI = 0.143-0.800; P = 0.014). CONCLUSION: High BMI, chemotherapy including a taxane within 1 month of evaluation of laxative effect, no use of naldemedine, and addition or switching due to insufficient prior laxatives were identified as risk factors for OIC in advanced cancer patients with cancer pain.

    DOI: 10.1007/s00520-022-07002-9

    PubMed

  • Evaluation of Lung Toxicity Related to the Treatment With Alectinib Using a Pharmacovigilance Database. Reviewed International journal

    Junya Sato, Mayako Uchida, Haruka Wakabayashi, Tadashi Shimizu

    Anticancer research   42 ( 6 )   3109 - 3116   2022.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND/AIM: The anaplastic lymphoma kinase (ALK) inhibitor alectinib is recommended as a first-line treatment for ALK lung cancer. Interstitial lung disease is the most common adverse event leading to discontinuation of alectinib. The purpose of this study was to use the Japanese Adverse Drug Event Report database for the evaluation of incidence trends and timing of alectinib toxicity in the lungs. PATIENTS AND METHODS: Adverse drug reactions (ADRs) by alectinib were extracted between April 2004 and March 2021. Data related to lung toxicity ADRs were analyzed, and the relative risk was estimated using the reporting odds ratio (ROR) and 95% confidence interval (CI). The time of onset of the lung toxicity signs was noted. RESULTS: We obtained 524 reports of ADRs associated with alectinib. Of these, 157 were lung toxicity, including interstitial lung disease, lung disorder, pneumonitis, and pulmonary edema. The RORs for these signs were 10.28 (95%CI=8.38-12.60), 9.19 (5.58-15.13), 7.40 (3.67-14.88), and 7.01 (3.13-15.69), respectively. The median onset times (quartiles, 25-75%) of interstitial lung disease, lung disorder, pneumonitis, and pulmonary edema associated with alectinib treatment were 92 (36-195), 57 (51-129), 228 (62-431), and 83 (22-96) days, respectively. CONCLUSION: Among the lung toxicity signs, interstitial lung disease had the highest ROR, suggesting a strong causal relationship with alectinib treatment. Interstitial lung disease most frequently developed within 60 days after the start of treatment. These results will be useful for monitoring adverse events associated with the use of alectinib.

    DOI: 10.21873/anticanres.15799

    PubMed

  • Comprehensive analysis of ixazomib-induced adverse events using the Japanese pharmacovigilance database. Reviewed International journal

    Kenta Yamaoka, Masaki Fujiwara, Mayako Uchida, Yoshihiro Uesawa, Nobuyuki Muroi, Tadashi Shimizu

    Oncology   100 ( 7 )   413 - 418   2022.5

     More details

    Language:English  

    BACKGROUND: Ixazomib is an orally available proteasome inhibitor for multiple myeloma with adverse effects such as gastrointestinal symptoms, skin rashes, and thrombocytopenia reported in clinical trials and post-marketing surveillance, resulting in treatment discontinuation. However, comprehensive adverse event (AE) assessments for ixazomib are lacking. OBJECTIVES: Herein, we aimed to determine the frequency and risk of AEs associated with ixazomib in Japanese patients using the Japanese Adverse Event Reporting Database (JADER). Additionally, the time to onset and post hoc outcomes of unique AEs were clarified. METHODS: To investigate the association between ixazomib and AEs, we analyzed the JADER database, comprising voluntary AE reports submitted to the Pharmaceuticals and Medical Devices Agency, between April 2004 and June 2021. AEs with > 10 reports were included in the analysis, and criteria for the presence of AE signals were defined as meeting the requirements of proportional report ratio (PRR) ≥ 2 and χ2 ≥ 4. Characteristic AEs were analyzed considering time to onset and onset outcomes. RESULTS: Of 34 extracted AEs, 18 presented AE signals. The 12 post hoc outcomes with fatality rates ˃10% included septic shock (50.0%), infection (41.2%), heart failure (16.7%), pneumonia (14.2%), and tumor necrosis syndrome (13.3%). A histogram of the time to onset showed that 11 of the 18 AEs occurred from ixazomib initiation to approximately 1 month later. CONCLUSION: Our results suggest that ixazomib may increase the incidence of 18 AEs, 11 of which occurred within the first month of treatment. Furthermore, 8 AEs were found to have potentially fatal outcomes at a rate > 10%. Therefore, monitoring AEs during the first month of treatment appears necessary.  Conclusion: Our results suggest that ixazomib may increase the incidence of 18 AEs, 11 of which occurred within the first month of treatment. Furthermore, 8 AEs were found to have potentially fatal outcomes at a rate > 10%. Therefore, monitoring AEs during the first month of treatment appears necessary. .

    DOI: 10.1159/000524806

    PubMed

  • Time to Onset of Bendamustine-associated Skin Damage Using the Spontaneous Reporting System. Reviewed International journal

    Misui Kashiwagi, Tadashi Shimizu, Rika Kawai, Takehiro Kawashiri, Yoshihiro Uesawa, Mayako Uchida

    Anticancer research   42 ( 5 )   2737 - 2741   2022.5   ISSN:0250-7005 eISSN:1791-7530

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND/AIM: Bendamustine-associated skin damage occurs frequently in Japan and can have a profound impact on health-related quality of life. To our knowledge, there are no reports on the timing of skin damage caused by bendamustine. This study assessed trends in and the time to onset of skin damage caused by bendamustine using the Japanese Adverse Drug Reaction Reporting Database (JADER). PATIENTS AND METHODS: Data related to skin damage with more than five reported cases from April 2004 to March 2021 were extracted from JADER, and the relative risk of adverse events was estimated using the reporting odds ratio and 95% confidence interval. The data were analyzed for time to onset of skin damage. RESULTS: JADER included a total of 2,450 reports of adverse drug reactions from bendamustine. Of these, 170 skin ailments of 10 types were reported to be associated with bendamustine. Significant associations for skin damage were found for rash, herpes zoster, and infusion-related reactions. The reporting odds ratios (with 95% confidence interval) for rash, herpes zoster, and infusion-related reaction were 1.63 (1.19-2.21), 3.25 (2.20-4.78), and 7.25 (4.84-10.85), respectively. The median onset (interquartile range) of rash, herpes zoster, and infusion-related reactions caused by bendamustine were 13 (10-28), 60 (28-107), and 6 (1-28) days, respectively. CONCLUSION: A comprehensive study using a pharmacovigilance approach enabled us to identify that a rash or infusion-related reaction may be expected within 2 weeks of treatment with bendamustine and that the onset of herpes zoster occurs at a median of 2 months after treatment with bendamustine.

    DOI: 10.21873/anticanres.15752

    Web of Science

    Scopus

    PubMed

  • Evaluation of Medication Instruction Sheets for Patients Undergoing R-CHOP Therapy in Non-Hodgkin’s Lymphoma Reviewed International journal

    MAYAKO UCHIDA, RIKA KAWAI, RIE HISAMITSU, SAYAKA MAI, SHIGERU ISHIDA, HIROYUKI WATANABE, TAKEHIRO KAWASHIRI, KOJI KATO, KEIKO HOSOHATA, TOSHIHIRO MIYAMOTO, NOBUAKI EGASHIRA, TSUTOMU NAKAMURA, KOICHI AKASHI, ICHIRO IEIRI

    In Vivo   36 ( 3 )   1461 - 1467   2022.5   ISSN:0258-851X eISSN:1791-7549

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Anticancer Research USA Inc.  

    BACKGROUND/AIM: High-dose chemotherapy is frequently administered to patients with hematologic malignancies, thereby causing severe adverse drug reactions (ADRs) at a relatively high frequency. To precisely monitor ADRs, we developed a medication instruction sheet (MIS) for patients who received rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) combination therapy for non-Hodgkin's lymphoma (NHL). Herein, we evaluated the usefulness of the MIS for managing ADRs in patients who received R-CHOP therapy. PATIENTS AND METHODS: We included patients aged ≥20 years who received R-CHOP therapy as first-line treatment for NHL at the Department of Hematology, Kyushu University Hospital, between August 2014 and December 2018. Medical professionals evaluated the possible occurrence of ADRs according to the present MIS and ADRs were graded according to the Common Toxicity Criteria, version 4.0 (National Cancer Institute, Bethesda, MD, USA). Finally, the accuracy of the MIS in predicting the occurrence of ADRs of different grades and during definite periods was evaluated. RESULTS: Seventy-five patients with NHL were included in the present study. Overall, 359 ADR events were monitored, which were predicted ADR items listed in the MIS. Among these, 254 (71%) events occurred during the same period as those listed in the MIS. The onset timing of any grade of an infusion reaction and peripheral neuropathy precisely matched those listed in the MIS. However, the accuracy of the MIS was reduced in patients with thrombocytopenia (42%). CONCLUSION: The present MIS could be useful for monitoring ADRs in patients with cancer undergoing R-CHOP therapy.

    DOI: 10.21873/invivo.12852

    Web of Science

    Scopus

    PubMed

  • JASPOスタートアップセミナー2020参加者アンケートから見えてくるCOVID-19流行下での薬剤師教育のあり方

    寺薗 英之, 土屋 雅美, 牧 陽介, 吉川 直樹, 河原 陽介, 西村 佳子, 篠原 佳祐, 小川 大介, 森 理保, 岩本 義弘, 板垣 文雄, 益子 寛之, 米村 雅人, 内田 まやこ

    日本臨床腫瘍薬学会雑誌   25   190 - 190   2022.5   eISSN:2189-129X

     More details

    Language:Japanese   Publisher:(一社)日本臨床腫瘍薬学会  

  • JASPOブラッシュアップセミナー2020参加者アンケートから見えてくるCOVID-19流行下での薬剤師教育のあり方

    土屋 雅美, 寺薗 英之, 牧 陽介, 吉川 直樹, 河原 陽介, 西村 佳子, 篠原 佳祐, 小川 大介, 森 理保, 岩本 義弘, 板垣 文雄, 益子 寛之, 米村 雅人, 内田 まやこ

    日本臨床腫瘍薬学会雑誌   25   188 - 188   2022.5   eISSN:2189-129X

     More details

    Language:Japanese   Publisher:(一社)日本臨床腫瘍薬学会  

  • Multicentre prospective observational study on community pharmacist interventions to reduce inappropriate medications. Reviewed International journal

    Mayako Uchida, Shinya Suzuki, Hideki Sugawara, Yukio Suga, Takayuki Nakagawa, Hisamitsu Takase

    The International journal of pharmacy practice   30 ( 5 )   427 - 433   2022.4

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVES: The status of community pharmacists' involvement in inappropriate prescription practices among outpatients who visit community pharmacies has not been reported in Japan. Therefore, this study described community pharmacists' interventions aimed at the discontinuation of inappropriate drugs or the reduction of drug doses. METHODS: We conducted a multicentre prospective observational study of pharmacists' interventions on inappropriate prescriptions for outpatients during a 1-month period in September 2018. A total of 28 pharmacists from 28 community pharmacies in Japan participated in this study. We analysed cases in which pharmacists discontinued drugs or changed the doses due to drugs being inappropriate, adverse effects, duplication of pharmacological effects and drug-drug interactions. KEY FINDINGS: Community pharmacists provided interventions for 736 patients at an average of 26.2 patients per day during the study period. The pharmacists recommended that doctors discontinue inappropriate drugs or reduce the doses of regular drugs for 103 patients (13.9%). Among the 107 pharmacist recommendations to decrease inappropriate prescriptions, 83 (77.6%) were accepted, including 62 cases of discontinuation (57.9%) and 21 of drug dose reduction (19.6%). A total of 122 drugs were discontinued according to pharmacists' recommendations. In addition, pharmacists' intervention improved sleepiness, sedation and cognitive function. CONCLUSIONS: This study shows the active involvement of community pharmacists in polypharmacy by discontinuing inappropriate drugs or reducing the dose of regular drugs, which may contribute to the improvement of adverse effects among outpatients.

    DOI: 10.1093/ijpp/riac032

    PubMed

  • Usefulness of Medication Guidance Sheets for Patients With Non-Hodgkin's Lymphoma Receiving ESHAP±R Therapy. Reviewed International journal

    Mayako Uchida, Saeko Murata, Hanae Morikawa, Hiroko Yonemitsu, Shigeru Ishida, Kimitaka Suetsugu, Toshikazu Tsuji, Hiroyuki Watanabe, Takehiro Kawashiri, Koji Kato, Keiko Hosohata, Toshihiro Miyamoto, Nobuaki Egashira, Tsutomu Nakamura, Koichi Akashi, Ichiro Ieiri

    Anticancer research   42 ( 4 )   2053 - 2060   2022.4   ISSN:0250-7005 eISSN:1791-7530

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND/AIM: The occurrence of chemotherapy-related serious adverse events (AEs) is associated with a poor prognosis of hematopoietic malignancies. We have developed a medication guidance sheet (MGS) for monitoring AEs occurring when combining chemotherapy with etoposide, methylprednisolone, cisplatin, cytarabine, and rituximab (ESHAP±R). In this study, the usefulness of MGS was investigated in non-Hodgkin's lymphoma patients. PATIENTS AND METHODS: The MGS was used to monitor AEs in 48 adult patients receiving ESHAP±R. The prediction accuracy of the MGS was estimated before and after modification based on practical data. RESULTS: A total of 246 AEs developed, all of which were predicted by the MGS. Among them, 149 events (61%) occurred during the same period as those predicted by the MGS. After modification of MGS for the onset and duration of AEs, the accuracy increased to 84%. CONCLUSION: The accuracy of the original MGS for ESHAP±R was insufficient but greatly improved after the AEs duration modification.

    DOI: 10.21873/anticanres.15686

    Web of Science

    Scopus

    PubMed

  • Effect of Sokeikakketsuto Combined with Interventional Treatment on Low Back Pain - A Case Report. Reviewed

    Hiroko Nakamura, Mayako Uchida, Yuko Miyamae, Shinnosuke Kurata, Kenji Shin, Daisuke Kobayashi, Takehiro Kawashiri, Takao Shimazoe

    13 ( 4 )   555869   2022.4

  • Comprehensive analysis of everolimus-induced adverse events using the Japanese real-world database. Reviewed International journal

    Mayako Uchida, Kana Nakano, Masaki Fujiwara, Yoshihiro Uesawa, Tadashi Shimizu

    Journal of clinical pharmacy and therapeutics   47 ( 8 )   1173 - 1180   2022.3

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

    WHAT IS KNOWN AND OBJECTIVES: As for adverse events (AEs) caused by everolimus, findings from clinical trials and post-marketing surveillance have reported interstitial lung disease, hyperglycaemia, cardiovascular disease, etc. However, these reports are limited to incidence, and detailed studies on the risk of occurrence, time to onset and post-event clinical outcomes are only related to hyperglycaemia. The purpose of this study was to perform a comprehensive analysis of adverse events during everolimus therapy in patients with renal cell carcinoma (RCC) using the Japanese Adverse Event Report database. METHODS: Data reported between April 2004 and June 2021 in the Japanese Adverse Drug Event Report database were extracted for use. The reported odds ratio, time to onset and post-event course were analysed for the top 30 adverse events reported. RESULTS AND DISCUSSION: Among the top 30 adverse events, 23 adverse event signals were detected and classified into seven categories: lung-related AEs, haematological-related AEs, cancer progression, blood glucose-related AEs, hepatic-related AEs, renal-related AEs and others. The lung-related adverse events category was the most common, and the proportion of fatal outcomes after the occurrence of two adverse events related to infectious pneumonia was more than 10%. WHAT IS NEW AND CONCLUSION: A comprehensive survey of adverse events associated with everolimus administration using the pharmacovigilance database revealed that pulmonary and haematological AEs are frequently reported. The results suggest that attention should be paid to the occurrence of lung disorders because they may lead to fatal outcomes.

    DOI: 10.1111/jcpt.13648

    PubMed

  • 薬局薬剤師を対象とした無菌調製実技セミナーに関する生涯教育の有用性

    音窪 麻衣, 内田 まやこ, 井上 薫, 金 美惠子, 河合 悦子, 中村 敏明

    大阪医科薬科大学薬学部雑誌   1   119 - 125   2022.3

     More details

    Language:Japanese   Publisher:大阪医科薬科大学薬学部  

    無菌調製実技セミナーの受講者を対象に、受講前、セミナー第1部受講後(座学講義および基礎実技)、第2部受講後(応用実技等)に質問紙調査を実施し、セミナーの有用性について評価、検討した。受講者は11名(勤務年数10年以上7名、5年以上10年未満2名、1年から5年未満1名、無回答1名)であり、調査用紙は全員から回収された。セミナーの満足度は無菌調製に必要な基本的な知識や基礎実技に対しての満足度は、「満足」5名、「やや満足」2名であった。クリーンベンチを使用した無菌操作を伴った実技での満足度は「満足」8名、「やや満足」との回答はなかった。セミナーの難易度は第1部、第2部ともに「難しい」と回答した受講者が半数以上となった。セミナーの活用度については「非常に役に立つ」7名、「役に立つ」4名との回答で、「役に立たない」との回答はなかった。実施したセミナーの意義は高く、有用であったと考えられた。

  • 薬局薬剤師を対象とした無菌調製実技セミナーに関する生涯教育の有用性 Reviewed

    音窪麻衣, 内田まやこ, 井上薫, 金美惠子, 河合悦子, 中村敏明

    大阪医科薬科大学薬学部紀要   1   119 - 125   2022.1

     More details

    Language:Japanese   Publisher:大阪医科薬科大学薬学部  

    無菌調製実技セミナーの受講者を対象に、受講前、セミナー第1部受講後(座学講義および基礎実技)、第2部受講後(応用実技等)に質問紙調査を実施し、セミナーの有用性について評価、検討した。受講者は11名(勤務年数10年以上7名、5年以上10年未満2名、1年から5年未満1名、無回答1名)であり、調査用紙は全員から回収された。セミナーの満足度は無菌調製に必要な基本的な知識や基礎実技に対しての満足度は、「満足」5名、「やや満足」2名であった。クリーンベンチを使用した無菌操作を伴った実技での満足度は「満足」8名、「やや満足」との回答はなかった。セミナーの難易度は第1部、第2部ともに「難しい」と回答した受講者が半数以上となった。セミナーの活用度については「非常に役に立つ」7名、「役に立つ」4名との回答で、「役に立たない」との回答はなかった。実施したセミナーの意義は高く、有用であったと考えられた。

  • Evaluation of a Webinar for Pharmacists Learning Basic Clinical-Oncology during COVID-19 Pandemic in Japan. Reviewed

    Hideyuki Terazono, Masami Tsuchiya, Yosuke Maki, Naoki Yoshikawa, Yosuke Kawahara, Keiko Nishimura, Keisuke Shinohara, Daisuke Ogawa, Riho Mori, Yoshihiro Iwamoto, Fumio Itagaki, Hiroyuki Masuko, Masahito Yonemura, Mayako Uchida

    Biological & pharmaceutical bulletin   45 ( 7 )   856 - 862   2022

     More details

    Authorship:Last author   Language:English   Publishing type:Research paper (scientific journal)  

    It is essential for oncology pharmacists to update their knowledge, skills, and ethical attitudes. The Japanese Society of Pharmaceutical Oncology is an academic society for healthcare professionals involved in cancer treatment. It has conducted in-person seminars every year to cultivate the knowledge necessary for practicing advanced cancer medicine. Owing to the coronavirus disease (COVID-19) pandemic, the society was obligated to conduct a web-based seminar this year. A questionnaire survey was conducted before and after the webinar to explain how it works and to assess the learning attitudes of beginner and moderately skilled pharmacists in the field of oncology. Questionnaire surveys were conducted with the participants before and after watching the webinar. The questionnaires sought to determine participants' perspectives on the webinar and their knowledge of the seven modules. Of the 1756 webinar attendees, 1661 (94.6%) answered the pre-webinar survey and 1586 (90.3%) answered the post-webinar survey. Results indicate that the median post-webinar knowledge score was significantly higher than the median pre-webinar score (p < 0.001) in all modules. Principal component analysis of the degree of knowledge of seven modules revealed that the improved score group consisted of those from younger age groups, with less experience as pharmacists, non-society members, and those with less experience in past society seminars. Moreover, the web-based seminar provided a uniform learning effect throughout the country without distinguishing between urban and rural learners. The web-based educational program was an acceptable educational tool for Japanese oncology pharmacists.

    DOI: 10.1248/bpb.b21-00844

    PubMed

  • Factors associated with non-response to naldemedine for opioid-induced constipation in cancer patients: A subgroup analysis. Reviewed International journal

    Yuko Kanbayashi, Mayumi Shimizu, Yuichi Ishizuka, Shohei Sawa, Katsushige Yabe, Mayako Uchida

    PloS one   17 ( 12 )   e0278823   2022

     More details

    Authorship:Last author   Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Opioid-induced constipation (OIC) is one of the most common adverse events of opioid therapy and can severely reduce quality of life (QOL). Naldemedine is the orally available peripheral-acting μ-opioid receptor antagonist approved for OIC treatment. However in daily clinical practice, some cancer patients show insufficient control of OIC even while receiving naldemedine. OBJECTIVE: To identify factors associated with non-response to naldemedine in cancer patients. METHODS: This study retrospectively analyzed 127 cancer patients prescribed naldemedine at Seirei Hamamatsu General Hospital in Japan between November 2016 and June 2021. For the regression analysis of factors associated with OIC, variables were extracted manually from electronic medical records. Naldemedine had been prescribed by the attending physician after the presence of OIC had been defined with reference to Rome IV diagnostic criteria. Naldemedine was evaluated as "effective" in cases where the number of defecations increased at least once in the first 3 days after starting naldemedine. Multivariate logistic regression analysis was performed to identify factors associated with non-response to naldemedine. The data used were from the group of patients who received naldemedine in our previous study. RESULTS: Factors significantly associated with non-response to naldemedine included chemotherapy with taxanes within 1 month of evaluation of naldemedine effect (odds ratio [OR] = 0.063; 95% confidence interval [CI] = 0.007-0.568), and addition of or switching to naldemedine due to insufficient efficacy of prior laxatives (OR = 0.352, 95% CI = 0.129-0.966). CONCLUSION: The identification of factors associated with non-response to naldemedine prescribed for OIC may help improve QOL among cancer patients.

    DOI: 10.1371/journal.pone.0278823

    PubMed

  • Evaluation of Cardiac Adverse Events Associated with Carfilzomib Using a Japanese Real-World Database. Reviewed International journal

    Shuhei Nakao, Mayako Uchida, Aya Satoki, Kenya Okamoto, Yoshihiro Uesawa, Tadashi Shimizu

    Oncology   100 ( 1 )   60 - 64   2022

     More details

    Language:English  

    BACKGROUND: Carfilzomib is a proteasome inhibitor widely used for the treatment of multiple myeloma. However, cardiac adverse events (CAEs) are a serious side effect of carfilzomib administration. Observational studies based on systematic reviews and real-world data have revealed that the risk of CAEs tends to be high. However, there have been no reports on the incidence of CAEs associated with carfilzomib in Japanese patients. Furthermore, there have been no reports on the timing and post-event outcomes of CAEs. OBJECTIVES: The purpose of this study was to identify the trends in carfilzomib-associated adverse events, the time to onset of CAEs, and the clinical outcomes after the occurrence of CAEs using the Japanese Adverse Drug Event Report (JADER) database. METHOD: We analyzed data from the JADER database, which contains reports of spontaneous adverse events submitted to the Pharmaceutical and Medical Device Agency, between April 2004 and December 2020. The relative risk of adverse events was estimated using the reporting odds ratio. The time to onset and post-event outcomes were evaluated for adverse cardiotoxic events with >10 reports. RESULTS: The reporting rate was significantly higher for all 6 detected CAEs. A time-to-onset histogram of the 6 CAEs showed that they all occurred early after carfilzomib administration. The median time of onset of heart failure, congestive heart failure, and acute heart failure was approximately 2 weeks after treatment. The adverse events with the largest proportion of fatal clinical outcomes were acute heart failure (26%) and heart failure (9.5%). CONCLUSIONS: This study suggests that the early signs and symptoms of potential fatal heart failure should be monitored during carfilzomib treatment.

    DOI: 10.1159/000519687

    PubMed

  • Comprehensive Analysis of Bortezomib-Induced Adverse Events Using the Japanese Real-World Database. Reviewed International journal

    Aya Satoki, Mayako Uchida, Masaki Fujiwara, Yoshihiro Uesawa, Tadashi Shimizu

    Oncology   100 ( 3 )   188 - 194   2021.12

     More details

    Language:English  

    BACKGROUND: Bortezomib is used as first-line therapy for multiple myeloma. Observational studies based on the FDA Adverse Event Reporting System (FAERS) database analysis and systematic reviews indicate that the incidence of peripheral neuropathy and tumor lysis syndrome (TLS) tends to be higher with bortezomib than that of other drugs. In a comprehensive analysis assessing drugs that cause peripheral neuropathy in Japanese patients, the incidence of bortezomib-induced adverse events (AEs) was reportedly high. However, a comprehensive assessment of bortezomib is lacking. OBJECTIVES: The purpose of this study was to determine the frequency of bortezomib AEs in Japanese patients and to determine the incidence, time to onset, and post hoc outcomes of unique AEs using the Japanese Adverse Drug Event Report (JADER) database. METHOD: To investigate the association between bortezomib and AEs, we analyzed the JADER database, which contains spontaneous AE reports submitted to the Pharmaceuticals and Medical Devices Agency from April 2004 to December 2020. Criteria indicating the presence of an AE signal were met when the following requirements were fulfilled: proportional reporting ratios (PRR) ≥ 2 and χ2 ≥ 4. Time to onset and post-event outcomes were analyzed for characteristic AEs. RESULTS: Among 26 extracted AEs, 13 presented AE signals. The post-exposure outcomes of 12 AEs showed fatal outcomes at rates exceeding 10%, including cardiac failure (30%), lung disorder (24%), pneumonia (18%), and TLS (10%). Furthermore, a histogram of time to onset revealed that the 12 AEs were concentrated from the beginning to approximately one month after bortezomib administration. The median onset times for cardiac failure, lung disorder, pneumonia, and TLS were 28, 13, 42, and 5 days, respectively. CONCLUSIONS: Cardiac failure, lung disorder, pneumonia, and TLS had a higher rate of fatal clinical outcomes after onset than other AEs. These AEs exhibited a greater onset tendency in the early post-dose period. This study suggests that there is a need to monitor signs of cardiac failure, lung disorder, pneumonia, and TLS, potentially resulting in serious outcomes.

    DOI: 10.1159/000521448

    PubMed

  • Evaluation of a web-based educational programme for pharmacists during the COVID-19 pandemic in Japan. Reviewed International journal

    Masami Tsuchiya, Hideyuki Terazono, Yosuke Maki, Naoki Yoshikawa, Yosuke Kawahara, Keiko Nishimura, Keisuke Shinohara, Daisuke Ogawa, Riho Mori, Yoshihiro Iwamoto, Fumio Itagaki, Hiroyuki Masuko, Masahito Yonemura, Mayako Uchida

    Journal of clinical pharmacy and therapeutics   46 ( 6 )   1743 - 1749   2021.9

     More details

    Authorship:Last author   Language:English   Publishing type:Research paper (scientific journal)  

    WHAT IS KNOWN AND OBJECTIVE: Continuing education is essential for pharmacists to acquire and maintain the knowledge, skills, and ethical attitudes necessary for clinical practice. However, with the emergence of COVID-19, the social circumstances and face-to-face learning environments have changed. The objectives of this study were to determine Japanese pharmacists' perception of a web-based educational programme in oncology, and assess changes in their understanding of pharmaceutical care in oncology before and after their participation in the webinar. METHODS: Questionnaire-based surveys were conducted for the participants of the web-based educational programme to determine their perspectives on the webinar, and their degree of comprehension of the five cancer types covered before and after watching the webinar. RESULTS AND DISCUSSION: Of the 1936 pharmacists taking the programme, all participated in the pre-webinar survey, and 1861 (96.1%) in the post-webinar survey. Compared with previous seminars that were held in the offline mode before the COVID-19 pandemic, 76.8% of respondents were significantly satisfied with the web-based educational programme. The median post-webinar comprehension scores in all modules were significantly higher than the median pre-webinar scores (p < 0.0001). A majority of the participants agreed that a web-based educational programme was satisfactory in acquiring knowledge. WHAT IS NEW AND CONCLUSION: This web-based educational programme was effective for Japanese pharmacists for postgraduate education in pharmaceutical care in oncology. To the best of our knowledge, our study is the first to report the effectiveness of a web-based educational programme for oncology pharmacists using a large population.

    DOI: 10.1111/jcpt.13526

    PubMed

  • Preclinical and Clinical Evidence of Therapeutic Agents for Paclitaxel-Induced Peripheral Neuropathy. Reviewed International journal

    Takehiro Kawashiri, Mizuki Inoue, Kohei Mori, Daisuke Kobayashi, Keisuke Mine, Soichiro Ushio, Hibiki Kudamatsu, Mayako Uchida, Nobuaki Egashira, Takao Shimazoe

    International journal of molecular sciences   22 ( 16 )   2021.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Paclitaxel is an essential drug in the chemotherapy of ovarian, non-small cell lung, breast, gastric, endometrial, and pancreatic cancers. However, it frequently causes peripheral neuropathy as a dose-limiting factor. Animal models of paclitaxel-induced peripheral neuropathy (PIPN) have been established. The mechanisms of PIPN development have been elucidated, and many drugs and agents have been proven to have neuroprotective effects in basic studies. In addition, some of these drugs have been validated in clinical studies for their inhibitory PIPN effects. This review summarizes the basic and clinical evidence for therapeutic or prophylactic effects for PIPN. In pre-clinical research, many reports exist of neuropathy inhibitors that target oxidative stress, inflammatory response, ion channels, transient receptor potential (TRP) channels, cannabinoid receptors, and the monoamine nervous system. Alternatively, very few drugs have demonstrated PIPN efficacy in clinical trials. Thus, enhancing translational research to translate pre-clinical research into clinical research is important.

    DOI: 10.3390/ijms22168733

    PubMed

  • Analysis of secondary leukemia and myelodysplastic syndrome after chemotherapy for solid organ tumors using the food and drug administration adverse event reporting system (Faers)

    Takehiro Kawashiri, Daisuke Kobayashi, Mayako Uchida, Shiori Hiromoto, Masashi Inoue, Hajime Ikeda, Mizuki Inoue, Takao Shimazoe

    Journal of Pharmacy and Pharmaceutical Sciences   24   499 - 508   2021.7   ISSN:1482-1826

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Canadian Society for Pharmaceutical Sciences  

    Purpose: As the prognosis of cancer patients deteriorates, secondary carcinogenesis after chemotherapy, especially secondary hematological malignancies, becomes a serious problem. However, information on the frequency and time of onset of secondary hematological malignancies and the risk of hematological malignancy with different drugs is scarce. This study aimed to evaluate the incidence of leukemia and myelodysplastic syndrome in patients with solid tumors, including breast, colon, gastric, pancreatic, small cell lung, non-small cell lung, esophageal, ovarian, cervical, and endometrial cancers. Methods: Using the United States Food and Drug Administration Adverse Event Reporting System, we analyzed the reporting rates, reporting odds ratios, and the reporting onset times of secondary leukemia and myelodysplastic syndrome for each drug used. Results: The leukemia reporting rates were higher in breast, small cell lung, ovarian, and endometrial cancers than in other cancers, and the myelodysplastic syndrome reporting rates were higher in ovarian and endometrial cancers than in other cancers. For each cancer type, the reporting odds ratios of cytocidal anticancer agents, such as taxanes, anthracyclines, alkylating agents, platinum, and topoisomerase inhibitors, were higher than those of other drugs. Alternatively, the reporting odds ratios of molecular targeted drugs and immune checkpoint inhibitors were not higher than those of other drugs. Approximately half of the cases of leukemia and myelodysplastic syndrome were reported within 1 to 4 years after chemotherapy. Conclusions: Our study clarified the risks of leukemia and myelodysplastic syndrome for several anticancer drugs in patients with solid tumors. Our data may aid in the assessment of the risks of secondary leukemia and myelodysplastic syndrome when medical oncologists, clinical pharmacists, and patients select chemotherapy regimens.

    DOI: 10.18433/jpps31862

    Scopus

    PubMed

  • [Application of artificial intelligence for the prediction of health examination results of workers: A pilot study].

    Uchida M, Tsutsui Y, Noshita K, Koyama H

    Sangyo eiseigaku zasshi = Journal of occupational health   63 ( 3 )   95 - 98   2021.5   ISSN:1341-0725

     More details

    Language:Japanese  

    DOI: 10.1539/sangyoeisei.2020-031-C

    PubMed

  • Use of omeprazole, the proton pump inhibitor, as a potential therapy for the capecitabine-induced hand-foot syndrome. Reviewed International journal

    Shiori Hiromoto, Takehiro Kawashiri, Natsumi Yamanaka, Daisuke Kobayashi, Keisuke Mine, Mizuki Inoue, Mayako Uchida, Takao Shimazoe

    Scientific reports   11 ( 1 )   8964 - 8964   2021.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Hand-foot syndrome (HFS), also known as palmar-plantar erythrodysesthesia (PPE), is a major side effect of capecitabine. Although the pathogenesis of HFS remains unknown, some studies suggested a potential involvement of inflammation in its pathogenesis. Proton pump inhibitors (PPIs) have been reported to have anti-inflammatory effects. In this study, we investigated the ameliorative effects of omeprazole, a PPI on capecitabine-related HFS in mice model, and a real-world database. Repeated administration of capecitabine (200 mg/kg, p.o., five times a week for 3 weeks) increased fluid content, redness, and tumor necrosis factor (TNF)-α substance of the mice hind paw. Co-administration of omeprazole (20 mg/kg, p.o., at the same schedule) significantly inhibited these changes induced by capecitabine. Moreover, based on the clinical database analysis of the Food and Drug Administration Adverse Event Reporting System, the group that has used any PPIs had a lower reporting rate of capecitabine-related PPE than the group that has not used any PPIs. (6.25% vs. 8.31%, p < 0.0001, reporting odds ratio (ROR) 0.74, 95% confidence interval (CI) 0.65-0.83). Our results suggest that omeprazole may be a potential prophylactic agent for capecitabine-induced HFS.

    DOI: 10.1038/s41598-021-88460-9

    PubMed

  • Association between a low dose of proton pump inhibitors and kidney function decline in elderly hypertensive patients: a retrospective observational study. Reviewed International journal

    Tomohito Wakabayashi, Keiko Hosohata, Saki Oyama, Ayaka Inada, Iku Niinomi, Hiroko Kambara, Tatsuya Iida, Keiko Hasebe, Hiroyuki Matsuoka, Mayako Uchida, Etsuko Kumagai

    The Journal of international medical research   49 ( 4 )   3000605211006653 - 3000605211006653   2021.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVES: Proton pump inhibitors (PPIs) are widely used for acid suppression therapy. Recently, PPI use was reported to be associated with chronic kidney disease (CKD); however, whether a low dose of PPIs is associated with CKD remains unknown. METHODS: This retrospective observational study included hypertensive patients who visited Kenwakai Hospital between 2017 and 2019. Renal parameters, such as the estimated glomerular filtration rate (eGFR) and serum creatinine (Scr), were extracted from medical records and compared between three years before treatment and the baseline. PPI use was assessed as cumulative exposure for three years. RESULTS: The study population included 152 patients (57.9% men; mean age, 74.5 years). Of those, 35.5% were PPI users (low dose, 17.1%; high dose, 18.4%). A significant decrease in eGFR and an increase in Scr were observed between three years before treatment and the baseline in the high-dose PPI group but not the non-use or low-dose PPI groups. CONCLUSIONS: Our results suggest that a low dose of PPIs may be safe in clinical settings, but further prospective studies are needed to clarify our findings.

    DOI: 10.1177/03000605211006653

    PubMed

  • Evaluation of changes in pharmacist behaviors following a systematic education program on palliative care in cancer. Reviewed International journal

    Masahiro Yamada, Mayako Uchida, Masao Hada, Daigo Inma, Shunji Ariyoshi, Hidetoshi Kamimura, Tohru Haraguchi

    Currents in pharmacy teaching & learning   13 ( 4 )   417 - 422   2021.4

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND AND PURPOSE: Attitudes, experience, and knowledge of healthcare professionals guide the care they provide and are particularly important factors affecting the quality of palliative care. Palliative care education for pharmacists is crucial for improving quality of care and effective participation on the palliative care team. EDUCATIONAL ACTIVITY AND SETTING: We previously developed and reported a systematic and multifaceted pharmacist education program for cancer-related palliative care. We compared 12 behavioral changes immediately (August 2017) and two years after (October 2019) participation in this systematic education program (SEP) to evaluate if participants were performing pharmaceutical management appropriately and to assure that behaviors had not deteriorated. FINDINGS: Of 88 participants in the SEP, 36 responded to the survey (response rate 40.9%). There was no significant difference in the behavioral change items of pharmacists immediately after participating in the SEP (2017) and two years later (2019) (4.47 vs. 4.58, P = .47). SUMMARY: We confirmed that behavioral changes developed by the SEP were maintained over a significant time. This indicates that knowledge was firmly established in the participants such that they could continue utilizing it long after participating in the SEP. Our study showed that participating in this SEP not only enabled participants to acquire knowledge regarding palliative medicine but also led to continued behavioral changes based on this knowledge.

    DOI: 10.1016/j.cptl.2020.11.014

    PubMed

  • Drug-induced neuropsychiatric adverse events using post-marketing surveillance. Reviewed International journal

    Tomohito Wakabayashi, Takahiro Nakatsuji, Hiroko Kambara, Iku Niinomi, Saki Oyama, Ayaka Inada, Sayaka Ueno, Mayako Uchida, Kazunori Iwanaga, Tatsuya Iida, Keiko Hosohata

    Current clinical pharmacology   17 ( 2 )   144 - 148   2021.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Several studies reported that abnormal behavior was noted in pediatric patients receiving several drugs, including neuraminidase inhibitors (NIs). However, the information on drugs associated with abnormal behavior in a real-world setting remains limited. The purpose of this study was to clarify the drugs associated with abnormal behavior using a spontaneous reporting system database. METHODS: We performed a retrospective pharmacovigilance disproportionality analysis using the Japanese Adverse Drug Event Report database. Adverse event reports submitted to the Pharmaceuticals and Medical Devices Agency were analyzed, and the reporting odds ratio at 95% confidence interval
    were calculated. RESULTS: A total of 1,144 reports of abnormal behavior were identified. The signals were detected through the association of 4 neuraminidase inhibitors (oseltamivir, zanamivir, laninamivir, and peramivir) with the abnormal behaviour. These signals were stronger for oseltamivir than other neuraminidase inhibitors. The signals were also detected for acetaminophen and montelukast. CONCLUSION: Our results should be able to raise physicians’ awareness of drugs associated with abnormal behavior, but further investigation of these medications is warranted.

    DOI: 10.2174/1574884716666210215104540

    PubMed

  • Analgesic Effects of Sokeikakketsuto on Chemotherapy-Induced Mechanical Allodynia and Cold Hyperalgesia in Rats

    Nakamura Hiroko, Kawashiri Takehiro, Kobayashi Daisuke, Uchida Mayako, Egashira Nobuaki, Shimazoe Takao

    Biological and Pharmaceutical Bulletin   44 ( 2 )   271 - 274   2021.2   ISSN:09186158 eISSN:13475215

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:The Pharmaceutical Society of Japan  

    <p>The anticancer agents including oxaliplatin, paclitaxel, and bortezomib cause severe peripheral neuropathy. The Kampo medicine Sokeikakketsuto (SOKT) has been widely used to treat several types of pain. In this study, the analgesic effects of SOKT on oxaliplatin-, paclitaxel-, and bortezomib-induced peripheral neuropathy were investigated in rat models. Rats were treated with oxaliplatin (4 mg/kg, intraperitoneally (i.p.), twice a week for four weeks), paclitaxel (4 mg/kg, i.p., twice a week for two weeks), or bortezomib (0.2 mg/kg, i.p., twice a week for two weeks). SOKT (0.3 or 1.0 g/kg) or duloxetine hydrochloride (30 mg/kg, as a positive control) was administered orally after neuropathy developed. Mechanical allodynia and cold hyperalgesia were assessed using the von Frey test and the acetone test, respectively. These tests were performed immediately before and 30, 60, 90, and 120 min after the administration of the drugs. Repeated treatment of oxaliplatin induced mechanical allodynia and cold hyperalgesia. A single administration of SOKT (1 g/kg, <i>per os </i>(<i>p.o.</i>)), as well as duloxetine, temporarily reversed both the mechanical allodynia and the cold hyperalgesia. Repeated administration of paclitaxel and bortezomib also induced the mechanical allodynia. SOKT and duloxetine reversed the mechanical allodynia caused by bortezomib, but not by paclitaxel. SOKT might have the potential to become a new drug to relieve the symptom of oxaliplatin- or bortezomib-induced peripheral neuropathy.</p>

    DOI: 10.1248/bpb.b20-00620

    PubMed

    CiNii Research

  • ラットにおける化学療法誘発性機械的アロディニアおよび冷痛覚過敏症に対する疎経活血湯の鎮痛効果(Analgesic Effects of Sokeikakketsuto on Chemotherapy-Induced Mechanical Allodynia and Cold Hyperalgesia in Rats)

    Nakamura Hiroko, Kawashiri Takehiro, Kobayashi Daisuke, Uchida Mayako, Egashira Nobuaki, Shimazoe Takao

    Biological & Pharmaceutical Bulletin   44 ( 2 )   271 - 274   2021.2   ISSN:0918-6158

     More details

    Language:English   Publisher:(公社)日本薬学会  

    オキサリプラチン(OXA)やパクリタキセル(PAC)、ボルテゾミブ(BOR)誘発末梢神経障害に対する漢方薬の疎経活血湯(SOKT)の鎮痛効果をラットで調べた。神経障害の発症後、SOKT(0.3または1.0g/kg)または塩酸デュロキセチン(DXT、30mg/kg、陽性対照)を経口投与した。OXAの反復投与は、機械的アロディニア(MA)と冷痛覚過敏症(CH)を誘発した。SOKT(1.0g/kg)およびDXTの単回投与は、一時的にMAとCHの両者を改善した。PACとBORの反復投与もMAを誘発した。SOKTとDXTは、BORによるMAを改善したが、PACによるMAについては効果がみられなかった。SOKTは、OXAまたはBOR誘発性末梢神経障害の症状緩和に役立つ可能性があると考えられた。

  • Therapeutic Agents for Oxaliplatin-Induced Peripheral Neuropathy; Experimental and Clinical Evidence. Reviewed International journal

    Takehiro Kawashiri, Keisuke Mine, Daisuke Kobayashi, Mizuki Inoue, Soichiro Ushio, Mayako Uchida, Nobuaki Egashira, Takao Shimazoe

    International journal of molecular sciences   22 ( 3 )   2021.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Oxaliplatin is an essential drug in the chemotherapy of colorectal, gastric, and pancreatic cancers, but it frequently causes peripheral neuropathy as a dose-limiting factor. So far, animal models of oxaliplatin-induced peripheral neuropathy have been established. The mechanisms of development of neuropathy induced by oxaliplatin have been elucidated, and many drugs and agents have been proven to have neuroprotective effects in basic studies. In addition, some of these drugs have been validated in clinical studies for their inhibitory effects on neuropathy. In this review, we summarize the basic and clinical evidence for the therapeutic effects of oxaliplatin. In basic research, there are many reports of neuropathy inhibitors that target oxidative stress, inflammatory response, sodium channel, transient receptor potential (TRP) channel, glutamate nervous system, and monoamine nervous system. Alternatively, very few drugs have clearly demonstrated the efficacy for oxaliplatin-induced peripheral neuropathy in clinical trials. It is important to activate translational research in order to translate basic research into clinical research.

    DOI: 10.3390/ijms22031393

    PubMed

  • Pharmacovigilance Evaluation of Bendamustine-related Skin Disorders using the Japanese Adverse Drug Event Report Database. Reviewed International journal

    Mayako Uchida, Takehiro Kawashiri, Nami Maegawa, Aoi Takano, Keiko Hosohata, Yoshihiro Uesawa

    Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques   24   16 - 22   2021

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: Bendamustine is used in hematologic malignancies such as non-Hodgkin lymphoma, chronic lymphocytic leukemia, and multiple myeloma. This study evaluated the association of bendamustine-related skin disorders using the Japanese Adverse Drug Event Report (JADER) database. METHODS: We identified and analyzed reports of skin disorders between April 2004 and November 2019 from the JADER database and calculated the reported odds ratios (RORs) using disproportionality analysis. Additionally, we analyzed the relationship between skin disorders related to bendamustine use and patient information (age and sex). RESULTS: The symptoms, ranked in order of decreasing strength of association with skin disorders, were infusion-related reaction (ROR=5.708), herpes zoster (ROR=4.658), hypersensitivity (ROR=3.271), and rash (ROR=1.472). Additionally, analysis of the relationships between rash related to bendamustine and sex or age showed significant relationships for female sex and age younger than 70 years (ROR=2.247 and 2.176, respectively). Meanwhile, analysis of the relationship between herpes zoster and sex showed a significantly stronger association for male than female sex (ROR=2.887). CONCLUSION: Our analysis of skin disorders related to bendamustine use reported in the spontaneous reporting system databases showed that the association of rash with bendamustine use was affected by sex (female) and age (younger than 70 years). Additionally, the association of herpes zoster with bendamustine was affected by sex (male). Bendamustine is an outpatient chemotherapy regimen, and so we recommend close monitoring of female patients or those younger than 70 years who experience rash-like symptoms and male patients who experience herpes zoster-like symptoms.

    DOI: 10.18433/jpps31597

    PubMed

  • 非ホジキンリンパ腫患者におけるベンダムスチンを用いた化学療法に関連する皮膚毒性の危険因子(Risk Factors for Skin Toxicities Associated with Bendamustine-Based Chemotherapy in Patients with Non-Hodgkin Lymphoma)

    Uchida Mayako, Mori Yasuhiro, Akiba Kenta, Miyasaka Moena, Hirano Tatsuya, Ikesue Hiroaki, Yamaguchi Yuki, Takano Aoi, Maegawa Nami, Shimomura Yoshimitsu, Hosohata Keiko, Muroi Nobuyuki, Ishikawa Takayuki, Hashida Tohru, Nakamura Tsutomu

    Biological & Pharmaceutical Bulletin   43 ( 10 )   1577 - 1582   2020.10   ISSN:0918-6158

     More details

    Language:English   Publisher:(公社)日本薬学会  

    非ホジキンリンパ腫(NHL)患者について、ベンダムスチン(Ben)投与による皮膚毒性と関連のある因子を調べた。2011年4月~2018年3月にNHLと診断され、Ben単独またはリツキシマブ併用(BR)療法を受けた20歳以上の患者95名(男46名、女49名、年齢中央値69歳)を対象に、カルテから患者背景と治療前の特徴を後ろ向きに調べ、皮膚毒性の予測因子について検討した。多変量ロジスティック回帰解析より、ベースラインの化学療法の非治療歴が皮膚毒性の発生に影響を与える要因であった。グレード3以上の重篤な副作用を経験した患者はいないことから、Benは一次治療として極めて有用と考えられた。

  • Risk factors for febrile neutropenia induced by docetaxel chemotherapy in patients with non-small cell lung cancer Reviewed

    Mayako Uchida, Yuki Yamaguchi, Syuhei Hosomi, Hiroaki Ikesue, Yasuhiro Mori, Nami Maegawa, Aoi Takano, Yuki Sato, Keiko Hosohata, Nobuyuki Muroi, Keisuke Tomii, Tohru Hashida, Tsutomu Nakamura

    Biol Pharm Bull.   43 ( 8 )   1235 - 1240   2020.8

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    We retrospectively obtained data of patient background and pretreatment characteristics from medical records and identified the predictive factors of febrile neutropenia (FN) in patients with non-small cell lung cancer (NSCLC) treated with docetaxel alone or in combination with the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab. Patients were eligible for inclusion in the study if they were 20 years or older, diagnosed with NSCLC, and received docetaxel monotherapy alone or in combination with bevacizumab at the Department of Respiratory Medicine, Kobe City Medical Center General Hospital, between July 1, 2011, and March 31, 2018. Eighty-one patients with recurrent or advanced NSCLC were included. Multivariate stepwise logistic regression analysis with backward selection revealed that lower baseline Eastern Cooperative Oncology Group performance status (ECOG-PS) scores of 1 and 2 (odds ratio (OR), 5.098; 95% confidence interval (CI), 1.045-24.879, p = 0.021) and baseline platelet count below 18.8 × 104/µL (OR, 3.861; 95% CI, 1.211-12.311, p = 0.022) were significant factors influencing the FN occurrence rate. Our results demonstrated that ECOG-PS 1-2 and lower baseline platelet count were significant risk factors of FN in patients with NSCLC receiving docetaxel-based chemotherapy. Moreover, the combination of anti-VEGF antibodies and docetaxel might be associated with increased FN frequency. Despite the limitations of this study including its retrospective design, single-center site, and small sample size, baseline ECOG-PS score and platelet count may be regarded as important indices to identify patients for prophylactic granulocyte-colony stimulating factor (G-CSF) treatment before docetaxel-based chemotherapy.

    DOI: 10.1248/bpb.b20-00266

    PubMed

  • 非小細胞肺癌患者のドセタキセル化学療法により誘発される発熱性好中球減少症の危険因子(Risk Factors for Febrile Neutropenia Induced by Docetaxel Chemotherapy in Patients with Non-small Cell Lung Cancer)

    Uchida Mayako, Yamaguchi Yuki, Hosomi Syuhei, Ikesue Hiroaki, Mori Yasuhiro, Maegawa Nami, Takano Aoi, Sato Yuki, Hosohata Keiko, Muroi Nobuyuki, Tomii Keisuke, Hashida Tohru, Nakamura Tsutomu

    Biological & Pharmaceutical Bulletin   43 ( 8 )   1235 - 1240   2020.8   ISSN:0918-6158

     More details

    Language:English   Publisher:(公社)日本薬学会  

    医療記録から患者背景と治療前特性のデータを後ろ向きに収集し、ドセタキセル(DTX)単独またはベバシズマブ(BEV)との併用で治療した非小細胞肺癌(NSCLC)患者における発熱性好中球減少症(FN)予測因子を特定した。2011年7月~2018年3月に、20歳以上でNSCLCと診断され、DTX単独療法またはBEVとの併用療法を受けた患者81名(男51名、女30名)を対象とした。FN発症の有無により2群に分け、多変量回帰分析を行った。その結果、ベースラインのEastern Cooperative Oncology Group performance statusスコアが1および2と低く、ベースラインの血小板数が18.8×10^4/μL未満であることが、FNの発症率に影響する因子であった。

  • Risk factors for skin toxicities associated with bendamustine-based chemotherapy in patients with non-Hodgkin lymphoma Reviewed

    Mayako Uchida, Yasuhiro Mori, Kenta Akiba, Moena Miyasaka, Tatsuya Hirano, Hiroaki Ikesue, Yuki Yamaguchi, Aoi Takano, Nami Maegawa, Yoshimitsu Shimomura, Keiko Hosohata, Nobuyuki Muroi, Takayuki Ishikawa, Tohru Hashida, Tsutomu Nakamura

    Biol Pharm Bull.   43 ( 10 )   1577 - 1582   2020.8

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    Bendamustine plays an especially important role as a treatment for non-Hodgkin lymphoma (NHL). However, patients administered bendamustine alone or in combination with rituximab (BR) may experience drug-associated skin toxicities that can profoundly impact their health-related QOL through both physical discomfort and psychological distress. Moreover, worsening skin symptoms may lead to dose reduction or termination in the management of cancer chemotherapy. We retrospectively investigated patient backgrounds and pretreatment characteristics from medical records of NHL patients treated with bendamustine alone or BR therapy and identified predictive factors for skin toxicities at the start of chemotherapy. Patients were eligible for the study if they were 20 years older, diagnosed with NHL, and received bendamustine alone or BR therapy at the Department of Hematology, Kobe City Medical Center General Hospital, between April 1, 2011, and March 31, 2018. This study included 95 patients with newly diagnosed or refractory or relapsed NHL. Multivariate stepwise logistic regression analysis with backward selection revealed that baseline non-prior chemotherapy (odds ratio (OR), 15.72; 95% confidence interval (CI), 4.24-83.13, p < 0.001) was a significant factor influencing the occurrence of skin toxicity. Our results demonstrated that non-prior chemotherapy was a significant risk factor for skin toxicities in patients with NHL receiving bendamustine alone or BR therapy. No patient experience serious side effects of grade 3 or higher and that bendamustine is very useful as a first-line treatment.

    DOI: 10.1248/bpb.b20-00428

    PubMed

  • Neuroprotective effect of alogliptin on oxaliplatin-induced peripheral neuropathy in vivo and in vitro Reviewed International journal

    Nao Shigematsu, Takehiro Kawashiri, Daisuke Kobayashi, Shiori Shimizu, Keisuke Mine, Shiori Hiromoto, Mayako Uchida, Nobuaki Egashira, Takao Shimazoe

    Scientific reports   10 ( 1 )   6734 - 6734   2020.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Oxaliplatin is a platinum-based antineoplastic drug commonly used for treating colorectal, gastric, and pancreatic cancer. However, it frequently causes peripheral neuropathy as dose-limiting toxicity and is lacking a strategy for prevention. Alogliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, is an oral antidiabetic drug. Previous studies have shown that DPP-4 inhibitors have pleiotropic effects, including neuroprotection. In this study, we investigated the effects of alogliptin on oxaliplatin-induced peripheral neuropathy using in vitro and in vivo models. In PC12 cells, alogliptin attenuated neurite disorders induced by oxaliplatin and cisplatin. The repeated injection of oxaliplatin caused mechanical allodynia and axonal degeneration of the sciatic nerve in rats. These neuropathies were ameliorated by co-administration of alogliptin. Moreover, alogliptin did not attenuate tumor cytotoxicity of oxaliplatin in the cultured colon, gastric, or pancreatic cancer cell lines and tumor-bearing mice. These findings suggest that alogliptin may be beneficial for preventing oxaliplatin-induced peripheral neuropathy.

    DOI: 10.1038/s41598-020-62738-w

    PubMed

  • Improvement of blood pressure control by adherence check in patients with apparent treatment-resistant hypertension: A Case Series Reviewed International journal

    Keiko Hosohata, Ayaka Inada, Saki Oyama, Takashi Doi, Iku Niinomi, Tomohito Wakabayashi, Mayako Uchida, Kazunori Iwanaga, Hiroyuki Matsuoka

    Clin Med Insights Case Rep.   13   1 - 4   2020.2

     More details

    Language:English  

    Adherence to medications is an important challenge while treating chronic disease such as resistant hypertension, which is defined as uncontrolled blood pressure (BP) despite treatment with more than 3 antihypertensive drugs to achieve targets. It is possible that poor adherence is the most significant contributor to rates of pseudo-resistance among treated hypertensive patients. In this report, we describe 4 patients with apparent treatment-resistant hypertension, who received intervention to promote adherence by pharmacists who set the prescribed medicines in a weekly medication calendar and conducted a weekly pill count. The results showed that the intervention of pharmacists to medication adherence improved systolic BP in patients with apparent treatment-resistant hypertension; however, further controlled trials are required to strengthen supporting evidence.

    DOI: 10.1177/1179547620904884

    PubMed

  • Comparison of Adverse Event Profiles of Tumor Necrosis Factor-Alfa Inhibitors: Analysis of a Spontaneous Reporting Database. Reviewed International journal

    Tomohito Wakabayashi, Keiko Hosohata, Saki Oyama, Ayaka Inada, Sayaka Ueno, Hiroko Kambara, Tatsuya Iida, Takahiro Nakatsuji, Mayako Uchida, Kazunori Iwanaga

    Therapeutics and clinical risk management   16   741 - 747   2020

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Introduction: Concerns over safety profiles of tumor necrosis factor (TNF)-alfa inhibitors have been raised. The purpose of this study was to clarify the adverse events associated with TNF-alfa inhibitors using a spontaneous reporting system database. Materials and Methods: A retrospective pharmacovigilance disproportionality analysis was conducted using the Japanese Adverse Drug Event Report (JADER) database. Adverse event reports submitted to the Pharmaceuticals and Medical Devices Agency between 2004 and 2017 were analyzed, and the reporting odds ratio (ROR) and 95% confidence interval (CI) for each adverse event were calculated. Results: Among the 34,031 reports of adverse events associated with TNF-alfa inhibitors, 65.8% were women, who were frequently in their 60s (28.2%). Signals were detected for pneumonia (ROR, 5.36; 95% CI, 5.14-5.6), interstitial lung disease (ROR, 2.04; 95% CI, 1.95-2.15), pneumocystis jirovecii pneumonia (ROR, 11.8; 95% CI, 11.1-12.5), and herpes zoster (ROR, 6.4; 95% CI, 5.92-6.91) for TNF-alfa inhibitors as a class. There was variability in their signal strength across individual TNF-alfa inhibitors. Conclusion: The strength of the associations of TNF-alfa inhibitors with adverse events is variable, and further studies are required to evaluate the identified signals.

    DOI: 10.2147/TCRM.S246328

    PubMed

  • Evaluation of acute kidney injury associated with anti-cancer drugs used in gastric cancer in the Japanese adverse drug event report database Reviewed International journal

    Mayako Uchida, Yuki Kondo, Shinya Suzuki, Keiko Hosohata

    Ann Pharmacother.   53 ( 12 )   1200 - 1206   2019.12

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    Background: Development of acute kidney injury (AKI) depends on the severity of renal dysfunction, clinical setting, comorbid factors, and geographical location. Gastric cancer is one of the deadliest malignancies worldwide, and its incidence is significantly high in Japan. Objective: We analyzed the rank-order of the association of anticancer agents for gastric cancer with AKI using a spontaneous reporting system database, the Japanese Adverse Drug Event Report database. Methods: We performed a retrospective pharmacovigilance disproportionality analysis using the adverse event reports submitted to the Pharmaceuticals and Medical Devices Agency between April 2004 and March 2017. Results: Anticancer drug-related AKI was common in patients in their 60s and 70s (39.2% and 43.2%, respectively). AKI occurred most frequently within 1 month after anticancer drug administration. The signals of AKI were reported after treatment with S-1 (tegafur/gimeracil/oteracil), cisplatin (CDDP), and capecitabine, with significant adjusted reporting odds ratios (95% CI) of 1.50 (1.09-2.07), 3.43 (2.48-4.74), and 1.82 (1.15-2.90), respectively. CDDP-induced AKI was more likely to occur in patients who were male, hypertension, or diabetes mellitus. Conclusion and Relevance: This study showed that most AKI cases were related to S-1 and/or CDDP adjuvant chemotherapy for gastric cancer treatment. The data also clarified that AKIs occurred within 1 month and that their clinical outcomes were more severe than previous reports of drug-induced AKI in general medicine. Our study provides useful information to minimize the risks of administration to patients at high risk for S-1 and/or CDDP containing chemotherapy-induced AKI.

    DOI: 10.1177/1060028019865870

    PubMed

  • [Application of deep learning for the occupational health of VDT workers].

    Uchida M, Noshita K, Koyama H

    Sangyo eiseigaku zasshi = Journal of occupational health   61 ( 6 )   256 - 260   2019.11   ISSN:1341-0725

     More details

    Language:Japanese  

    DOI: 10.1539/sangyoeisei.2018-040-C

    PubMed

  • Evaluation of adverse events focusing on infection associated with infliximab originator and biosimilar using a spontaneous reporting system database Reviewed International journal

    Iku Niinomi, Keiko Hosohata, Yasuhiro Mori, Yuki, Yamaguchi, Tomohito Wakabayashi, Mayako Uchida, Kazunori Iwanaga

    J Pharm Health Care Sci.   5 ( 21 )   eCollection - 21   2019.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Background: Infliximab (IFX) has changed the management of many life-threatening immune-mediated diseases. The high cost of IFX and its patent expiry have led to pharmaceutical companies developing a biosimilar; however, its safety profile remains unknown in the real world. The purpose of this study was to clarify the adverse events associated with IFX originator and its biosimilar using the Japanese Adverse Drug Event Report (JADER) database. Methods: Adverse event reports submitted to the Pharmaceuticals and Medical Devices Agency between the third quarter of 2014 and the fourth quarter of 2018. We calculated the reporting odds ratio and 95% confidence interval for each adverse event. Results: We obtained 2771 reports of adverse events associated with IFX originator and 402 reports with IFX biosimilar. Signals were detected for pneumonia, interstitial lung disease, tuberculosis, and sepsis with both IFX originator and its biosimilar, whereas there was no signal for infection with the biosimilar. Conclusions: The strength of the association between IFX originator and its biosimilar with adverse events is partly different, but reports were quite limited for the biosimilar compared with originator. It is recommended that research be continued in order to accumulate a wide variety of information, and that newly reported data be placed in the multifaceted viewpoints for improvement of care levels.

    DOI: 10.1186/s40780-019-0149-z

    PubMed

  • オピオイド適正使用に向けた薬剤師の取り組み 緩和医療におけるポリファーマシーに対する薬剤師の介入に関する多施設前向き観察研究

    内田 まやこ, 鈴木 真也, 菅 幸生, 菅原 英輝, 国分 秀也, 植沢 芳広, 中川 貴之, 高瀬 久光

    日本臨床精神神経薬理学会・日本神経精神薬理学会合同年会プログラム・抄録集   29回・49回   234 - 234   2019.10

     More details

    Language:Japanese   Publisher:日本臨床精神神経薬理学会・日本神経精神薬理学会  

  • オピオイド適正使用に向けた薬剤師の取り組み 緩和ケア領域におけるポリファーマシーの現状と病院/薬局薬剤師の介入実態に関する全国アンケート調査

    中川 貴之, 鈴木 真也, 内田 まやこ, 菅原 英輝, 菅 幸生, 国分 秀也, 植沢 芳広, 高瀬 久光

    日本臨床精神神経薬理学会・日本神経精神薬理学会合同年会プログラム・抄録集   29回・49回   233 - 233   2019.10

     More details

    Language:Japanese   Publisher:日本臨床精神神経薬理学会・日本神経精神薬理学会  

  • オピオイド適正使用に向けた薬剤師の取り組み 我が国の大規模医薬品副作用データベースJADERに基づくオピオイド関連有害事象の解析

    菅原 英輝, 菅 幸生, 内田 まやこ, 鈴木 真也, 植沢 芳広, 中川 貴之, 高瀬 久光

    日本臨床精神神経薬理学会・日本神経精神薬理学会合同年会プログラム・抄録集   29回・49回   234 - 234   2019.10

     More details

    Language:Japanese   Publisher:日本臨床精神神経薬理学会・日本神経精神薬理学会  

  • インフリキシマブの先発品とバイオシミラーに関連する感染に注目した有害事象の、自発報告システムデータベースによる評価(Evaluation of adverse events focusing on infection associated with infliximab originator and biosimilar using a spontaneous reporting system database)

    Niinomi Iku, Hosohata Keiko, Mori Yasuhiro, Yamaguchi Yuki, Wakabayashi Tomohito, Uchida Mayako, Iwanaga Kazunori

    Journal of Pharmaceutical Health Care and Sciences   5   1 of 4 - 4 of 4   2019.10

     More details

    Language:English   Publisher:(一社)日本医療薬学会  

    日本医薬品副作用データベースを用いて、インフリキシマブ(IFX)の先発品とバイオシミラー(BS)に関連する有害事象について比較した。2014年第3四半期~2018年第4四半期に、医薬品医療機器総合機構に報告された有害事象を分析した。IFXに関連する有害事象は、先発品では2771件、BSでは402件であった。先発品とBSの両者で、肺炎、間質性肺疾患、結核および敗血症に関連するシグナルが検出されたが、BSでは感染に関連するシグナルは検出されなかった。先発品とBSの有害事象との関連性の強さは一部異なっており、先発品と比べてBSに関する報告は限定されていた。

  • Usefulness of medication instruction sheets for sharing information on cancer chemotherapy within the health care team Reviewed

    Mayako Uchida, Tsutomu Nakamura, Hiroyuki, Watanabe, Koji Kato, Toshihiro Miyamoto, Koichi Akashi, Satohiro Masuda

    Pharmazie.   74 ( 9 )   566 - 569   2019.9

     More details

    Authorship:Lead author, Corresponding author  

  • 添付文書の利活用状況ならびに学習ニーズに関する調査

    森山 真由, 角山 香織, 中村 任, 宮崎 誠, 内田 まやこ, 永井 純也, 中村 敏明

    社会薬学   38 ( Suppl. )   63 - 63   2019.9   ISSN:0911-0585 eISSN:2188-2754

     More details

    Language:Japanese   Publisher:(一社)日本社会薬学会  

  • Impact of a systematic education model for palliative care in cancer Reviewed

    Mayako Uchida, Masao Hada, Masahiro Yamada, Daigo Inma, Shunji Ariyoshi, Kazuko Aoki, Syoji Inoue, Takao Shimazoe, Kiyoshi Mitsuiki, Toru Haraguchi

    Pharmazie.   74 ( 8 )   499 - 504   2019.8

     More details

    Authorship:Lead author, Corresponding author  

  • A nationwide survey of community pharmacist interventions on polypharmacy in opioid use and non-use cancer patients in Japan Reviewed

    Shinya Suzuki, Mayako Uchida, Yukio Suga, Hideki Sugawara, Hideya Kokubun, Yoshihiro Uesawa, Takayuki Nakagawa, Hisamitsu Takase

    Biol Pharm Bull.   42 ( 7 )   1164 - 1171   2019.7   ISSN:0918-6158 eISSN:1347-5215

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:(公社)日本薬学会  

    オピオイドを含む6種類以上の薬剤を定期的に使用している癌患者に対する地域薬剤師の貢献について、2017年10月〜11月までの2ヵ月間、日本緩和医療薬学会の地域薬剤師を対象にオンラインアンケート調査を実施した。地域薬剤師579名のうち、83名(14.3%)から回答を得た。調査結果から、オピオイドの使用が癌患者のポリファーマシーのリスク増加と関連すること、地域薬剤師による提案がオピオイド使用および非使用癌患者の両者でポリファーマシーによる不適切な薬物療法を減らし、副作用を改善することが示唆された。外来化学療法を含む癌治療の進歩により地域薬剤師の役割が変化しており、外来患者向けの投薬に加えて、その役割は在宅医療や緩和ケアにまで拡大されている。ポリファーマシーの現状、不適切な処方および地域薬剤師の貢献に関する本調査は、緩和ケアにおける地域薬剤師の役割の拡大をさらに促進するのに役立つと考えられた。

    DOI: 10.1248/bpb.b19-00043

    PubMed

    Other Link: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2019&ichushi_jid=J04684&link_issn=&doc_id=20190709280016&doc_link_id=130007672140&url=http%3A%2F%2Fci.nii.ac.jp%2Fnaid%2F130007672140&type=CiNii&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00003_1.gif

  • 緩和療法を受けている癌患者に対する多剤投与を改善するための、病院薬剤師介入に関する全国調査(A nationwide survey of hospital pharmacist interventions to improve polypharmacy for patients with cancer in palliative care in Japan)

    Uchida Mayako, Suzuki Shinya, Sugawara Hideki, Suga Yukio, Kokubun Hideya, Uesawa Yoshihiro, Nakagawa Takayuki, Takase Hisamitsu

    Journal of Pharmaceutical Health Care and Sciences   5   1 of 13 - 13 of 13   2019.7

     More details

    Language:English   Publisher:(一社)日本医療薬学会  

    2017年10~11月に、日本緩和医療薬学会は6種以上の薬を定期的に使用している癌患者について、病院薬剤師へのオンライン質問票調査を行った。オピオイド処方患者に関しては、40.9%と22.3%の薬剤師が、6種以上の薬の処方患者の割合は40~69%と70~99%と回答した。多剤投与に関しては、73.0%は不適切な処方の割合は低いかまたは中程度と回答した。薬剤師の勧告により薬を減らした割合が0%、1~39%、40%以上と回答したのは、24.2%、46.8%、23.4%であった。薬剤師の介入により、制吐薬、消化器薬および催眠鎮静薬を含む不適切な薬の使用が減少し、錐体外路症状、せん妄および不眠のような有害薬物反応が低下または防止できた。薬剤師が介入した多剤投与で不適切な投与を減らした患者の割合は、オピオイド投与患者の方が多かった。以上より、多剤投与に対する認定薬剤師の勧告が多剤投与癌患者への不適切な薬の使用を減らすために寄与していた。

  • 癌患者におけるオピオイド関連呼吸抑制に関する日本の医薬品副作用データベースに基づいた分析(Analyses of Respiratory Depression Associated with Opioids in Cancer Patients Based on the Japanese Adverse Drug Event Report Database)

    Sugawara Hideki, Uchida Mayako, Suzuki Shinya, Suga Yukio, Uesawa Yoshihiro, Nakagawa Takayuki, Takase Hisamitsu

    Biological & Pharmaceutical Bulletin   42 ( 7 )   1185 - 1191   2019.7   ISSN:0918-6158

     More details

    Language:English   Publisher:(公社)日本薬学会  

    オピオイド(Opi)の適正使用促進のためのデータを得るため、医薬品副作用データベースを用いて2004年4月~2017年3月の呼吸抑制の発生率を調べた。Opiに関する9種の疑わしい報告オッズ比(ROR)を算出し、最初の出現時の1日投与量と有害事象発生時期プロファイルを分析した。ROR分析では全てのOpiの有害事象についてシグナルが検出された。モルヒネ(MP)は70歳以上の高齢患者で有意に大きなROR値を示した。呼吸抑制を誘発する経口MPとオキシコドン(OC)の1日投与量の中央値は比較的低かったが(30mg/d、経口MP当量)、経皮フェンタニル(FT)は120mg/dであった。経口MP、経口OCおよび経皮FTの発生時期の中央値はそれぞれ5.5、11および12.5日であった。以上より、Opiは比較的低用量で投与した場合でも、特にMPを投与した高齢患者では、最初の1週間~1ヵ月間は患者を注意深く監視する必要があると考えられた。

  • 日本のオピオイド使用および非使用癌患者におけるポリファーマシーに対する地域薬剤師の貢献に関する全国調査(A Nationwide Survey of Community Pharmacist Contributions to Polypharmacy in Opioid-Using and Non-using Cancer Patients in Japan)

    Suzuki Shinya, Uchida Mayako, Suga Yukio, Sugawara Hideki, Kokubun Hideya, Uesawa Yoshihiro, Nakagawa Takayuki, Takase Hisamitsu

    Biological & Pharmaceutical Bulletin   42 ( 7 )   1164 - 1171   2019.7   ISSN:0918-6158

     More details

    Language:English   Publisher:(公社)日本薬学会  

    オピオイドを含む6種類以上の薬剤を定期的に使用している癌患者に対する地域薬剤師の貢献について、2017年10月~11月までの2ヵ月間、日本緩和医療薬学会の地域薬剤師を対象にオンラインアンケート調査を実施した。地域薬剤師579名のうち、83名(14.3%)から回答を得た。調査結果から、オピオイドの使用が癌患者のポリファーマシーのリスク増加と関連すること、地域薬剤師による提案がオピオイド使用および非使用癌患者の両者でポリファーマシーによる不適切な薬物療法を減らし、副作用を改善することが示唆された。外来化学療法を含む癌治療の進歩により地域薬剤師の役割が変化しており、外来患者向けの投薬に加えて、その役割は在宅医療や緩和ケアにまで拡大されている。ポリファーマシーの現状、不適切な処方および地域薬剤師の貢献に関する本調査は、緩和ケアにおける地域薬剤師の役割の拡大をさらに促進するのに役立つと考えられた。

  • Clinical Pharmacology Research for Promoting Individualized Cancer Chemotherapy

    Watanabe Hiroyuki, Uchida Mayako, Masuda Satohiro

    YAKUGAKU ZASSHI   139 ( 6 )   901 - 909   2019.6   ISSN:00316903 eISSN:13475231

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:The Pharmaceutical Society of Japan  

    <p>Cancer chemotherapy has progressed remarkably with conventional and molecular-targeted anticancer drugs as well as immune checkpoint inhibitors. However, adverse drug reaction (ADR) management remains a challenge in cancer chemotherapy. Therefore, improving the quality of medical care through clinical pharmacology research is warranted. Intravenous injection of bendamustine in patients with follicular or mantle cell lymphoma frequently causes venous irritation. Because the underlying mechanisms are not clear, we investigated the factors responsible for bendamustine-induced venous irritation. Based on the results of our analysis, we altered the administration regimen and observed that the incidence of venous irritation, which manifested in a concentration-dependent manner following conventional approaches, significantly decreased when following the modified regimen. Guidelines on the management of chemotherapy-induced nausea and vomiting recommend aprepitant, a selective neurokinin-1 (NK-1) receptor antagonist, 5-hydroxytryptamine 3 (5-HT<sub>3</sub>) receptor antagonists, and dexamethasone as prophylactic antiemetics. Pretreatment with high-dose chemotherapy before hematopoietic stem cell transplantation has extremely high emetogenic potential. This can be countered by using aprepitant in combination with conventional antiemetics. However, the safety and efficacy of such combinations are unexplored. Upon evaluation, we observed improved antiemetic effects without an increase in ADRs. At this symposium, I highlight the significance of clinical pharmacology research for promoting individualized cancer chemotherapy.</p>

    DOI: 10.1248/yakushi.18-00213-1

    PubMed

    CiNii Research

  • がん薬物療法の適正化推進に向けた臨床薬学的研究 Reviewed

    渡邊裕之, 内田まやこ, 増田智先

    YAKUGAKU ZASSHI   139 ( 6 )   901   2019.6

  • 日本におけるオピオイド鎮痛薬に関連する有害事象の現状 日本国内の有害事象自発報告データベースに基づく評価(Current Status of Adverse Events Related with Opioid Analgesics in Japan: Assessment Based on Japanese Adverse Drug Event Report Database)

    Suga Yukio, Uchida Mayako, Suzuki Shinya, Sugawara Hideki, Torigoe Kazuhiro, Futamura Akihiko, Uesawa Yoshihiro, Nakagawa Takayuki, Takase Hisamitsu

    Biological & Pharmaceutical Bulletin   42 ( 5 )   801 - 806   2019.5   ISSN:0918-6158

     More details

    Language:English   Publisher:(公社)日本薬学会  

    日本の医薬品副作用データベースを用いて、2004年~2017年のオピオイド関連有害事象と死亡の発生の時間的変化を調べた。調査期間中に各オピオイドの年間消費量と共通成分が変化したにもかかわらず、オピオイド関連有害事象の全体的な発生率に大きな変化はなかった。しかし、フェンタニル関連の有害事象の数と割合、死亡転帰は2010年以降増加しており、モルヒネやオキシコドンに関連する有害事象の中で最も多かった。フェンタニル関連有害事象による死亡転帰は、主に呼吸抑制が原因であった。以上より、オピオイド関連有害事象は日本の医療従事者による適切な監視や管理を通じて制御できるが、重篤なフェンタニル誘発性有害事象には継続的に注意を払う必要があると考えられた。

  • Evaluation of the compliance with antiemetic guidelines for prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancy Reviewed

    Mayako Uchida, Tsutomu Nakamura, Takahiro Shima, Yasuo Mori, Goichi Yoshimoto, Mototsugu Shimokawa, Koji Kato, Keiko Hosohata, Toshihiro Miyamoto, Koichi Akashi

    Pharmazie.   74 ( 4 )   250 - 254   2019.4

     More details

    Authorship:Lead author, Corresponding author  

  • Evaluation of medication-related osteonecrosis of the jaw using the Japanese adverse drug event report database Reviewed International journal

    Ayaka Inada, Keiko Hosohata, Saki Oyama, Iku Niinomi, Yasuhiro Mori, Yuki Yamaguchi, Mayako Uchida, Kazunori Iwanaga

    Ther Clin Risk Manag.   15   59 - 64   2019.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Background: Bisphosphonates (BPs) and denosumab are widely used to treat osteoporosis and complications associated with bone metastases. However, medication-related osteonecrosis of the jaw (MRONJ) is a serious problem. Objective: The objective of this study was to evaluate the frequency, outcome, and characteristics of patients with drug-induced MRONJ. Methods: Retrospective pharmacovigilance disproportionality analysis was conducted using the Japanese Adverse Drug Event Report (JADER) database from the Pharmaceuticals and Medical Devices Agency. Adverse event reports submitted to JADER between 2004 and 2017 were analyzed, and the reporting odds ratio (ROR) was calculated. Results: Among the BPs that cause MRONJ, zoledronate was the most common; therefore, we compared the characteristics of cases of MRONJ induced by zoledronate with those induced by denosumab. Among the 3,875 (68.1% women) cases of MRONJ, zoledronate-related MRONJ accounted for 1,283 (56.0% women) and denosumab-related MRONJ accounted for 322 (55.3% women). MRONJ was more frequent after 70 years of age regardless of the use of either zoledronate or denosumab; onset occurred after 1 year from the denosumab treatment, but it is unknown when onset occurred after zoledronate treatment. The outcomes for MRONJ were poor, with 406 reports on zoledronate (31.6%) and 152 reports on denosumab (47.2%) demonstrating nonrecovery. Zoledronate (ROR: 319.3, 95% CI: 296.0-344.4) had the highest ROR among BP agents. Denosumab had a high ROR (ROR: 155.2, 95% CI: 136.5-176.3). Zoledronate and denosumab were used in similar patient backgrounds, and their use resulted in a similar frequency of MRONJ. Conclusion: The findings of this comprehensive evaluation of MRONJ using the JADER database will be helpful for prescribing medications to elderly patients.

    DOI: 10.2147/TCRM.S176620

    PubMed

  • A nationwide survey of hospital pharmacist interventions to improve polypharmacy for patients with cancer in palliative care in Japan. Reviewed International journal

    Mayako Uchida, Shinya Suzuki, Hideki Sugawara, Yukio Suga, Hideya Kokubun, Yoshihiro Uesawa, Takayuki Nakagawa, Hisamitsu Takase

    Journal of pharmaceutical health care and sciences   5 ( 14 )   14 - 14   2019

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    Background: There is no nationwide data on polypharmacy in palliative care in Japan. In this study, the research committee of the Japanese Society for Pharmaceutical Palliative Care and Sciences conducted an online survey on polypharmacy and inappropriate prescriptions involving its members who worked as hospital pharmacists. Methods: The online questionnaire included questions about hospital pharmacist interventions for cancer patients who regularly used six or more drugs during a two-month period from October to November 2017. Results: Of 2618 hospital pharmacists, 359 responded (13.7%). With regard to cancer patients receiving opioids, 40.9 and 22.3% of the respondents replied that percentages of patients prescribed six or more regular medications were "40-69%" and "70-99%," respectively. Regarding patients on polypharmacy, 73.0% of the respondents reported a low or moderate rate of inappropriate prescriptions, with responses such as "long-term administration of irresponsible or aimless medications", "adverse drug reactions," and "duplication of the pharmacological effect". Furthermore, 24.2, 46.8, and 23.4% of respondents replied that the rates of drug reduction due to pharmacist recommendations were "0", "1-39%", and "more than 40%," respectively. Pharmacist interventions decreased the use of inappropriate medications, including antiemetics, gastrointestinal medications, and hypnotic sedatives, and reduced or prevented adverse drug reactions such as extrapyramidal symptoms, delirium, and sleepiness. Similar results were obtained for cancer patients who did not use opioids. However, the rates of cancer patients on polypharmacy and with reduction of inappropriate medications by pharmacist interventions were significantly higher in cancer patients receiving opioids. Finally, recommendations of board-certified pharmacists in palliative pharmacy contributed to a decrease in the use of inappropriate medications in cancer patients on polypharmacy (p = 0.06). Conclusion: This nationwide survey clarified pharmacist interventions for polypharmacy in palliative care in Japan. Our data showed frequent polypharmacy in cancer patients receiving opioids, and benefits of pharmacist interventions, especially by board-certified pharmacists in palliative pharmacy, for reducing inappropriate medications and improving adverse drug reactions. Trial registration: The study approval numbers in the institution; 0046. Registered November 6, 2017.

    DOI: 10.1186/s40780-019-0143-5

    PubMed

  • Current Status of Adverse Events Related with Opioid Analgesics in Japan: Assessment Based on Japanese Adverse Drug Event Report Database. Reviewed

    Yukio Suga, Mayako Uchida, Shinya Suzuki, Hideki Sugawara, Kazuhiro Torigoe, Akihiko Futamura, Yoshihiro Uesawa, Takayuki Nakagawa, Hisamitsu Takase

    Biological & pharmaceutical bulletin   42 ( 5 )   801 - 806   2019

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Opioid analgesics have greatly contributed to the advancement of pain management. However, although opioids have been appropriately used in Japan, they rarely induce serious adverse events, such as respiratory depression. The present study aimed to investigate the temporal changes in the occurrence of opioid-related adverse events and deaths between 2004 and 2017 in Japan using the Japanese Adverse Drug Event Report (JADER) database. We analyzed the following points using data extracted from JADER website: 1) temporal changes in the number and proportion of opioid-related adverse event reports; 2) temporal changes in the number of morphine-, oxycodone-, and fentanyl-related adverse event reports per annual consumption; and 3) cases in which the reported outcome following opioid-related adverse events was death. Our results showed no dramatic changes in the overall incidence of opioid-related adverse events, despite the temporal changes in the annual consumption and shared component of each opioid during the survey period. However, the number and rate of fentanyl-related adverse events and their outcome "death" increased since 2010, being the highest among all adverse event including those related to morphine and oxycodone. Outcome "death" by fentanyl-related adverse events was caused mainly due to respiratory depression. These findings suggest that, although opioid-related adverse events can be controlled through proper monitoring and management by medical personnel in Japan, extra caution should be continuously paid for the rare but serious fentanyl-induced adverse events.

    DOI: 10.1248/bpb.b18-00997

    PubMed

  • Analyses of Respiratory Depression Associated with Opioids in Cancer Patients Based on the Japanese Adverse Drug Event Report Database. Reviewed

    Hideki Sugawara, Mayako Uchida, Shinya Suzuki, Yukio Suga, Yoshihiro Uesawa, Takayuki Nakagawa, Hisamitsu Takase

    Biological & pharmaceutical bulletin   42 ( 7 )   1185 - 1191   2019

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Opioid-induced respiratory depression is a potentially life-threatening adverse drug event. The purpose of this study was to evaluate the incidence of respiratory depression using the Japanese Adverse Drug Event Report (JADER) Database to obtain data to promote proper use of opioids. The JADER database from April 2004 to March 2017 was obtained from the Pharmaceuticals and Medical Devices Agency. We calculated the reporting odds ratios (RORs) of suspected opioids (morphine, fentanyl, oxycodone, tapentadol, methadone, tramadol, pentazocine, buprenorphine, and codeine phosphate hydrate), analyzed the daily dose at first appearance and the time-to-onset profile, and assessed the hazard type using the Weibull shape parameter. ROR analysis detected adverse event signals for all opioids. Morphine showed a large ROR value with statistical significance in elderly (≥70 years old) patients. The median daily doses of oral morphine and oxycodone for inducing respiratory depression were comparably low (30 mg/d as oral morphine equivalent dose), while that of transdermal fentanyl was 120 mg/d (oral morphine equivalent dose). On time-to-onset analysis using the Weibull distribution, those opioids were classified as the early failure type. The median time-to-onset of oral morphine, oral oxycodone and transdermal fentanyl was 5.5, 11 and 12.5 d, respectively, and almost 50% of cases were reported within 30 d. Taken together, our results suggest that it is important to monitor patients carefully for at least the first one week to one month, even if opioids are administered at a relatively low dose, especially in elderly patients administered morphine.

    DOI: 10.1248/bpb.b19-00105

    PubMed

  • [Application of a deep learning for occupational health and safety recognition: a pilot study in a logistics industry].

    Uchida M, Noshita K, Tsutsui Y, Koyama H

    Sangyo eiseigaku zasshi = Journal of occupational health   60 ( 6 )   191 - 195   2018.12   ISSN:1341-0725

     More details

    Language:Japanese  

    DOI: 10.1539/sangyoeisei.2018-022-C

    PubMed

  • Comparative Quantification of Chemotherapy-Induced Nausea and Emesis between the Common Terminology Criteria for Adverse Events and the Multinational Association of Supportive Care in Cancer Antiemesis Tool

    Uchida Mayako, Nakamura Tsutomu, Shima Takahiro, Yoshimoto Goichi, Kato Koji, Hosohata Keiko, Miyamoto Toshihiro, Akashi Koichi

    Biological and Pharmaceutical Bulletin   41 ( 11 )   1667 - 1671   2018.11   ISSN:09186158 eISSN:13475215

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:The Pharmaceutical Society of Japan  

    <p>Chemotherapy-induced nausea and vomiting (CINV) are generally evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE). The Multinational Association for Supportive Care in Cancer (MASCC) developed the MASCC Antiemesis Tool (MAT) to facilitate recognition for CINV between patients and oncology specialists. In the present study, MAT and CTCAE were comparatively assessed in Japanese patients with hematological malignancies. A total of 61 patients were eligible for this study. The CTCAE data were collected from an electronic medical record system. The patients were asked to complete the Japanese version of MAT in the hospital, on the first and fourth days after the start of chemotherapy. The percentages of patients in whom nausea was completely controlled, with severity scores of zero, ranged from 70.5 to 82.0% for CTCAE and from 59.0 to 75.4% for MAT, during the first five days after the chemotherapy. The percentages of patients who had no vomiting ranged from 93.4 to 96.7% for CTCAE and from 90.2 to 98.4% for MAT. During the observation periods, the day-to-day response profiles of patients who received antiemetic treatment were comparable between CTCAE and MAT cohorts, and these two assessment tools showed good, positive correlations for nausea severity scores. The present study shows that the MAT is a useful tool for assessing the severity of CINV in patients with hematological malignancy, is comparable to CTCAE, and facilitates the identification of poor cancer care conditions by medical staff.</p>

    DOI: 10.1248/bpb.b18-00336

    PubMed

    CiNii Research

  • Burden of Human Metapneumovirus and Respiratory Syncytial Virus Infections in Asthmatic Children.

    Furuta T, Hasegawa S, Mizutani M, Iwai T, Ohbuchi N, Kawano S, Tashiro N, Uchida M, Hasegawa M, Motoyama M, Sekino T, Nakatsuka K, Ichihara K, Shirabe K, Ohga S

    The Pediatric infectious disease journal   37 ( 11 )   1107 - 1111   2018.11   ISSN:0891-3668

     More details

    Language:English  

    DOI: 10.1097/INF.0000000000002038

    PubMed

  • 化学療法による嘔気・嘔吐の有害事象共通用語基準とMultinational Association of Supportive Care in Cancer Antiemesis Toolとの比較定量化(Comparative Quantification of Chemotherapy-Induced Nausea and Emesis between the Common Terminology Criteria for Adverse Events and the Multinational Association of Supportive Care in Cancer Antiemesis Tool)

    Uchida Mayako, Nakamura Tsutomu, Shima Takahiro, Yoshimoto Goichi, Kato Koji, Hosohata Keiko, Miyamoto Toshihiro, Akashi Koichi

    Biological & Pharmaceutical Bulletin   41 ( 11 )   1667 - 1671   2018.11   ISSN:0918-6158

     More details

    Language:English   Publisher:(公社)日本薬学会  

    Multinational Association of Supportive Care in Cancer(MASCC)は、患者と腫瘍専門医間での化学療法による嘔気・嘔吐(CINV)に関する理解を容易にするため、MASCC Antiemesis Tool(MAT)を開発した。血液悪性腫瘍の日本人患者61名(男29名、女32名、年齢中央値63歳)を対象に、MATと有害事象共通用語基準(CTCAE)を比較した。化学療法後の最初の5日間で、重症度スコアが0で、嘔気が完全に抑制された患者の割合は、CTCAEでは70.5~82.0%、MATでは59.0~75.4%であった。嘔吐のない患者の割合は、CTCAEでは93.4~96.7%、MATでは90.2~98.4%であった。制吐薬で治療を受けた患者の反応はCTCAEとMATコホートで同等で、この2つの評価手段は嘔気重症度スコアに関して良好な正相関を示した。以上より、MATはCINVの重症度を評価するための有用な手段で、CTCAEと同等であり、医療スタッフによる癌の治療状況の悪さの特定を容易にすると考えられた。

  • Differential profiles of adverse events associated with mycophenolate mofetil between adult and pediatric renal transplant patients. Reviewed International journal

    Hosohata K, Matsuoka E, Inada A, Oyama S, Niinomi I, Mori Y, Yamaguchi Y, Uchida M, Iwanaga K

    The Journal of international medical research   46 ( 11 )   4617 - 4623   2018.11   ISSN:0300-0605

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVE: Immunosuppressive regimens after renal transplantation usually include a combination of calcineurin inhibitors, corticosteroids, and a proliferation inhibitor, either azathioprine or mycophenolate mofetil (MMF), to prevent rejection and maintain graft function. MMF has a stronger immunosuppressive effect than does azathioprine. This study aimed to examine MMF-associated adverse events in renal transplant patients. METHODS: Retrospective pharmacovigilance disproportionality analysis was conducted using the Japanese Adverse Drug Event Report database. RESULTS: A total of 11,594 adverse drug events were reported in renal transplant patients; 10,272 (88.6%) involved adults and 1322 (11.4%) involved children. In adult patients, the most frequent adverse events induced by MMF were cytomegalovirus infection (272 reports), urinary tract infection (69 reports), and polyomavirus-associated nephropathy (61 reports). Among adverse events, the highest reporting odds ratio (ROR) was found for cytomegalovirus infection (ROR, 1.58; 95% confidence interval, 1.36-1.83). In pediatric patients, the rank order for MMF-associated adverse events was cytomegalovirus infection (27 reports), bronchitis (23 reports), and cytomegalovirus viremia (19 reports), but these adverse events were not detected as a signal. CONCLUSION: Our results show the safety profile of MMF in pediatric renal transplant patients. These findings can be used to update information used for prescriptions for pediatric patients.

    DOI: 10.1177/0300060518786917

    PubMed

  • 医薬品リスク管理計画(RMP)の利活用に関する卒後研修会の有用性評価

    角山 香織, 中村 敏明, 中村 任, 内田 まやこ, 芝野 真喜雄, 宮崎 誠, 永井 純也

    日本医薬品情報学会総会・学術大会講演要旨集   21回   157 - 157   2018.6

     More details

    Language:Japanese   Publisher:(一社)日本医薬品情報学会  

  • ABVD療法誘発性悪心嘔吐に対するグラニセトロンまたはパロノセトロン単独およびコルチコステロイドとの併用の制吐効果および安全性(Antiemetic efficacy and safety of granisetron or palonosetron alone and in combination with a corticosteroid for ABVD therapy-induced nausea and vomiting)

    Uchida Mayako, Nakamura Tsutomu, Hata Kojiro, Watanabe Hiroyuki, Mori Yasuo, Kato Koji, Kamezaki Kenjiro, Takenaka Katsuto, Shiratsuchi Motoaki, Hosohata Keiko, Miyamoto Toshihiro, Akashi Koichi

    Journal of Pharmaceutical Health Care and Sciences   4 ( January )   1 - 7   2018.1

     More details

    Language:English   Publisher:(一社)日本医療薬学会  

    アドリアマイシン、ブレオマイシン、ビンブラスチンおよびダカルバジン(ABVD)療法を受けているホジキンリンパ腫患者39名を対象に、化学療法誘発性悪心嘔吐(CINV)に対するグラニセトロン(GRA)またはパロノセトロン(PAL)単独およびコルチコステロイド(CS)との併用による制吐効果と安全性を遡及的に評価した。ABVD療法前にGRAまたはPALを静注し、全般期(ABVD療法開始後0~120時間)、急性期(0~24時間)および遅延期(24~120時間)における嘔吐が完全に制御された患者の割合を評価した。GRAまたはPALをCSと併用した患者の58.3%でCINVは全般期に完全に制御されたが、併用しなかった患者では11.1%であった。PAL群の方がGRA群よりも、食欲不振、白血球減少および好中球減少の頻度が有意に高かった。以上より、5-HT3受容体遮断薬とCSの併用が、ABVD療法を受けているホジキンリンパ腫患者のCINV制御のために好ましいことが示唆された。

  • Antiemetic efficacy and safety of granisetron or palonosetron alone and in combination with a corticosteroid for ABVD therapy-induced nausea and vomiting. Reviewed International journal

    Uchida M, Nakamura T, Hata K, Watanabe H, Mori Y, Kato K, Kamezaki K, Takenaka K, Shiratsuchi M, Hosohata K, Miyamoto T, Akashi K

    Journal of pharmaceutical health care and sciences   4   1 - 1   2018   ISSN:2055-0294

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    Background: Antiemetic effects and safety of granisetron or palonosetron alone and in combination with a corticosteroid against chemotherapy-induced nausea and vomiting (CINV) were retrospectively evaluated in patients with Hodgkin lymphoma receiving adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) therapy. Methods: A total of 39 patients were eligible for this study. Before ABVD therapy, granisetron or palonosetron was intravenously administered with or without a corticosteroid (dexamethasone or hydrocortisone) and aprepitant. The proportions of patients with complete control (CC) during the overall (0-120 h after the start of ABVD therapy), acute (0-24 h) and delayed (24-120 h) phases were evaluated. CC was defined as no vomiting and no use of antiemetic rescue medication with only grade 0-1 nausea. Results: Granisetron and palonosetron were administered in 21 and 18 patients, respectively. The CC rate during the acute, delayed and overall phases was not statistically different between the two groups. The CINV was completely controlled during overall phase in 58.3% of patients receiving granisetron or palonosetron in combination with a corticosteroid, whereas in 11.1% of those without co-treatment of a corticosteroid (P < 0.05). There were significantly higher frequencies of anorexia, leucopenia and neutropenia in the palonosetron group. There is a statistically significant difference in the frequency of febrile neutropenia between presence and absence of a corticosteroid (p = 0.024). Conclusion: These findings suggested that a combination use of a corticosteroid with a 5-HT3 receptor antagonist was preferable for CINV control in patients with Hodgkin lymphoma receiving ABVD therapy, although the careful management of febrile neutropenia is required. Trial registration: The study approval numbers in the institution; 24-12 and 24-359. Registered April 17, 2012 and June 21, 2012.

    DOI: 10.1186/s40780-017-0097-4

    PubMed

  • Drug-induced tubulointerstitial nephritis in a retrospective study using spontaneous reporting system database. Reviewed International journal

    Oyama S, Hosohata K, Inada A, Niinomi I, Mori Y, Yamaguchi Y, Uchida M, Iwanaga K

    Therapeutics and clinical risk management   14   1599 - 1604   2018   ISSN:1176-6336

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Introduction: Tubulointerstitial nephritis (TIN) is a problem in clinical settings because drug therapy is the cause in most cases. Patients often present with nonspecific symptoms, which can lead to delays in the diagnosis and treatment of the disease. The purpose of this study was to clarify the rank-order of the association of TIN with the causative drugs using a spontaneous reporting system database. Materials and methods: Data were extracted from the Japanese Adverse Drug Event Report database of the Pharmaceuticals and Medical Devices Agency (Japan). Based on 5,195,890 reports of all adverse reactions, we obtained 3,088 reports of TIN caused by all drugs and calculated the reporting odds ratio (ROR) and 95% CI for TIN. Results: The 5 drugs with the highest RORs were gliclazide (ROR, 30.5; 95% CI, 17.4-53.2), tosufloxacin tosilate hydrate (ROR, 29.5; 95% CI, 21.3-41.0), piperacillin-tazobactam (ROR, 24.3; 95% CI, 19.4-30.5), cefteram pivoxil (ROR, 23.5; 95% CI, 12.5-44.2), and mefenamic acid (ROR, 22.5; 95% CI, 13.4-37.7). No sex-related difference was observed in drug-induced TIN. Most of the reports about TIN onset following the administration of culprit drugs were recorded within 12 weeks. Conclusion: Based on the results, a comprehensive study using a pharmacovigilance database enabled us to identify the dugs that most frequently induced TIN, so these drugs should be used carefully in clinical practice to avoid TIN.

    DOI: 10.2147/TCRM.S168696

    PubMed

  • Comparison of antiemetic effects of granisetron and palonosetron in patients receiving bendamustine-based chemotherapy Reviewed

    M. Uchida, T. Nakamura, Y. Makihara, K. Suetsugu, H. Ikesue, Y. Mori, K. Kato, M. Shiratsuchi, K. Hosohata, T. Miyamoto, K. Akashi

    Pharmazie   73 ( 5 )   304 - 308   2018   ISSN:0031-7144

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:Govi-Verlag Pharmazeutischer Verlag GmbH  

    The antiemetic effects and safety of granisetron and palonosetron against chemotherapy-induced nausea and vomiting (CINV) were retrospectively evaluated in patients with non-Hodgkin lymphoma receiving bendamustine-based chemotherapy. A total of 61 patients were eligible for this study. Before starting the bendamustine-based chemotherapy, granisetron or palonosetron were intravenously administered with or without aprepitant and/or dexamethasone. The proportions of patients with complete control (CC) during the overall (during the 6 days after the start of the chemotherapy), acute (up to 2 days), and delayed (3 to 6 days) phases were assessed. CC was defined as complete response with only grade 0–1 nausea, no vomiting, and no use of antiemetic rescue medication. Granisetron or palonosetron alone were administered to 9 and 19 patients, respectively. Aprepitant and/or dexamethasone were combined with granisetron and palonosetron in 28 and 5 patients, respectively. Acute CINV was completely controlled in all patients. Both granisetron monotherapy and palonosetron combination therapy could provide good control of delayed CINV, although the CC rates during the delayed and overall phases were not significantly different among mono- and combination therapy of the antiemetics. There was no significant difference in the frequencies of adverse drug events between the granisetron and palonosetron treatment groups. The present study showed that the antiemetic efficacy and safety of granisetron-based therapy were non-inferior to those of palonosetron-based therapy. Taken together with treatment costs, granisetron monotherapy would be adequate to prevent CINV in patients with non-Hodgkin lymphoma receiving bendamustine-based chemotherapy.

    File: Uchida M,2018.pdf

    DOI: 10.1691/ph.2018.7948

    Scopus

  • R-CHOPで治療した日本人患者における化学療法誘発性悪心嘔吐に対するパロノセトロンとグラニセトロンの制吐作用の比較(Comparison between Antiemetic Effects of Palonosetron and Granisetron on Chemotherapy-Induced Nausea and Vomiting in Japanese Patients Treated with R-CHOP)

    Uchida Mayako, Mori Yasuo, Nakamura Tsutomu, Kato Koji, Kamezaki Kenjiro, Takenaka Katsuto, Shiratsuchi Motoaki, Kadoyama Kaori, Miyamoto Toshihiro, Akashi Koichi

    Biological & Pharmaceutical Bulletin   40 ( 9 )   1499 - 1505   2017.9   ISSN:0918-6158

     More details

    Language:English   Publisher:(公社)日本薬学会  

    リツキシマブ、シクロホスファミド、ドキソルビシン、ビンクリスチン、プレドニゾン(R-CHOP)にて治療した悪性リンパ腫患者74名(男33名、女41名)における、化学療法誘発性悪心嘔吐(CINV)に対するパロノセトロン(Palo)の制吐作用をグラニセトロン(Gran)と比較した。R-CHOP療法前にPalo(0.75mg)またはGran(3mg)を静注し、overall phase(R-CHOP療法開始後0~120時間)、acute phase(0~24時間)およびdelayed phase(24~120時間)での完全寛解(CR)率を評価した。delayed phaseでのPalo群のCR率(90.6%)は、Gran群(61.9%)より有意に高かった。ロジスティック回帰分析より、PaloはGranと比較してdelayed phaseでのCR率を改善した。女性、60歳未満の年齢、非常習的アルコール摂取および米国東海岸癌臨床試験パフォーマンスステータスのスコア1が、非CRに関連する有意な危険因子であった。以上より、悪性リンパ腫患者におけるCINVで、PaloがGranより優れていると考えられた。

  • Analysis of the variable factors influencing tacrolimus blood concentration during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation Reviewed

    Kimitaka Suetsugu, Hiroaki Ikesue, Toshihiro Miyamoto, Motoaki Shiratsuchi, Nanae Yamamoto-Taguchi, Yuichi Tsuchiya, Kumi Matsukawa, Mayako Uchida, Hiroyuki Watanabe, Koichi Akashi, Satohiro Masuda

    INTERNATIONAL JOURNAL OF HEMATOLOGY   105 ( 3 )   361 - 368   2017.3   ISSN:0925-5710 eISSN:1865-3774

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:SPRINGER JAPAN KK  

    The aim of this retrospective study was to identify variable factors affecting tacrolimus blood concentration during the switch from continuous intravenous infusion to twice-daily oral administration in allogeneic hematopoietic stem cell transplant recipients (n = 73). The blood concentration/dose ratio of tacrolimus immediately before the change from continuous infusion (C/Div) was compared with that between 3 and 5 days after the change to oral administration (C/Dpo). Median (C/Dpo)/(C/Div) was 0.21 (range 0.04-0.58). Multiple regression analysis showed that concomitant use of oral itraconazole or voriconazole significantly increased the (C/Dpo)/(C/Div) of tacrolimus (p = 0.002), probably owing to the inhibition of enterohepatic cytochrome P450 3A4. In addition, 5 of 18 (28%) patients who had the lowest quartile (C/Dpo)/(C/Div) values developed acute graft-versus-host-disease (GVHD), which was significantly higher than in others [5 of 55 (9%) patients, p = 0.045]. Although the switch from intravenous to oral administration at a ratio of 1:5 appeared to be appropriate, a lower conversion ratio was suitable in patients taking oral itraconazole or voriconazole. In patients whose blood concentration decreases after the switch, the development of GVHD should be monitored and tacrolimus dosage should be readjusted to maintain an appropriate blood concentration.

    DOI: 10.1007/s12185-016-2135-7

    Web of Science

    PubMed

  • 同種造血幹細胞移植後にタクロリムスを持続点滴静注から経口投与に切り替えた際のタクロリムス血中濃度に影響を及ぼす変動因子の解析(Analysis of the variable factors influencing tacrolimus blood concentration during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation)

    Suetsugu Kimitaka, Ikesue Hiroaki, Miyamoto Toshihiro, Shiratsuchi Motoaki, Yamamoto-Taguchi Nanae, Tsuchiya Yuichi, Matsukawa Kumi, Uchida Mayako, Watanabe Hiroyuki, Akashi Koichi, Masuda Satohiro

    International Journal of Hematology   105 ( 3 )   361 - 368   2017.3   ISSN:0925-5710

     More details

    Language:English   Publisher:(一社)日本血液学会  

    同種造血幹細胞移植のレシピエント73例(男性36例、女性37例、年齢20~69歳)を対象に、タクロリムス持続点滴静注から1日2回経口投与に切り替えた際のタクロリムス血中濃度に影響を及ぼす変動因子を同定した。持続点滴静注からの切り替え直前のタクロリムスの血中濃度/用量比(C/Div)を、経口投与切り替えから3~5日後の比(C/Dpo)と比較した。タクロリムス濃度中央値は、切り替え前は12.4ng/mL(4.7~18.1ng/mL)、切り替え後は8.0ng/mL(1.8~18.1ng/mL)であった。(C/Dpo)/(C/Div)中央値は0.21(0.04~0.58)であった。重回帰分析により、イトラコナゾールまたはボリコナゾールの併用はタクロリムスの(C/Dpo)/(C/Div)を有意に増加させ、これはおそらく腸肝チトクロームP450 3A4の阻害によるものと考えられた。さらに、(C/Dpo)/(C/Div)の四分位値が最も低い18例中28例(28%)が急性移植片対宿主病(GVHD)を発症し、他の患者よりも有意に高かった。切り替え後にタクロリムスの血中濃度が低下する患者では、GVHDの発症をモニタリングし、タクロリムスの投与量を調整して適切な血中濃度を維持する必要があると考えられた。

  • Comparison between Antiemetic Effects of Palonosetron and Granisetron on Chemotherapy-Induced Nausea and Vomiting in Japanese Patients Treated with R-CHOP

    Uchida Mayako, Mori Yasuo, Nakamura Tsutomu, Kato Koji, Kamezaki Kenjiro, Takenaka Katsuto, Shiratsuchi Motoaki, Kadoyama Kaori, Miyamoto Toshihiro, Akashi Koichi

    Biological and Pharmaceutical Bulletin   40 ( 9 )   1499 - 1505   2017   ISSN:09186158 eISSN:13475215

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:The Pharmaceutical Society of Japan  

    <p>In the present study, the antiemetic effect of palonosetron, not combined with dexamethasone and aprepitant, on chemotherapy-induced nausea and vomiting was evaluated in patients with malignant lymphoma receiving first-line rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy, and was compared to that of granisetron. A total of 74 patients with non-Hodgkin lymphoma were included in this study (April 2007 to December 2015). Palonosetron (0.75 mg) or granisetron (3 mg) was intravenously administered before R-CHOP therapy. The proportions of patients with complete response (CR) during the overall (0–120 h after the start of R-CHOP therapy), acute (0–24 h) and delayed (24–120 h) phases were evaluated. CR was defined as no vomiting and no use of antiemetic rescue medication. A total of 32 and 42 patients were treated with palonosetron and granisetron, respectively. The CR rate in the palonosetron group was significantly higher than that in the granisetron group during the delayed phase (90.6 and 61.9%, respectively; <i>p</i>=0.007). Logistic regression analysis showed that use of palonosetron improved the CR rate during the delayed phase, compared to use of granisetron. Female sex, age less than 60 years, no habitual alcohol intake, and Eastern Cooperative Oncology Group performance status (ECOG-PS) score of 1 were significant risk factors associated with non-CR. The findings of this study suggested the superiority of palonosetron to granisetron, without accompanying dexamethasone and aprepitant, for chemotherapy-induced nausea and vomiting in patients with malignant lymphoma.</p>

    DOI: 10.1248/bpb.b17-00318

    Web of Science

    PubMed

    CiNii Research

  • Search for the cluster states in <sup>13</sup>C using the alpha inelastic scattering

    Inaba K., Kawabata T., Sasamoto Y., Uesaka T., Shimizu Y., Suda K., Maeda Y., Sakaguchi S., Hatanaka K., Fujiwara M., Tamii A., Yoshida H. P., Nakanishi K., Kawase K., Tameshige Y., Matsubara H., Itoh M., Uchida M., Itoh K.

    Meeting Abstracts of the Physical Society of Japan   72.1 ( 0 )   394 - 394   2017   eISSN:21890803

     More details

    Language:Japanese   Publisher:The Physical Society of Japan  

    DOI: 10.11316/jpsgaiyo.72.1.0_394

    CiNii Research

  • Time Course of Calcium Concentrations and Risk Factors for Hypocalcemia in Patients Receiving Denosumab for the Treatment of Bone Metastases From Cancer Reviewed International journal

    Hiroaki Ikesue, Toshikazu Tsuji, Koujiro Hata, Hiroyuki Watanabe, Kazuto Mishima, Mayako Uchida, Nobuaki Egashira, Toshihiro Miyamoto, Eishi Baba, Koichi Akashi, Koichi Takayama, Yoichi Nakanishi, Eriko Tokunaga, Tatsuro Okamoto, Yoshihiko Maehara, Akira Yokomizo, Seiji Naito, Makoto Kubo, Masao Tanaka, Satohiro Masuda

    ANNALS OF PHARMACOTHERAPY   48 ( 9 )   1159 - 1165   2014.9   ISSN:1060-0280 eISSN:1542-6270

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:SAGE PUBLICATIONS INC  

    Background:Severe hypocalcennia sometimes develops during denosumab treatment for bone metastases from cancer and is, therefore, an important issue. However, limited information is available on the risk factors for hypocalcemia and the appropriate interval for monitoring serum calcium concentration. Objective: The present study aimed to identify the risk factors for grade &gt;= 2 hypocalcennia and to investigate the time course of serum calcium concentrations in patients receiving denosumab for bone metastases from cancer. Method: The medical records of 66 cancer patients treated with denosumab between April 2012 and August 2013 were retrospectively reviewed. Result: Of the 66 enrolled patients, 11, 5, and 1 developed grade 1, 2, and 3 hypocalcemia, respectively. All 4 patients with a baseline estimated glomerular filtration rate (eGFR) of &lt;30 mL/min developed hypocalcemia. Hypocalcemia occurred in only 20%, 24%, and 15% of patients with an eGFR of 30 to 59, 60 to 89, and &gt;= 90 mL/min, respectively. Multivariate logistic regression analysis revealed that lower eGFR values (odds ratio, 1.72 per 10 mL/min decrease, P = 0.02) were significantly associated with grade &gt;= 2 hypocalcemia. In 11 patients who developed hypocalcemia during the first treatment course, the mean calcium concentrations decreased from 9.8 mg/dL at baseline to 8.4 mg/dL during the first week and reached a nadir of 8.1 mg/dL during the second week. Conclusion: Our results support more frequent monitoring of serum calcium concentrations at baseline and during the first 2 weeks of treatment in patients receiving denosumab, especially those with an eGFR &lt;30 mL/min.

    DOI: 10.1177/1060028014539919

    Web of Science

    PubMed

  • 28-P4PM-068 造血幹細胞移植におけるタクロリムス投与経路変更時の血中濃度変動要因の解析(TDM・投与設計2,一般演題(ポスター),新時代を拓く医療薬学フロンティア)

    末次 王卓, 内田 まやこ, 愼原 洋子, 池末 裕明, 渡邊 裕之, 矢野 貴久, 大畠 俊一, 宮本 敏浩, 江頭 伸昭, 増田 智先

    日本医療薬学会年会講演要旨集   24 ( 0 )   438   2014.8   eISSN:24242470

     More details

    Language:Japanese   Publisher:一般社団法人 日本医療薬学会  

    DOI: 10.20825/amjsphcs.24.0_438_6

    CiNii Research

  • Pancreatic stellate cells and CX3CR1: occurrence in normal pancreas and acute and chronic pancreatitis and effect of their activation by a CX3CR1 agonist.

    Uchida M, Ito T, Nakamura T, Hijioka M, Igarashi H, Oono T, Kato M, Nakamura K, Suzuki K, Takayanagi R, Jensen RT

    Pancreas   43 ( 5 )   708 - 19   2014.7   ISSN:0885-3177

     More details

    Language:English  

    DOI: 10.1097/MPA.0000000000000109

    PubMed

  • PSCs and GLP-1R: occurrence in normal pancreas, acute/chronic pancreatitis and effect of their activation by a GLP-1R agonist.

    Nakamura T, Ito T, Uchida M, Hijioka M, Igarashi H, Oono T, Kato M, Nakamura K, Suzuki K, Jensen RT, Takayanagi R

    Laboratory investigation; a journal of technical methods and pathology   94 ( 1 )   63 - 78   2014.1   ISSN:0023-6837

     More details

    Language:English  

    DOI: 10.1038/labinvest.2013.133

    PubMed

  • Efficacy and Safety of an Increased-dose of Dexamethasone in Patients Receiving Fosaprepitant Chemotherapy in Japan Reviewed International journal

    Hozumi Kumagai, Hitoshi Kusaba, Yuta Okumura, Masato Komoda, Michitaka Nakano, Shingo Tamura, Mayako Uchida, Kenichiro Nagata, Shuji Arita, Hiroshi Ariyama, Shigeo Takaishi, Koichi Akashi, Eishi Baba

    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION   15 ( 1 )   461 - 465   2014   ISSN:1513-7368 eISSN:2476-762X

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:ASIAN PACIFIC ORGANIZATION CANCER PREVENTION  

    Background: Antiemetic triplet therapy including dexamethasone (DEX) is widely used for patients receiving highly emetogenic chemotherapy (HEC). In Japan, the appropriate dose of DEX has not been established for this combination. Materials and Methods: To assess the efficacy and safety of increased-dose DEX, we retrospectively examined patients receiving HEC with antiemetic triplet therapy. Results: Twenty-four patients (fosaprepitant group) were given an increased-dose of DEX (average total dose: 45.8mg), fosaprepitant, and 5-HT3 antagonist. A lower-dose of DEX (33.6mg), oral aprepitant, and 5-HT3 antagonist were administered to the other 48 patients (aprepitant group). The vomiting control rates in the fosaprepitant and aprepitant groups were 100% and 85.4% in the acute phase, and were 75.0% and 64.6% in the delayed phase. The incidences of toxicity were similar comparing the two groups. Conclusions: Triplet therapy using an increased-dose of DEX is suggested to be safe and effective for patients receiving HEC.

    DOI: 10.7314/APJCP.2014.15.1.461

    Web of Science

    PubMed

  • Efficacy and Safety of Aprepitant in Allogeneic Hematopoietic Stem Cell Transplantation Reviewed International journal

    Mayako Uchida, Koji Kato, Hiroaki Ikesue, Kimiko Ichinose, Hiromi Hiraiwa, Asako Sakurai, Tsuyoshi Muta, Katsuto Takenaka, Hiromi Iwasaki, Toshihiro Miyamoto, Takanori Teshima, Motoaki Shiratsuchi, Kimitaka Suetsugu, Kenichiro Nagata, Nobuaki Egashira, Koichi Akashi, Ryozo Oishi

    PHARMACOTHERAPY   33 ( 9 )   893 - 901   2013.9   ISSN:0277-0008 eISSN:1875-9114

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:WILEY-BLACKWELL  

    STUDY OBJECTIVE To evaluate the efficacy and safety of aprepitant added to standard antiemetic regimens used in high-dose chemotherapy for allogeneic hematopoietic stem cell transplantation (allo-HSCT).
    DESIGN Retrospective medical record review.
    SETTING Hematology ward of a university hospital in Japan.
    PATIENTS Of 88 patients treated with high-dose chemotherapy followed by allo-HSCT, 46 received aprepitant and granisetron as antiemetic therapy (between April 1, 2010, and December 31, 2011), and 42 received granisetron alone (between April 1, 2008, and March 31, 2010).
    INTERVENTIONS Patients in both groups received 3 mg of granisetron intravenously 30 minutes before the administration of anticancer drugs. In the aprepitant group, 125 mg of aprepitant was administered orally 60-90 minutes before the administration of the first moderately to highly emetogenic anticancer drug. On the following days, 80 mg of aprepitant was administered orally every morning. The mean administration duration of aprepitant was 3.3 days (range 3-6 days).
    MEASUREMENTS AND MAIN RESULTS The primary objective was to evaluate the percentage of patients who achieved complete response (CR; no vomiting and none to mild nausea). The CR rate in the aprepitant group was significantly higher than that in the control group (48% vs 24%, p=0.02). Multivariate analysis showed that nonprophylactic use of aprepitant was associated with failure to achieve CR (odds ratio [OR] 2.92; 95% confidence interval [CI] 1.13-7.99, p=0.03). The frequency of abdominal pain was lower in the aprepitant group (9% vs 25%, p=0.03). Rates of other frequently observed adverse drug events were similar between groups. There was no significant difference in neutrophil engraftment (median 18 vs 17 days), platelet engraftment (median 32 vs 32 days), the incidence of acute graft-versus-host-disease (63% vs 55%, p=0.52), viral infection (74% vs 67%, p=0.49), or 1-year overall survival (63% vs 62%, p=0.90) between the two groups.
    CONCLUSIONS The addition of aprepitant to granisetron increases the antiemetic effect without influencing transplantation-related toxicities in allo-HSCT.

    DOI: 10.1002/phar.1294

    Web of Science

    PubMed

  • 土-P3-382 VTD療法における薬剤管理指導業務への展開(がん薬物療法(服薬指導・情報提供),ポスター発表,一般演題,再興、再考、創ろう最高の医療の未来)

    近森 綾子, 内田 まやこ, 末次 王卓, 渡邊 裕之, 池末 裕明, 國分 千代, 金谷 朗子, 末安 正典, 江頭 伸昭

    日本医療薬学会年会講演要旨集   23 ( 0 )   315   2013.8   eISSN:24242470

     More details

    Language:Japanese   Publisher:一般社団法人 日本医療薬学会  

    DOI: 10.20825/amjsphcs.23.0_315_4

    CiNii Research

  • Quality Indicatorによる緩和ケアの評価 質の向上を目指して

    村上 一徳, 水元 一博, 嶋本 正弥, 清水 祐紀子, 内田 まやこ, 土谷 美智子, 山川 文子, 津隈 さやか

    日本医療マネジメント学会雑誌   14 ( Suppl. )   292 - 292   2013.6   ISSN:1881-2503

     More details

    Language:Japanese   Publisher:(NPO)日本医療マネジメント学会  

  • 自己造血系幹細胞移植に先行する高用量化学療法を受けている日本人患者における嘔吐抑制性制吐薬の有効性と安全性(Effectiveness and Safety of Antiemetic Aprepitant in Japanese Patients Receiving High-Dose Chemotherapy Prior to Autologous Hematopoietic Stem Cell Transplantation)

    Uchida Mayako, Ikesue Hiroaki, Miyamoto Toshihiro, Kato Koji, Suetsugu Kimitaka, Ichinose Kimiko, Hiraiwa Hiromi, Sakurai Asako, Takenaka Katsuto, Muta Tsuyoshi, Iwasaki Hiromi, Teshima Takanori, Shiratsuchi Motoaki, Egashira Nobuaki, Akashi Koichi, Oishi Ryozo

    Biological & Pharmaceutical Bulletin   36 ( 5 )   819 - 824   2013.5   ISSN:0918-6158

     More details

    Language:English   Publisher:(公社)日本薬学会  

    自己末梢血幹細胞移植(auto-PBSCT)に先行して高用量の化学療法を受けている悪性血液疾患の日本人患者に対して、5-ヒドロキシトリプタミン3(5-HT3)阻害剤と併用した制吐薬(ニューロキニン-1受容体阻害薬)治療の嘔吐抑制に対する有効性と安全性を後ろ向きに評価した。患者26名は制吐薬とグラニセトロンを摂取し(制吐薬群)、患者22名はグラニセトロンを単独摂取した(対照群)。全ての患者は化学療法薬投与の30分前に3mgのグラニセトロンの経静脈的投与を受けた。制吐薬群の患者は更に初日に中程度から強い程度の吐き気を催す化学療法薬を投与する60~90分前に125mgの制吐薬の投与を受けた。翌日以降から最終日迄は午前中に80mgの制吐薬の投与を受けた。グレード1-2の吐き気のみで嘔吐しない完全陰性化(CR)を達成した患者の割合は対照群(5%)に比べて制吐薬群(42%)で有意に高かった(P=0.003)。ロジスティック回帰分析の結果、制吐薬を予防的に利用しないことを非CRとの間に有意な関連性が認められた。薬剤有害事象(ADEs)の頻度は2群間で有意差が認められなかった。以上の結果から、auto-PBSCTを受ける前に高用量化学療法を受けている患者ではグラニセトロンに制吐薬を合わせて服用することによりADEsを増加させることなく嘔吐抑制作用を改善することができると考えられた。

  • ベンダムスチンの投与濃度の調節による静脈炎の減少(Decrease in Venous Irritation by Adjusting the Concentration of Injected Bendamustine)

    Watanabe Hiroyuki, Ikesue Hiroaki, Tsujikawa Tomoko, Nagata Kenichiro, Uchida Mayako, Suetsugu Kimitaka, Egashira Nobuaki, Muta Tsuyoshi, Kato Koji, Takenaka Katsuto, Ohga Saiji, Matsushima Takamitsu, Shiratsuchi Motoaki, Miyamoto Toshihiro, Teshima Takanori, Akashi Koichi, Oishi Ryozo

    Biological & Pharmaceutical Bulletin   36 ( 4 )   574 - 578   2013.4   ISSN:0918-6158

     More details

    Language:English   Publisher:(公社)日本薬学会  

    濾胞性リンパ腫またはマントル細胞性リンパ腫の患者において、ベンダムスチンにより引き起こされる静脈炎に関連する危険因子の評価を行った。また、ベンダムスチンの調製方法の変更が有効かどうかも検証した。全データは電子的な医療情報システムから後ろ向きに収集した。最初の解析ではベンダムスチン療法を受けた全43例を対象とした。殆どの患者(88%)は日本のベンダムスチンの添付文書の指示にしたがって250mLに希釈したベンダムスチンが投与されていた。ベンダムスチンの希釈液の最終用量が250mLと500mLではベンダムスチン溶液の中間濃度(0.56mg/mL対0.24mg/mL)と静脈炎の発症率(66%対0%、p=0.01)は有意に異なっていた。この結果をもとに、ベンダムスチンの希釈液の用量を250mLから他国で推奨されている500mLに変更することを推奨した。静脈炎の発症率は濃度依存的に増加した(40mg/mL以下では6%、0.41~0.60mg/mLの範囲では62%、60mg/mLより高い場合は75%、p<0.001)。以上の結果から、高濃度のベンダムスチン溶液は血管炎発症の危険因子であり、500mLの希釈液量が望ましいと考えられた。血管炎の発症率を更に減少させるためにはベンダムスチン溶液の濃度は0.40mg/mL以下が推奨されると考えられた。

  • Endoscopic approach through the minor papilla for the management of pancreatic diseases.

    Fujimori N, Igarashi H, Asou A, Kawabe K, Lee L, Oono T, Nakamura T, Niina Y, Hijioka M, Uchida M, Kotoh K, Nakamura K, Ito T, Takayanagi R

    World journal of gastrointestinal endoscopy   5 ( 3 )   81 - 8   2013.3   ISSN:1948-5190

     More details

    Language:English  

    DOI: 10.4253/wjge.v5.i3.81

    PubMed

  • Antiemetic effectiveness and safety of aprepitant in patients with hematologic malignancy receiving multiday chemotherapy Reviewed International journal

    Mayako Uchida, Hiroaki Ikesue, Koji Kato, Kimiko Ichinose, Hiromi Hiraiwa, Asako Sakurai, Katsuto Takenaka, Hiromi Iwasaki, Toshihiro Miyamoto, Takanori Teshima, Nobuaki Egashira, Koichi Akashi, Ryozo Oishi

    American Journal of Health-System Pharmacy   70 ( 4 )   343 - 349   2013.2   ISSN:1079-2082

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

    Purpose. Antiemetic effectiveness and safety of aprepitant in patients with hematologic malignancy receiving multiday chemotherapy were evaluated. Methods. All data were retrospectively collected from the Kyushu University Hospital's electronic medical record system. Patients age 20 years or older with hematologic malignancies who received multiday chemotherapy were included in the study. All patients received 3 mg of granisetron i.v. 30 minutes before chemotherapy administration. Patients in the aprepitant group received 125 mg of aprepitant orally 60-90 minutes before administration of the first moderately to highly emetogenic chemotherapy (day 1). On day 2 or thereafter, an 80-mg oral dose of aprepitant was administered in the morning for up to five days. The primary endpoint was the percentage of patients who achieved complete response (CR). Results. A total of 42 patients were treated with aprepitant and granisetron as antiemetic prophylaxis between April and December 2010 (aprepitant group), and 40 patients were treated with only granisetron between March 1, 2009, and March 31, 2010, before the introduction of aprepitant. The percentage of patients who achieved CR in the aprepitant group was significantly higher than that in the control group (p = 0.01). Factors that were significantly associated with non-CR included the prophylactic use of aprepitant and chemotherapies containing ≥4 g/m2/day of cytarabine. The rates of adverse drug events (ADEs) did not significantly differ between groups. Conclusion. The addition of aprepitant to granisetron increased the antiemetic effect without influencing ADEs in patients treated with moderately to highly emetogenic multiday chemotherapy for hematologic malignancies. Copyright © 2013, American Society of Health-System Pharmacists, Inc.

    DOI: 10.2146/ajhp120363

    Scopus

    PubMed

  • Retroperitoneal fibrosis associated with immunoglobulin G4-related disease.

    Fujimori N, Ito T, Igarashi H, Oono T, Nakamura T, Niina Y, Hijioka M, Lee L, Uchida M, Takayanagi R

    World journal of gastroenterology   19 ( 1 )   35 - 41   2013.1   ISSN:1007-9327

     More details

    Language:English  

    DOI: 10.3748/wjg.v19.i1.35

    PubMed

  • ERK pathway and sheddases play an essential role in ethanol-induced CX3CL1 release in pancreatic stellate cells.

    Uchida M, Ito T, Nakamura T, Igarashi H, Oono T, Fujimori N, Kawabe K, Suzuki K, Jensen RT, Takayanagi R

    Laboratory investigation; a journal of technical methods and pathology   93 ( 1 )   41 - 53   2013.1   ISSN:0023-6837

     More details

    Language:English  

    DOI: 10.1038/labinvest.2012.156

    PubMed

  • Decrease in Venous Irritation by Adjusting the Concentration of Injected Bendamustine

    Watanabe Hiroyuki, Ikesue Hiroaki, Tsujikawa Tomoko, Nagata Kenichiro, Uchida Mayako, Suetsugu Kimitaka, Egashira Nobuaki, Muta Tsuyoshi, Kato Koji, Takenaka Katsuto, Ohga Saiji, Matsushima Takamitsu, Shiratsuchi Motoaki, Miyamoto Toshihiro, Teshima Takanori, Akashi Koichi, Oishi Ryozo

    Biological and Pharmaceutical Bulletin   36 ( 4 )   574 - 578   2013   ISSN:09186158 eISSN:13475215

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:The Pharmaceutical Society of Japan  

    Intravenous injection of bendamustine often causes venous irritation and also deteriorates the patient’s quality of life. Thus, we evaluated the risk factors associated with venous irritation induced by bendamustine in patients with follicular lymphoma or mantle cell lymphoma. We also evaluated the effectiveness of intervention of changing the preparation procedure for bendamustine. All data were retrospectively collected from the electronic medical record system. In the initial analysis of the total 43 courses of bendamustine therapy, most patients (88%) were administered bendamustine with 250 mL of diluent according to the bendamustine package insert in Japan. The median concentration of bendamustine solution (0.56 mg/mL <i>vs.</i> 0.24 mg/mL) and the incidences of venous irritation (66% <i>vs.</i> 0%, <i>p</i>=0.01) were significantly different between the patients receiving bendamustine at 250 mL and 500 mL of diluent. Based on this result, we proposed changing the final volume of bendamustine dissolution from 250 to 500 mL, which is recommended in other countries. After this intervention, the incidence of venous irritation was significantly reduced from 58 to 20% (<i>p</i>=0.02). The incidence of venous irritation increased in a concentration-dependent manner (≤0.40 mg/mL: 6%; 0.41–0.60 mg/mL: 62%, <i>p</i><0.001; >0.60 mg/mL: 75%, <i>p</i><0.001). We conclude that a high concentration bendamustine solution is a risk factor for venous irritation and that 500 mL of diluent is ideal. To further reduce the incidence of venous irritation, the concentration of bendamustine solution is recommended to be 0.40 mg/mL or less.

    DOI: 10.1248/bpb.b12-00901

    Web of Science

    PubMed

    CiNii Research

  • Effectiveness and safety of aprepitant in allogeneic hematopoietic stem cell transplantation recipients Reviewed

    内田 まやこ

    Pharmacotherapy   (In press)   2013

     More details

  • Effectiveness and Safety of Antiemetic Aprepitant in Japanese Patients Receiving High-Dose Chemotherapy Prior to Autologous Hematopoietic Stem Cell Transplantation

    Uchida Mayako, Ikesue Hiroaki, Miyamoto Toshihiro, Kato Koji, Suetsugu Kimitaka, Ichinose Kimiko, Hiraiwa Hiromi, Sakurai Asako, Takenaka Katsuto, Muta Tsuyoshi, Iwasaki Hiromi, Teshima Takanori, Shiratsuchi Motoaki, Egashira Nobuaki, Akashi Koichi, Oishi Ryozo

    Biological and Pharmaceutical Bulletin   36 ( 5 )   819 - 824   2013   ISSN:09186158 eISSN:13475215

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:The Pharmaceutical Society of Japan  

    For patients receiving high-dose chemotherapy, a 5-hydroxytryptamine 3 receptor antagonist combined with dexamethasone is a standard antiemetic therapy. Despite this prophylactic anti-emetic treatment, many patients still suffer from uncontrollable emesis. In this study, we retrospectively evaluated the antiemetic effectiveness and safety of aprepitant (a neurokinin-1 receptor antagonist) in addition to 5-HT<sub>3</sub> antagonist in Japanese patients with hematologic malignancy receiving high-dose chemotherapy prior to autologous peripheral blood stem cell transplantation (auto-PBSCT). Twenty-six patients received aprepitant and granisetron (the aprepitant group), whereas, 22 patients received granisetron alone (the control group). All patients received 3 mg of granisetron intravenously 30 min before chemotherapy administration. Patients in the aprepitant group additionally received 125 mg of aprepitant 60–90 min before administration of the first moderately to highly emetogenic chemotherapy. On the next day or thereafter, 80 mg of aprepitant was administered in the morning until the last administration of moderately to highly emetogenic anticancer drugs. The percentage of patients who achieved complete response (CR), defined as no emesis with only grade 1–2 nausea, in the aprepitant group was significantly higher than that in the control group (42% <i>vs.</i> 5%, <i>p</i>=0.003). Logistic regression analysis showed that non-prophylactic use of aprepitant was significantly associated with non-CR. The frequencies of adverse drug events (ADEs) were not significantly different between two groups. In conclusion, the results of this study suggest that the addition of aprepitant to granisetron can improve the antiemetic effect without increasing ADEs in patients receiving high-dose chemotherapy prior to auto-PBSCT.

    DOI: 10.1248/bpb.b12-01012

    Web of Science

    PubMed

    CiNii Research

  • Effectiveness and safety of antiementic aprepitant in Japanese patients receiving high-dose chemotherapy prior to autologous hematopoietic stem cell transplantation Reviewed

    内田 まやこ

    Biol. Pharm. Bull.   (In press)   2013

     More details

  • P1-159 自家造血幹細胞移植前処置におけるアプレピタントの有用性および安全性の検討(がん薬物療法(制吐支持療法),ポスター,一般演題,岐路に立つ医療~千年紀の目覚め~よみがえれ!ニッポン!薬の改革は我らが手で!)

    末次 王卓, 内田 まやこ, 池末 裕明, 内田 沙織, 加藤 光次, 宮本 敏浩, 渡邊 裕之, 末安 正典, 江頭 伸昭, 大石 了三

    日本医療薬学会年会講演要旨集   22 ( 0 )   293   2012.10   eISSN:24242470

     More details

    Language:Japanese   Publisher:一般社団法人 日本医療薬学会  

    DOI: 10.20825/amjsphcs.22.0_293_3

    CiNii Research

  • Relationship between pancreatic and/or extrapancreatic lesions and serum IgG and IgG4 levels in IgG4-related diseases.

    Igarashi H, Ito T, Oono T, Nakamura T, Fujimori N, Niina Y, Hijioka M, Uchida M, Lee R, Iwao R, Nakamura K, Kotoh K, Takayanagi R

    Journal of digestive diseases   13 ( 5 )   274 - 9   2012.5   ISSN:1751-2972

     More details

    Language:English  

    DOI: 10.1111/j.1751-2980.2012.00583.x

    PubMed

  • 疼痛ケアにおける看護師への薬学的教育支援とその効果

    今井 智之, 辻 敏和, 長坂 明日香, 内田 まやこ, 渡邊 裕之, 末安 正典, 江頭 伸昭, 大石 了三

    医療薬学   38 ( 4 )   237 - 245   2012.4   ISSN:1346-342X

     More details

    Language:Japanese   Publisher:(一社)日本医療薬学会  

    看護師に対するり疼痛ケア教育の一環として、薬剤師と看護師で共用できる新たな患者向けの説明資料の作成、講習会の開催などの教育支援に取り組み、その効果について検討した。説明資料の運用、講習会の開催などの教育支援を実施した対象診療科の看護師99例に対して、支援前、支援1ヵ月後(講習会前)、支援2ヵ月後にアンケート調査を実施した。教育支援に応じた「適切な疼痛ケアの実践」のスコアは教育支援に応じて上昇し、支援前と支援2ヵ月後では有意差がみられた。これら実践スコアの「説明資料の活用方法」および「講習会受講の有無」による群別分類では、支援2ヵ月後に有意に上昇した。講習会受講による知識の向上を確認した。また、薬剤師による講習会などの教育支援の必要性については、「極めて必要である」は76.7%、「ある程度必要である」は20.5%で、「あまり必要でない」および「全く必要でない」は共に0%であった。

  • Cytosolic double-stranded DNA as a damage-associated molecular pattern induces the inflammatory response in rat pancreatic stellate cells: a plausible mechanism for tissue injury-associated pancreatitis.

    Nakamura T, Ito T, Igarashi H, Uchida M, Hijioka M, Oono T, Fujimori N, Niina Y, Suzuki K, Jensen RT, Takayanagi R

    International journal of inflammation   2012   504128   2012   ISSN:2090-8040

     More details

    Language:English  

    DOI: 10.1155/2012/504128

    PubMed

  • Pharmaceutical Education Support for Nurses in Pain Management

    Imai Tomoyuki, Tsuji Toshikazu, Nagasaka Asuka, Uchida Mayako, Watanabe Hiroyuki, Sueyasu Masanori, Egashira Nobuaki, Oishi Ryozo

    Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)   38 ( 4 )   237 - 245   2012   ISSN:1346342X eISSN:18821499

     More details

    Language:Japanese   Publisher:Japanese Society of Pharmaceutical Health Care and Sciences  

    Pain management is important in the care of cancer patients. However, narcotic drugs are still not well understood by either patients or medical staff in Japan, which is an obstacle to the development of appropriate pain management. In the present study, we attempted to improve pain management through pharmaceutical education support for nurses. We prepared explanatory materials on narcotic drugs for patients and asked nurses to use them for 2 months to improve pain management. We also held a lecture on pain management and narcotic drugs a month after distributing the materials. In addition, we carried out three questionnaire surveys on the nurses to evaluate the effect of pharmaceutical education support on the understanding of pain management, anxiety and implementation status. Our education support improved nurse's understanding of pain management (score: 4.7 to 6.4, <i>p</i><0.01), lessened anxiety (score: 5.9 to 3.8, <i>p</i><0.01), and led to appropriate practical pain management (score: 4.3 to 6.1, <i>p</i><0.01). These results suggest that the pharmaceutical education support for nurses is useful for improving practical pain management.

    DOI: 10.5649/jjphcs.38.237

    CiNii Research

    J-GLOBAL

  • 看護師の疼痛ケアに関する現状調査と薬学的支援の検討

    長坂明日香, 辻敏和, 別城朋子, 渡邊裕之, 内田まやこ, 平川良宏, 末安正典, 江頭伸昭, 大石了三

    九州薬学会会報   ( 65 )   43 - 46   2011.10   ISSN:0368-7279

     More details

    Language:Japanese  

    J-GLOBAL

  • Vasoactive intestinal peptide reduces oxidative stress in pancreatic acinar cells through the inhibition of NADPH oxidase.

    Fujimori N, Oono T, Igarashi H, Ito T, Nakamura T, Uchida M, Coy DH, Jensen RT, Takayanagi R

    Peptides   32 ( 10 )   2067 - 76   2011.10   ISSN:0196-9781

     More details

    Language:English  

    DOI: 10.1016/j.peptides.2011.08.027

    PubMed

  • 看護師の疼痛ケアに関する現状調査と薬学的支援の検討

    長坂 明日香, 辻 敏和, 別城 朋子, 渡邊 裕之, 内田 まやこ, 平川 良宏, 末安 正典, 江頭 伸昭, 大石 了三

    九州薬学会会報   ( 65 )   43 - 46   2011.10   ISSN:0368-7279

     More details

    Language:Japanese   Publisher:九州山口薬学会  

    2007年施行のがん対策基本法により,緩和医療ががん治療の早期から開始すべき医療と位置付けられた。本研究では,今後の薬学的支援を考えるために,医療用麻薬(以下,麻薬)を使用している診療科の病棟看護師を対象に,疼痛・副作用コントロールの現状,業務内容の状況,疼痛ケアにおける問題点に関してアンケート調査を実施した。その結果,疼痛・副作用コントロールは「どちらでもない」と「ある程度実施できている」との回答が多く,まだ不十分であることがわかった。業務内容に関しては,麻薬の相互作用・配合変化に関することの実施が不十分であった。また,「看護師への疼痛ケア教育」,「患者の麻薬に対する抵抗感」に対する問題意識が高かった。病院薬剤師は,患者ケアの充実を図るとともに疼痛ケアに関する看護師教育,情報提供などを積極的に行っていく必要がある。(著者抄録)

  • P-0078 造血器腫瘍におけるアプレピタントの効果と安全性の検討(一般演題 ポスター発表,がん薬物療法(副作用対策),Enjoy Pharmacists' Lifestyles)

    内田 まやこ, 一ノ瀬 喜美子, 平岩 ひろみ, 櫻井 麻子, 加藤 光次, 宮本 敏浩, 池末 裕明, 末安 正典, 江頭 伸昭, 大石 了三

    日本医療薬学会年会講演要旨集   21 ( 0 )   194   2011.9   eISSN:24242470

     More details

    Language:Japanese   Publisher:一般社団法人 日本医療薬学会  

    DOI: 10.20825/amjsphcs.21.0_194_6

    CiNii Research

  • 血液内科病棟での薬剤師の役割 : 同志の存在・横のつながりの必要性(シンポジウム21 血液腫瘍の世界へ飛び込め~HematologyとOncologyの壁を越えよう~,Enjoy Pharmacists' Lifestyles)

    内田 まやこ, 池末 裕明, 石丸 隆之, 渡邊 裕之, 三嶋 一登, 大石 了三

    日本医療薬学会年会講演要旨集   21 ( 0 )   87   2011.9   eISSN:24242470

     More details

    Language:Japanese   Publisher:一般社団法人 日本医療薬学会  

    DOI: 10.20825/amjsphcs.21.0_87_2

    CiNii Research

  • P-0537 薬剤管理指導業務の標準化を目的とした「指導の要点と記録のポイント集」の作成(一般演題 ポスター発表,品質管理,Enjoy Pharmacists' Lifestyles)

    池末 裕明, 児玉 亜由美, 別城 朋子, 内田 まやこ, 渡邊 裕之, 園田 正信, 末安 正典, 江頭 伸昭, 大石 了三

    日本医療薬学会年会講演要旨集   21 ( 0 )   271   2011.9   eISSN:24242470

     More details

    Language:Japanese   Publisher:一般社団法人 日本医療薬学会  

    DOI: 10.20825/amjsphcs.21.0_271_3

    CiNii Research

  • Bacterial DNA promotes proliferation of rat pancreatic stellate cells thorough toll-like receptor 9: potential mechanisms for bacterially induced fibrosis.

    Nakamura T, Ito T, Oono T, Igarashi H, Fujimori N, Uchida M, Niina Y, Yasuda M, Suzuki K, Takayanagi R

    Pancreas   40 ( 6 )   823 - 31   2011.8   ISSN:0885-3177

     More details

    Language:English  

    DOI: 10.1097/MPA.0b013e318224a501

    PubMed

  • Characteristics of pancreatic diabetes in patients with autoimmune pancreatitis.

    Ito T, Nakamura T, Fujimori N, Niina Y, Igarashi H, Oono T, Uchida M, Kawabe K, Takayanagi R, Nishimori I, Otsuki M, Shimosegawa T

    Journal of digestive diseases   12 ( 3 )   210 - 6   2011.6   ISSN:1751-2972

     More details

    Language:English  

    DOI: 10.1111/j.1751-2980.2011.00498.x

    PubMed

  • P1-533 九州大学病院がん化学療法薬薬連携セミナー開催とその評価(一般演題 ポスター発表,地域・在宅医療・薬薬連携,臨床から学び臨床へと還元する医療薬学)

    渡邊 裕之, 内田 まやこ, 池末 裕明, 三嶋 一登, 末次 王卓, 児玉 亜由美, 大林 かよ, 山路 寛子, 山口 麻美, 斎藤 麻美, 石川 瑠美佳, 末安 正典, 江頭 伸昭, 水元 一博, 大石 了三

    日本医療薬学会年会講演要旨集   20 ( 0 )   376   2010.10   eISSN:24242470

     More details

    Language:Japanese   Publisher:一般社団法人 日本医療薬学会  

    DOI: 10.20825/amjsphcs.20.0_376_1

    CiNii Research

  • S7-6 血液がん標準薬物治療と薬学的介入の実際(シンポジウムS7 がん治療における薬学的介入・薬剤管理指導の実際(がん専門薬剤師教育セミナー),臨床から学び臨床へと還元する医療薬学)

    三嶋 一登, 内田 まやこ, 池末 裕明, 大石 了三

    日本医療薬学会年会講演要旨集   20 ( 0 )   210   2010.10   eISSN:24242470

     More details

    Language:Japanese   Publisher:一般社団法人 日本医療薬学会  

    DOI: 10.20825/amjsphcs.20.0_210_2

    CiNii Research

  • P2-288 ゼヴァリン療法のクリティカルパス作成(一般演題 ポスター発表,癌薬物療法(入院化学療法),臨床から学び臨床へと還元する医療薬学)

    内田 まやこ, 山口 麻美, 池末 裕明, 松江 祥子, 平岩 ひろみ, 馬場 眞吾, 原田 直樹, 宮本 敏浩, 豊嶋 崇徳, 江頭 伸昭, 大石 了三

    日本医療薬学会年会講演要旨集   20 ( 0 )   437   2010.10   eISSN:24242470

     More details

    Language:Japanese   Publisher:一般社団法人 日本医療薬学会  

    DOI: 10.20825/amjsphcs.20.0_437_6

    CiNii Research

  • A case of lipomatous pseudohypertrophy of the pancreas diagnosed by typical imaging.

    Yasuda M, Niina Y, Uchida M, Fujimori N, Nakamura T, Oono T, Igarashi H, Ishigami K, Yasukouchi Y, Nakamura K, Ito T, Takayanagi R

    JOP : Journal of the pancreas   11 ( 4 )   385 - 8   2010.7

     More details

    Language:English  

    PubMed

  • 再発多発性骨髄腫に対するボルテゾミブ療法における副作用発現頻度と発現時期の調査

    槇枝 大貴, 久枝 真一郎, 木下 英樹, 内田 まやこ, 池末 裕明, 三嶋 一登, 渡邉 裕之, 末安 正典, 宮本 敏浩, 江頭 伸昭, 大石 了三

    医療薬学   36 ( 4 )   270 - 276   2010.4   ISSN:1346-342X

     More details

    Language:Japanese   Publisher:(一社)日本医療薬学会  

    再発多発性骨髄腫に対するボルテゾミブ療法における副作用発現頻度と発現時期について調査した。ボルテゾミブを単独またはデキサメタゾンとの併用で投与された再発性多発性骨髄腫患者15例を対象とした。15例中10例で、ボルテゾミブ投与当日および翌日に肺障害予防のためデキサメタゾンが併用された。高頻度に認めた副作用は、便秘12例、白血球減少11例、ヘモグロビン減少11例、倦怠感11例、末梢神経障害10例、血小板減少10例、好中球減少10例、下痢7例、食欲不振7例などで、全般的に先行の臨床試験と類似したものであった。その他、頻度は低いが重篤な副作用症状として、肺障害および麻痺性イレウスがそれぞれ1例発現した。血液毒性は、Grade3以上の好中球減少および血小板減少はともに7例で発現した。

  • Investigation of Adverse Drug Reactions in Bortezomib Therapy for Relapsed Multiple Myeloma

    Makieda Daiki, Hisaeda Shinichiro, Kinoshita Hideki, Uchida Mayako, Ikesue Hiroaki, Mishima Kazuto, Watanabe Hiroyuki, Sueyasu Masanori, Miyamoto Toshihiro, Egashira Nobuaki, Oishi Ryozo

    Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)   36 ( 4 )   270 - 276   2010   ISSN:1346342X eISSN:18821499

     More details

    Language:Japanese   Publisher:Japanese Society of Pharmaceutical Health Care and Sciences  

    Bortezomib was approved in 2006 for use in patients with multiple myeloma.Although a high frequency of adverse drug reactions (ADRs) was reported in some clinical studies on bortezomib,little information is available on the time of occurrence of the ADRs.Therefore,we investigated the ADRs in 15 patients with relapsed multiple myeloma who received bortezomib alone or combined with dexamethasone,for 2 cycles.The ADRs with high frequencies were constipation (80.0%),leucopenia (73.3%),anemia (73.3%),fatigue (73.3%),peripheral neuropathy (66.7%) and thrombocytopenia (66.7%).The number of leukocytes decreased to the minimum on the 9th day and had recovered on the 14th day.The number of platelets decreased to the minimum on the 13th day,and had recovered on the 19th day.Gastrointestinal adverse reactions including constipation,diarrhea,nausea and vomiting were observed from the 5th day.<br>Based on these results,we prepared a patient education sheet showing the times of occurrence of high frequency ADRs in the therapy schedule visually.This sheet should be useful in gaining the understanding of patients and their families regarding bortezomib therapy as well as enhancing its safety.

    DOI: 10.5649/jjphcs.36.270

    CiNii Research

    J-GLOBAL

  • アントラサイクリン系抗がん剤の投与時間の短縮による血管外漏出の減少

    伊藤 美代, 池末 裕明, 末次 王卓, 内田 まやこ, 三嶋 一登, 佐々木 智啓, 森山 智彦, 江頭 伸昭, 大石 了三

    日本病院薬剤師会雑誌   45 ( 12 )   1613 - 1615   2009.12   ISSN:1341-8815

     More details

    Language:Japanese   Publisher:(一社)日本病院薬剤師会  

    R-CHOP療法およびR-THP-COP療法において、ドキソルビシン(doxorubicin:以下、DXR)およびピラルビシン(pirarubicin:以下、THP)が血管外に漏出すると重大な皮膚障害を来し得る。九州大学病院消化管内科において心毒性を考慮してDXRおよびTHPを1時間で点滴静注していたが、血管外漏出が続発し、その発現頻度は10.8%(4件/37クール)であった。一方、放射線科ではDXRおよびTHPを5分以内で静脈内注射しており、血管外漏出は発現していなかった(0件/36クール)。そこで、血管外漏出の要因分析および文献調査を行い、投与方法についてカンファレンス等で協議し5分以内での静脈内注射へ変更したところ、その後血管外漏出は発現しなかった(0件/28クール)。DXRおよびTHPを5分以内で静脈内注射することで血管外漏出のリスクが著明に軽減されることが明らかとなった。(著者抄録)

    J-GLOBAL

  • アントラサイクリン系抗がん剤の投与時間の短縮による血管外漏出の減少

    伊藤 美代, 池末 裕明, 末次 王卓, 内田 まやこ, 三嶋 一登, 佐々木 智啓, 森山 智彦, 江頭 伸昭, 大石 了三

    日本病院薬剤師会雑誌   45 ( 12 )   1613 - 1615   2009.12   ISSN:1341-8815

     More details

    Language:Japanese   Publisher:(一社)日本病院薬剤師会  

    R-CHOP療法およびR-THP-COP療法において、ドキソルビシン(doxorubicin:以下、DXR)およびピラルビシン(pirarubicin:以下、THP)が血管外に漏出すると重大な皮膚障害を来し得る。九州大学病院消化管内科において心毒性を考慮してDXRおよびTHPを1時間で点滴静注していたが、血管外漏出が続発し、その発現頻度は10.8%(4件/37クール)であった。一方、放射線科ではDXRおよびTHPを5分以内で静脈内注射しており、血管外漏出は発現していなかった(0件/36クール)。そこで、血管外漏出の要因分析および文献調査を行い、投与方法についてカンファレンス等で協議し5分以内での静脈内注射へ変更したところ、その後血管外漏出は発現しなかった(0件/28クール)。DXRおよびTHPを5分以内で静脈内注射することで血管外漏出のリスクが著明に軽減されることが明らかとなった。(著者抄録)

  • 緩和ケアチームにおける薬剤師の取り組みとオピオイド使用量からみたその評価

    山路寛子, 渡邊裕之, 白水景子, 内田まやこ, 児玉亜由美, 角田朋子, 辻敏和, 平川良宏, 末安正典, 江頭伸昭, 大石了三

    九州薬学会会報   ( 63 )   43 - 46   2009.10   ISSN:0368-7279

     More details

    Language:Japanese  

    J-GLOBAL

  • 緩和ケアチームにおける薬剤師の取り組みとオピオイド使用量からみたその評価

    山路 寛子, 渡邊 裕之, 白水 景子, 内田 まやこ, 児玉 亜由美, 角田 朋子, 辻 敏和, 平川 良宏, 末安 正典, 江頭 伸昭, 大石 了三

    九州薬学会会報   ( 63 )   43 - 46   2009.10   ISSN:0368-7279

     More details

    Language:Japanese   Publisher:九州山口薬学会  

    2007年4月,がん対策基本法施行に伴い,九州大学病院において緩和ケアチームが発足した。薬剤師はチームの一員としてカンファレンスへの参加や,疼痛マニュアルの作成など様々な活動を行ってきたが,2008年10月より薬剤師は兼任制から専従制となった。緩和ケアチームにおける薬剤師参画の有用性をチーム発足前後でのオピオイド鎮痛薬の総使用量から検討した。またWHO 3段階除痛ラダーの遵守状況を確認するため患者166名において,レスキューあるいはNSAIDs・アセトアミノフェンの処方の有無を調査した。その結果,緩和ケアチームの発足後,薬剤師の介入により,オピオイド鎮痛薬の使用量は明らかな増加傾向を示したが,WHO 3段階除痛ラダーは必ずしも遵守されていないことが明らかとなった。(著者抄録)

  • O14-007 抗がん剤治療における体表面積算出に関する調査と算出式の統一(一般演題 口頭発表,がん薬物療法,医療薬学の創る未来 科学と臨床の融合)

    岡田 昌之, 成末 まさみ, 松浦 まなみ, 杉本 悠花, 岩本 英子, 池末 裕明, 内田 まやこ, 渡邊 裕之, 末安 正典, 大石 了三

    日本医療薬学会年会講演要旨集   19 ( 0 )   284   2009.9   eISSN:24242470

     More details

    Language:Japanese   Publisher:一般社団法人 日本医療薬学会  

    DOI: 10.20825/amjsphcs.19.0_284_4

    CiNii Research

  • S15-4 がん化学療法における副作用への対応(シンポジウムS15 がん治療に貢献する専門薬剤師,医療薬学の創る未来 科学と臨床の融合)

    池末 裕明, 末次 王卓, 渡邉 裕之, 内田 まやこ, 三嶋 一登, 末安 正典, 江頭 伸昭, 大石 了三

    日本医療薬学会年会講演要旨集   19 ( 0 )   227   2009.9   eISSN:24242470

     More details

    Language:Japanese   Publisher:一般社団法人 日本医療薬学会  

    DOI: 10.20825/amjsphcs.19.0_227

    CiNii Research

  • 化学放射線療法における患者理解度向上のための服薬指導シートの改善

    内田 まやこ, 池末 裕明, 伊藤 美代, 藤原 朋子, 三嶋 一登, 末安 正典, 江頭 伸昭, 大石 了三

    日本病院薬剤師会雑誌   45 ( 2 )   247 - 250   2009.2   ISSN:1341-8815

     More details

    Language:Japanese   Publisher:(一社)日本病院薬剤師会  

    今回我々は、がん化学療法および化学放射線療法に対する患者の理解を高めるとともに、患者自身によるセルフケアの支援を目指して、薬剤管理指導業務の際に使用する服薬指導シートの改善を行った。改善点としては、記載内容である投与スケジュール、薬効および副作用に副作用の好発時期を追加し、従来の文章中心の様式から、より視覚的に理解しやすいものに変更した。実際に、九州大学病院の放射線科病棟において薬剤管理指導業務を行う際に新様式の服薬指導シートを患者に交付し、これを基に服薬指導を行ったところ、患者および医療スタッフには大変好評であった。特に、患者には治療に対する理解が深まり、不安の軽減とともに治療への意欲向上にもつながると思われる。さらに、医師および看護師との情報交換も増加し、患者情報および薬剤情報の共有化にも有用であると考えられた。(著者抄録)

    J-GLOBAL

  • 化学放射線療法における患者理解度向上のための服薬指導シートの改善

    内田 まやこ, 池末 裕明, 伊藤 美代, 藤原 朋子, 三嶋 一登, 末安 正典, 江頭 伸昭, 大石 了三

    日本病院薬剤師会雑誌   45 ( 2 )   247 - 250   2009.2   ISSN:1341-8815

     More details

    Language:Japanese   Publisher:(一社)日本病院薬剤師会  

    今回我々は、がん化学療法および化学放射線療法に対する患者の理解を高めるとともに、患者自身によるセルフケアの支援を目指して、薬剤管理指導業務の際に使用する服薬指導シートの改善を行った。改善点としては、記載内容である投与スケジュール、薬効および副作用に副作用の好発時期を追加し、従来の文章中心の様式から、より視覚的に理解しやすいものに変更した。実際に、九州大学病院の放射線科病棟において薬剤管理指導業務を行う際に新様式の服薬指導シートを患者に交付し、これを基に服薬指導を行ったところ、患者および医療スタッフには大変好評であった。特に、患者には治療に対する理解が深まり、不安の軽減とともに治療への意欲向上にもつながると思われる。さらに、医師および看護師との情報交換も増加し、患者情報および薬剤情報の共有化にも有用であると考えられた。(著者抄録)

  • 29-S4-4 抗がん剤による有害事象の早期発見・回避に向けた取り組み(シンポジウム29-S4 一歩進んだ「がん薬物業務」,社会の期待に応える医療薬学を)

    池末 裕明, 三嶋 一登, 内田 まやこ, 渡邉 裕之, 末安 正典, 大石 了三

    日本医療薬学会年会講演要旨集   17 ( 0 )   152   2007.9   eISSN:24242470

     More details

    Language:Japanese   Publisher:一般社団法人 日本医療薬学会  

    DOI: 10.20825/amjsphcs.17.0_152_2

    CiNii Research

  • 30-P1-125 オピオイド鎮痛薬適正使用のための緩下薬予防投与の推進(がん薬物療法,社会の期待に応える医療薬学を)

    末次 王卓, 池末 裕明, 内田 まやこ, 白水 景子, 尾川 理恵, 峯 昌敏, 渡邊 裕之, 三嶋 一登, 末安 正典, 江頭 伸昭, 大石 了三

    日本医療薬学会年会講演要旨集   17 ( 0 )   313   2007.9   eISSN:24242470

     More details

    Language:Japanese   Publisher:一般社団法人 日本医療薬学会  

    DOI: 10.20825/amjsphcs.17.0_313_6

    CiNii Research

  • 進行および再発食道がんに対するLow dose FP放射線同時併用療法における副作用管理

    内田 まやこ, 野尻 宣仁子, 村上 裕子, 山路 寛子, 池末 裕明, 三嶋 一登, 古賀 友一郎, 末安 正典, 吉川 学, 伊藤 善規, 大石 了三

    日本病院薬剤師会雑誌   43 ( 3 )   361 - 364   2007.3   ISSN:1341-8815

     More details

    Language:Japanese   Publisher:(一社)日本病院薬剤師会  

    我々はこれまで、抗がん剤による副作用頻度や発現時期について文献的に調査することにより、種々の化学療法レジメンに対応したがん化学療法ワークシートを作成し、確実かつ効率的な薬剤管理指導業務の実践に役立ててきた。しかしながら、この方法は通常とは異なる用量、もしくは用法の化学療法レジメン、あるいは放射線との併用療法(化学放射線療法)には対応できていなかった。今回、九州大学病院放射線科にてLow dose FP放射線併用療法が行われた16人の食道がん患者に対して薬剤管理指導業務を実施し、そのなかで副作用の発現状況について詳しく調査するとともに、予防もしくは治療のための対策など薬学的関与の必要性について検討した。また、これらのデータを基に、より効率的かつ質の高い薬剤管理指導業務を支援するための処方チェック・副作用モニタリングシートを作成した。(著者抄録)

    J-GLOBAL

  • Evidence for an alpha cluster condensed state in ^<16>O(α,α') at 400 MeV(International Workshop on Nuclear Structure-New Pictures in the Extended Isospin Space(NS07)-)

    WAKASA T., IHARA E., FUJITA K., FUNAKI Y., HATANAKA K., HORHICHI H., ITOH M., KAMIYA J., ROPKE G., SAKAGUCHI H., SAKAMOTO N., SAKEMI Y., SCHUCK P., SHIMIZU Y., TAKASHINA M., TERASHIMA S., OHSAKI A., UCHIDA M., YOSHIDA H. P., YOSOI M

    Soryushiron Kenkyu Electronics   115 ( 3 )   C35   2007   ISSN:03711838 eISSN:24332895

     More details

    Language:English   Publisher:Soryushiron Kenkyu Editorial Office  

    DOI: 10.24532/soken.115.3_c35

    CiNii Research

  • Prophylactic effect of pemirolast, an antiallergic agent, against hypersensitivity reactions to paclitaxel in patients with ovarian cancer Reviewed International journal

    H Yahata, M Saito, T Sendo, Y Itoh, M Uchida, T Hirakawa, H Nakano, R Oishi

    INTERNATIONAL JOURNAL OF CANCER   118 ( 10 )   2636 - 2638   2006.5   ISSN:0020-7136

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:WILEY-LISS  

    We have previously shown that sensory nerve peptides contribute to the pathogenesis of pulmonary hypersensitivity reactions (HSRs) to paclitaxel in rats. Moreover, pemirolast, an antiallergic agent, reverses the HSRs to paclitaxel, although the mechanism is considered to result from the blockade of paclitaxel-induced release of sensory peptides, rather than the inhibition of histamine release. In the present study, we investigated the preventive effect of pemirolast against acute HSRs in a total of 84 patients who undertook postoperative paclitaxel plus carboplatin chemotherapy every 4 weeks for ovarian cancer. Patients were assigned to receive oral lactose (placebo) or pemirolast (10 mg), 2 hr before paclitaxel infusion. All patients received conventional premedication, including oral diphenhydramine, intravenous ranitidine and intravenous dexamethasone, 30 min before paclitaxel infusion. The HSRs that led to the discontinuance of paclitaxel infusion (grade &gt;= 2) occurred in 5 of 42 patients in placebo group, whereas none of pemirolast-treated 42 patients showed any signs of HSRs. Plasma histamine concentrations were not changed after paclitaxel infusion in either group. Our present findings suggest that pemirolast is potentially useful for prophylaxis of paclitaxel-induced HSRs. In this respect, the use of permirolast as premedication is expected to be beneficial to the safety management in patients who undergo chemotherapy containing paclitaxel. (c) 2005 Wiley-Liss, Inc.

    DOI: 10.1002/ijc.21680

    Web of Science

    PubMed

  • 心臓カテーテル検査における「お薬説明書」を用いた薬剤管理指導の有用性―ヨード造影剤の遅発性副作用による不安を軽減するために―

    内田まやこ, 安芸敬生, 白水景子, 池末裕明, 三嶋一登, 末安正典, 千堂年昭, 吉川学, 伊藤善規, 大石了三

    日本病院薬剤師会雑誌   42 ( 3 )   347 - 350   2006.3   ISSN:1341-8815

     More details

    Language:Japanese  

    J-GLOBAL

  • 心臓カテーテル検査における「お薬説明書」を用いた薬剤管理指導の有用性 ヨード造影剤の遅発性副作用による不安を軽減するために

    内田 まやこ, 安藝 敬生, 白水 景子, 池末 裕明, 三嶋 一登, 末安 正典, 千堂 年昭, 吉川 学, 伊藤 善規, 大石 了三

    日本病院薬剤師会雑誌   42 ( 3 )   347 - 350   2006.3   ISSN:1341-8815

     More details

    Language:Japanese   Publisher:(一社)日本病院薬剤師会  

    著者らは心臓カテーテル検査に使用される薬剤の「お薬説明書」を作成し,これを循環器内科の入院患者に用い,服薬指導を行なっている。そこで,これらを踏まえて,「お薬説明書」の有用性ならびに服薬指導の必要性について患者アンケート調査を行なった.その結果,検査前に医師より説明を受けているのにもかかわらず,服薬指導によってはじめて造影剤による遅発性副作用を知ったと答えた患者は65%もいた.また,一方で副作用に対する不安が軽減されたと答えた患者は68%いた.以上,これらのことから,心臓カテーテル検査において「お薬説明書」を用いた服薬指導は有用であると示唆された

  • Monitoring for potential adverse drug reactions in patients receiving chemotherapy.

    Ikesue H, Ishida M, Uchida M, Harada M, Haro T, Mishima K, Itoh Y, Kotsubo K, Yoshikawa M, Oishi R

    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists   61 ( 22 )   2366, 2368 - 9   2004.11   ISSN:1079-2082

     More details

    Language:English  

    DOI: 10.1093/ajhp/61.22.2366

    PubMed

  • Monitoring for potential adverse drug reactions in patients receiving chemotherapy Reviewed International journal

    H Ikesue, M Ishida, M Uchida, M Harada, T Haro, K Mishima, Y Itoh, K Kotsubo, M Yoshikawa, R Oishi

    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY   61 ( 22 )   2366 - +   2004.11   ISSN:1079-2082

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:AMER SOC HEALTH-SYSTEM PHARMACISTS  

    Web of Science

    PubMed

  • P-123 心臓カテーテル検査実施患者における薬剤管理指導業務(5.薬剤服用歴管理・服薬指導(入院患者服薬指導),"薬剤師がつくる薬物治療"-薬・薬・学の連携-)

    内田 まやこ, 安藝 敬生, 白水 景子, 末安 正典, 吉川 学, 伊藤 善規, 大石 了三

    日本医療薬学会年会講演要旨集   14 ( 0 )   247   2004.9   eISSN:24242470

     More details

    Language:Japanese   Publisher:一般社団法人 日本医療薬学会  

    DOI: 10.20825/amjsphcs.14.0_247_3

    CiNii Research

  • P-298 婦人科におけるがん化学療法ワークシートの有用性

    内田 まやこ, 原田 路子, 池末 裕明, 小坪 一哉, 伊藤 善規, 大石 了三

    日本医療薬学会年会講演要旨集   13 ( 0 )   233   2003.9   eISSN:24242470

     More details

    Language:Japanese   Publisher:一般社団法人 日本医療薬学会  

    DOI: 10.20825/amjsphcs.13.0_233_2

    CiNii Research

  • 眼科病棟における薬剤管理指導業務の標準化

    内田まやこ, 平川雅章, 工藤智世, 川重誠, 吉川学, 中尾泰史, 伊藤善規, 大石了三

    日本病院薬剤師会雑誌   39 ( 5 )   587 - 590   2003.5   ISSN:1341-8815

     More details

    Language:Japanese  

    J-GLOBAL

  • 眼科病棟における薬剤管理指導業務の標準化

    内田 まやこ, 平川 雅章, 工藤 智世, 川重 誠, 吉川 学, 中尾 泰史, 伊藤 善規, 大石 了三

    日本病院薬剤師会雑誌   39 ( 5 )   587 - 590   2003.5   ISSN:1341-8815

     More details

    Language:Japanese   Publisher:(一社)日本病院薬剤師会  

    眼科病棟における入院患者情報と薬物療法に関する情報,腎障害患者における薬剤投与設計のための情報を収集,分析し,その結果をもとに薬剤情報シート,副作用モニタリングシート,繁用薬の腎障害患者における投薬設計シートを作成,活用することで薬剤管理指導業務の標準化を行ったところ,それが業務の効率化に極めてよく貢献した

  • Recombinant human serotonin 5A receptors stably expressed in C6 glioma cells couple to multiple signal transduction pathways.

    Noda M, Yasuda S, Okada M, Higashida H, Shimada A, Iwata N, Ozaki N, Nishikawa K, Shirasawa S, Uchida M, Aoki S, Wada K

    Journal of neurochemistry   84 ( 2 )   222 - 32   2003.1   ISSN:0022-3042

     More details

    Language:English  

    DOI: 10.1046/j.1471-4159.2003.01518.x

    PubMed

  • Sn isotope neutron densities extracted via proton elastic scattering at 300MeV

    Terashima S., Sakaguchi H., Takeda H., Ishikawa T., Itoh M., Uchida M., Kawabata T., Noro T., Yasuda Y., Yoshida Y.P., Asaji S., Ishida K., Yonemura T.

    Meeting Abstracts of the Physical Society of Japan   58.1.1 ( 0 )   83   2003   eISSN:21890803

     More details

    Language:Japanese   Publisher:The Physical Society of Japan  

    DOI: 10.11316/jpsgaiyo.58.1.1.0_83_4

    CiNii Research

▼display all

Books

  • 緩和医療薬学改訂第2版

    内田まやこ( Role: Contributor第3章 緩和医療に関する知識と実践能力. 12. 高カルシウム血症マネジメント.)

    南江堂  2023.4 

  • 緩和医療薬学改訂第2版

    内田まやこ( Role: Contributor第3章 緩和医療に関する知識と実践能力. 12. 高カルシウム血症マネジメント.)

    南江堂  2023.4 

  • 2ページで理解する標準薬物治療ファイル 改訂4版

    内田まやこ( Role: Contributor悪性腫瘍. 64. 慢性骨髄性白血病, 65.慢性リンパ性白血病)

    南山堂  2023.3 

  • 2ページで理解する標準薬物治療ファイル 改訂4版

    内田まやこ( Role: Contributor悪性腫瘍. 64. 慢性骨髄性白血病, 65.慢性リンパ性白血病)

    南山堂  2023.3 

  • ナーシング・グラフィカ 疾病の成り立ちと回復の促進② 臨床薬理学 第7版

    武田泰生, 内田まやこ( Role: Joint author血液・造血器疾患に使用する薬)

    メディカ出版  2023.1 

  • ナーシング・グラフィカ 疾病の成り立ちと回復の促進② 臨床薬理学 第7版

    武田泰生, 内田まやこ( Role: Joint author血液・造血器疾患に使用する薬)

    メディカ出版  2023.1 

  • がん化学療法レジメン管理マニュアル

    青山 剛 (薬剤師), 池末 裕明, 内田 まやこ, 佐藤 淳也, 高田 慎也, 土屋 雅美, 濱 敏弘( Role: Edit造血器腫瘍)

    医学書院  2023    ISBN:9784260050289

     More details

    Total pages:xvii, 908p   Language:Japanese  

    CiNii Books

  • 高齢者機能評価とレジメンでわかるがん薬物療法

    安藤雄一, 内田まやこ( Role: Joint author高齢者機能評価のドメインと評価ツール, ポリファーマシーへの薬学的介入)

    中外医学社  2022.10 

  • 高齢者機能評価とレジメンでわかるがん薬物療法

    安藤雄一, 内田まやこ( Role: Joint author高齢者機能評価のドメインと評価ツール, ポリファーマシーへの薬学的介入)

    中外医学社  2022.10 

  • 臨床腫瘍薬学 第2版

    内田まやこ( Role: Joint author(疾患) 慢性リンパ性白血病, 慢性骨髄性白血病, (支持療法)便秘)

    じほう  2022.9 

  • 薬剤師のための薬物療法問題集

    内田まやこ( Role: Joint author悪性腫瘍, 多発性骨髄腫)

    じほう  2022.9 

  • 臨床腫瘍薬学 第2版

    内田まやこ( Role: Joint author(疾患) 慢性リンパ性白血病, 慢性骨髄性白血病, (支持療法)便秘)

    じほう  2022.9 

  • 薬剤師のための薬物療法問題集

    内田まやこ( Role: Joint author悪性腫瘍, 多発性骨髄腫)

    じほう  2022.9 

  • がん薬物療法 : 副作用対策&曝露対策 : マナビジュアルノート

    佐藤, 淳也, 中西, 弘和, 菅, 幸生, 内田, まやこ( Role: Joint author第2章 消化器毒性, 第5章 神経障害, 第7章 口腔粘膜炎・口腔ケア)

    南山堂  2021.4    ISBN:9784525705312

     More details

    Total pages:x, 203p   Language:Japanese  

    CiNii Books

  • 薬剤師レジメントマニュアル第3版

    内田まやこ( Role: Joint author15章 血液疾患. 23節. 貧血, 24節. DIC)

    医学書院  2021.3 

  • 白血病治療マニュアル 改訂第4版

    清井 仁, 宮本敏浩, 宮脇修一, 中尾真二, 内田まやこ( Role: Joint author第Ⅴ章 毒性と合併症の対策, 注意点. 3. 悪心・嘔吐の予防と治療)

    南江堂  2020.11    ISBN:9784524226641

     More details

    Total pages:xviii, 348p   Language:Japanese  

    CiNii Books

  • 図解 腫瘍薬学

    内田まやこ( Role: Joint author第15章 がん薬物療法の有害事象と支持療法 3. 消化器毒性, 5. 心毒性, 6. 神経障害, 7. インフュージョンリアクション)

    南山堂  2020.8 

  • がん薬物療法のひきだし 腫瘍薬学の基本から応用まで

    内田まやこ(分担執筆, 担当範囲:第3章 がん薬物療法 24. 慢性骨髄性白血病 )(第3章 がん薬物療法 24. 慢性骨髄性白血病)

    医学書院  2020.4 

  • 薬局で役立つ経口抗がん薬はじめの一歩

    内田まやこ(分担執筆, 担当範囲:第1章, がん種別, 薬物治療の概要, 慢性骨髄性白血病, 多発性骨髄腫, 第2章 経口抗がん薬の特徴と使い方, 分子標的薬, チロシンキナーゼ阻害薬, BCR-ABL阻害薬, プロテアソーム阻害薬, 免疫調節薬, Mi, ステロイドに関する諸注意, 第4章 疼痛緩(第1章 がん種別 薬物治療の概要 7. 慢性骨髄性白血病, 8.多発性骨髄腫, 第2章 経口抗がん薬の特徴と使い方 分子標的薬 ④チロシンキナーゼ阻害薬 (BCR-ABL阻害薬), ⑪プロテアソーム阻害薬, 免疫調節薬 (IMiDs), ステロイドに関する諸注意, 第4章 疼痛緩和治療薬)

    羊土社  2020.4 

  • フローチャート抗がん薬副作用

    内田まやこ( Role: Joint author第1章 総論 2. 有効性・安全性を正しく評価するために)

    じほう  2020.3 

  • 整理して理解する抗がん薬 : 薬理・作用機序から理解する抗がん薬の使い方

    濱, 敏弘, 鈴木, 賢一(薬学), 大橋, 養賢, 内田, まやこ, 藤田, 行代志( Role: Joint authorプロテアソーム阻害薬)

    じほう  2019.9    ISBN:9784840752275

     More details

    Total pages:xxvii, 299p   Language:Japanese  

    CiNii Books

  • がん化学療法レジメン管理マニュアル 第3版

    内田まやこ( Role: Joint author第9章 造血器腫瘍 Ⅰ. 非ホジキンリンパ腫, 65. リツキシマブ+ベンダムスチン)

    医学書院  2019.8 

  • 2ページで理解する標準薬物治療ファイル 改訂3版

    内田まやこ( Role: Joint author悪性腫瘍 61. 慢性骨髄性白血病・慢性リンパ性白血病)

    南山堂  2019.6 

  • 臨床腫瘍薬学

    内田まやこ( Role: Joint author第4章 疾患 19-4. 慢性リンパ性白血病, 19-5. 慢性骨髄性白血病, 第5章 支持療法 2-3. 下痢)

    じほう  2019.3 

  • 薬剤師レジデントマニュアル第2版

    内田まやこ( Role: Contributor貧血, DIC, 胃がん, 大腸がん)

    医学書院  2018 

  • がん患者ロジカル・トータルサポート

    内田まやこ( Role: Contributor悪心・嘔吐, 神経障害性疼痛, 排泄障害)

    じほう  2017 

  • がん化学療法レジメン管理マニュアル第2版

    内田まやこ( Role: Contributor悪性リンパ腫, ベンダムスチン+リツキシマブ療法)

    医学書院  2016 

  • がん薬物療法マネジメントブック

    内田まやこ( Role: Contributor悪性リンパ腫)

    じほう  2016 

  • 緩和医療薬学問題集

    内田まやこ( Role: Contributor第2章 緩和薬物療法, 第3章 がんの基礎知識)

    じほう  2014 

  • みんなに役立つGVHDの基礎と臨床

    豊嶋崇徳, 内田まやこ( Role: ContributorGVHD患者の服薬指導、薬剤相互作用)

    医薬ジャーナル  2013 

  • 緩和医療薬学

    内田まやこ( Role: Contributor5大がんの特徴と標準薬物療法, 血液がん)

    南江堂  2013 

  • がん化学療法レジメン管理マニュアル

    内田まやこ( Role: Contributor多発性骨髄腫, BD(ボルテ ゾミブ+デキサメタゾン))

    医学書院  2012 

  • がん化学療法ワークシート改訂第4版

    内田まやこ( Role: Contributor)

    じほう  2012 

  • がん化学療法ワークシート改訂第3版

    内田まやこ( Role: Contributor)

    じほう  2008 

  • がん化学療法ワークシート改訂第2版

    内田まやこ( Role: Contributor)

    じほう  2005 

▼display all

Presentations

  • 緩和ケアにおける薬剤師の役割 Invited

    内田まやこ

    第6回 福岡県薬剤師会 緩和ケアセミナー, 福岡, 2021  2021.3 

     More details

    Event date: 2021.3

  • 薬剤師の視点から見た 抗がん薬の副作用マネジメント Invited

    内田まやこ

    日本臨床腫瘍薬学会年会, 共催セミナー, 2021  2021.3 

     More details

    Event date: 2021.3

  • 薬剤師のしごと~がん化学療法による口内炎の副作用管理~ Invited

    内田まやこ

    基礎薬学講座, 高槻中学・高等学校, 大阪, 2020 (オンデマンド配信)  2020.10 

     More details

    Event date: 2020

  • 緩和医療におけるポリファーマシーの実態と薬剤師の介入意義

    内田 まやこ, 高瀬 久光

    Palliative Care Research  2022.7  (NPO)日本緩和医療学会

     More details

    Language:Japanese  

  • 糖尿病患者を対象とした服薬フォローアップ支援シートの試作と有用性の検討

    矢原 恵美, 一丸 智司, 清水 忠, 内田 まやこ, 井上 良祐, 津田 賢蔵, 木下 淳

    日本医薬品情報学会総会・学術大会講演要旨集  2023.6  (一社)日本医薬品情報学会

     More details

    Language:Japanese  

  • 有害事象自発報告データベースを用いた経口抗凝固薬による有害事象発現リスクの評価

    細畑 圭子, 飯田 達也, 若林 智仁, 新家 郁, 内田 まやこ, 尾山 早紀, 稲田 文香, 岩永 一範

    日本成人病(生活習慣病)学会会誌  2022.1  日本成人病(生活習慣病)学会

     More details

    Language:Japanese  

  • 有害事象自発報告データベースを上手く使った研究や業務への活かし方と課題 化学的着想に基づく有害事象報告データベースを用いた仮説生成と創薬研究への展望

    清水 忠, 山岡 健太, 藤原 正規, 内田 まやこ, 植沢 芳広, 遠藤 未来, 五島 誠, 室井 延之

    日本医薬品情報学会総会・学術大会講演要旨集  2023.6  (一社)日本医薬品情報学会

     More details

    Language:Japanese  

  • 医薬品副作用データベースを用いたベンダムスチン関連の皮膚障害に関する評価

    内田 まやこ, 川尻 雄大, 前川 奈美, 高野 碧, 細畑 圭子, 植沢 芳広

    日本血液学会学術集会  2023.10  (一社)日本血液学会

     More details

    Language:English  

  • がん患者におけるオピオイド誘発性便秘症の危険因子 単一施設における後方視的研究

    神林 祐子, 清水 真弓, 石塚 友一, 澤 昇平, 矢部 勝茂, 内田 まやこ

    Palliative Care Research  2023.6  (NPO)日本緩和医療学会

     More details

    Language:Japanese  

  • JASPOブラッシュアップセミナー2020参加者アンケートから見えてくるCOVID-19流行下での薬剤師教育のあり方

    土屋 雅美, 寺薗 英之, 牧 陽介, 吉川 直樹, 河原 陽介, 西村 佳子, 篠原 佳祐, 小川 大介, 森 理保, 岩本 義弘, 板垣 文雄, 益子 寛之, 米村 雅人, 内田 まやこ

    日本臨床腫瘍薬学会雑誌  2022.5  (一社)日本臨床腫瘍薬学会

     More details

    Language:Japanese  

  • JASPOスタートアップセミナー2020参加者アンケートから見えてくるCOVID-19流行下での薬剤師教育のあり方

    寺薗 英之, 土屋 雅美, 牧 陽介, 吉川 直樹, 河原 陽介, 西村 佳子, 篠原 佳祐, 小川 大介, 森 理保, 岩本 義弘, 板垣 文雄, 益子 寛之, 米村 雅人, 内田 まやこ

    日本臨床腫瘍薬学会雑誌  2022.5  (一社)日本臨床腫瘍薬学会

     More details

    Language:Japanese  

  • がん化学療法における薬剤師の役割

    内田まやこ

    血液がん化学療法セミナー  2013 

     More details

    Language:Japanese  

  • がん化学療法における薬剤師の役割

    内田まやこ

    四国がん薬物療法講演会  2011 

     More details

    Language:Japanese  

  • がん化学療法における病院薬剤師の役割

    渡邊裕之, 池末裕明, 内田まやこ, 三嶋一登, 末安正典, 大石了三

    第71回 九州山口薬学大会  2009 

  • がん化学療法における副作用への対応

    池末裕明, 末次王卓, 渡邉裕之, 内田まやこ, 三嶋一登, 末安正典, 江頭伸昭, 大石了三

    日本医療薬学会年会講演要旨集  2009.9 

     More details

    Language:Japanese  

  • がん化学療法における副作用について

    内田まやこ

    九州大学病院地域医療連携講演会  2018 

     More details

    Language:Japanese  

  • VTD療法における薬剤管理指導業務への展開

    近森綾子, 内田まやこ, 末次正卓, 渡邊裕之, 池末裕明, 國分千代, 金谷朗子, 末安正典, 江頭伸昭

    日本医療薬学会年会講演要旨集  2013.8 

     More details

    Language:Japanese  

  • SGLT2阻害薬の皮膚障害関連事象発現状況に関する市販後調査報告とJADERとの比較からみたJADERの特徴

    角山 香織, 多門 啓子, 細畑 圭子, 内田 まやこ, 中村 任, 岩永 一範, 中村 敏明

    日本薬剤疫学会学術総会抄録集  2016.11  (一社)日本薬剤疫学会

     More details

    Language:Japanese  

  • SGLT2阻害薬の皮膚障害関連事象発現状況に関する市販後調査報告とJADERとの比較からみたJADERの特徴

    角山香織, 多門啓子, 細畑圭子, 内田まやこ, 中村任, 岩永一範, 中村敏明

    日本薬剤疫学会学術総会抄録集  2016.11 

     More details

    Language:Japanese  

  • R‐CHOP療法におけるパロノセトロンの有用性検討

    内田まやこ, 内田まやこ, 森康雄, 宮本敏浩, 加藤光次, 中村任, 角山香織, 赤司浩一

    医療薬学フォーラム講演要旨集  2017.6 

     More details

    Language:Japanese  

  • R‐CHOPならびにR‐THP‐COP療法における薬剤師の介入による血管外漏出の減少

    伊藤美代, 佐々木智啓, 内田まやこ, 三嶋一登, 池末裕明, 森山智彦, 江頭伸昭, 大石了三

    医療薬学フォーラム講演要旨集  2008.7 

     More details

    Language:Japanese  

  • Quality Indicatorによる緩和ケアの評価 質の向上を目指して

    村上 一徳, 水元 一博, 嶋本 正弥, 清水 祐紀子, 内田 まやこ, 土谷 美智子, 山川 文子, 津隈 さやか

    日本医療マネジメント学会雑誌  2013.6  (NPO)日本医療マネジメント学会

     More details

    Language:Japanese  

  • Management of adverse reactions to low-dose chemoradiotherapy with cisplatin and 5-fluorouracil for treatment of advanced or recurrent esophageal cancer

    Uchida M, Ikesue H, Mishima K, Sueyasu M, Egashira N, Oishi R

    67th FIP World Congress of Pharmacy and Pharmaceutical Sciences  2007 

     More details

    Language:English  

  • Efficacy and safety of aprepitant in Japanese patients receiving high-dose chemotherapyfollowed by allogeneic hematopoietic stem cell transplantation

    Ikesue H, Uchida M, Suetsugu K, Nagata K, Egashira N, Masuda S

    74th FIP World Congress of Pharmacy and Pharmaceutical Sciences  2014 

     More details

    Language:English  

  • Contribution of pharmacists in prevention and management for extravasation of anticancer drugs

    Watanabe H, Ikesue H, Uchida M, Mishima K, Sueyasu M, Egashira N, Oishi R

    The 10th CJK Joint Symposium for Clinical Information on Parenteral Drugs  2012 

     More details

    Language:English  

  • Antiemetic efficacy and safety of aprepitant on multiday chemotherapy for hematological malignancies

    Ikesue H, Uchida M, Miyamoto T, Egashira N, Oishi R

    47th ASHP Midyear Clinical Meeting and Exhibition  2012 

     More details

    Language:English  

  • Analysis of the variable factors in the blood tacrolimus concentration during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation

    Suetsugu K, Ikesue H, Uchida M, Yano T, Watanabe H, Yamada T, Kawashiri T, Kajiwara M, Miyamoto T, Shiratsuchi M, Egashira N, Masuda S

    IATDMCT2015  2015 

     More details

    Language:English  

  • ABVD療法における悪心・嘔吐に対するグラニセトロンまたはパロノセトロン単独とコルチコステロイド併用による制吐効果と安全性

    内田まやこ, 中村任, 秦晃二郎, 渡邊裕之, 森康雄, 加藤光次, 宮本敏浩, 細畑圭子, 増田智先, 赤司浩一

    第28回 日本医療薬学会年会  2018 

     More details

    Language:Japanese  

  • 非ホジキンリンパ腫患者におけるESHAP±R療法の有害事象発現状況調査による服薬指導シートの有用性評価

    石田茂, 内田まやこ, 小澤奈々, 森川花絵, 舞彩華, 久光莉瑛, 米滿紘子, 末次王卓, 辻敏和, 渡邊裕之, 廣田豪, 家入一郎

    日本薬学会144年会, 横浜  2024.3 

  • 薬剤師のしごと Invited

    内田まやこ

    学校法人ヴォーリズ学園近江兄弟社高等学校, 滋賀, 学部学科セミナー  2022.7 

  • 薬剤師のしごと Invited

    内田まやこ

    大阪府立泉陽高等学校, 大阪, キャリアセミナー  2022.6 

  • 薬剤師のしごと Invited

    内田まやこ

    大阪府立泉陽高等学校, 大阪, キャリアセミナー  2023.6 

  • 薬剤師ってどんな仕事? Invited

    内田まやこ

    兵庫県立伊丹高等学校, 兵庫, 職業人講話  2023.1 

  • 薬剤師が実践する造血器腫瘍患者への臨床経過別の緩和ケア Invited

    内田まやこ

    第6回 大阪府病院薬剤師会専門薬剤師育成委員会講習会  2023.10 

  • 緩和薬物療法認定薬剤師の介入の医療経済効果に関する多施設共同後方視的観察研究 Invited

    川尻雄大, 菅原英輝, 槙原克也, 大野凜太郎, 宮本義浩, 飛鷹範明, 内田まやこ, 髙瀬久光

    第15回 日本緩和医療薬学会, 熊本, シンポジウム  2022.5 

  • 緩和薬物療法認定薬剤師による介入指導の実態調査および非認定薬剤師との比較検討 Invited

    田中怜, 菅幸生, 宮崎雅之, 佐藤由美, 中川隼一, 萩原諒一, 内田まやこ, 高瀬久光

    第15回 日本緩和医療薬学会, 熊本, シンポジウム  2022.5 

  • 緩和医療薬学シリーズ. <緩和医療に関する知識と実践能力>. 高カルシウム血症マネジメント Invited

    内田まやこ

    日本緩和医療薬学会e-ラーニング, 東京(収録)  2023.5 

  • 緩和医療を担う薬剤師育成のための教育プログラムの構築 Invited

    内田まやこ

    第29回日本緩和医療学会学術大会、第37回日本サイコオンコロジー学会総会, パネルディスカッション  2024.6 

  • 緩和医療におけるポリファーマシーの実態と薬剤師の介入意義 Invited

    内田まやこ

    第27回 日本緩和医療学会, 神戸, シンポジウム  2022.7 

  • 緩和ケアにおける薬剤師の副作用への介入:多施設パイロット調査 Invited

    中川左理, 仁木一順, 川添哲嗣, 橋詰淳哉, 鈴木訓史, 龍伸和, 小瀬英司, 内田まやこ, 高瀬久光

    第15回 日本緩和医療薬学会, 熊本, シンポジウム  2022.5 

  • 緩和ケアにおける地域包括ケアシステムの実現に向けて Invited

    内田まやこ

    第17回 緩和医療薬薬連携 WEBセミナー in Hanshin  2023.8 

  • 糖尿病患者を 対象とした服薬フォローアップ支援シートの試作と有用性の検討

    矢原恵美, 一丸智司, 清水忠, 内田まやこ, 井上良祐, 津田賢蔵, 木下淳

    第25回日本医薬品情報学会総会・学術大会, 京都  2023.6 

  • 有害事象自発報告データベースを用いた経口抗凝固薬の有害事象発現リスク因子評価

    細畑圭子, 飯田達也, 若林智仁, 新家都, 内田まやこ, 尾山早紀, 稲田文香, 岩永一範

    日本成人病(生活習慣病)学会  2022.1 

  • 日本の有害事象自発報告データベース(JADER)を用いたCDK4/6阻害剤(パルボシクリブ・アベマシクリブ)の関与が疑われる有害事象の解析

    藤原正規, 池末裕明, 内田まやこ, 植沢芳広, 清水忠, 室井延之

    第12回 日本薬剤師レジデントフォーラム  2023.3 

  • 急性骨髄性白血病患者に対するIDR+AraC寛解導入療法の服薬指導シートの評価

    望月絵梨香, 内田まやこ, 石田茂, 小澤奈々, 米滿紘子, 落合秀樹, 中村花絵, 川尻雄大, 江頭伸昭, 家入一郎

    日本医療薬学会第6回フレッシャーズ・カンファランス  2023.6 

  • 大規模データベース研究、はじめの一歩 Invited

    内田まやこ

    第15回 日本緩和医療薬学会, 熊本, シンポジウム  2022.5 

  • 大学教員の立場から~現況報告~ Invited

    内田まやこ

    九州大学病院薬剤部同門会, 福岡  2023.11 

  • 多職種協働による血液がん領域の支持療法の有用性と安全性の検討 Invited

    内田まやこ

    第33回 日本医療薬学会年会, 仙台  2023.11 

  • 医薬品副作用データベース(JADER)を用いたbevacizumabによる肺毒性評価

    神林祐子, 内田まやこ, 柏木美粋, 秋葉仁美, 清水忠

    第33回 日本医療薬学会年会, 仙台  2023.11 

  • 医薬品副作用データベースを用いたベンダムスチン関連皮膚障害の発現時期の評価 Invited

    内田まやこ, 清水忠, 川尻雄大, 植沢芳広

    第17回 日本緩和医療薬学会年会シンポジウム  2024.5 

  • 医薬品副作用データベースを用いたベンダムスチン関連の皮膚障害に関する評価

    内田まやこ, 川尻雄大, 前川奈美, 高野碧, 細畑圭子, 植沢芳広

    第85回 日本血液学会学術集会  2023.10 

  • 医療薬学会緩和薬物療法認定薬剤師によるがん患者への介入指導の実態調査および非認定薬剤師との比較検討

    中川隼一, 田中怜, 菅幸生, 宮崎雅之, 佐藤由美, 萩原諒一, 内田まやこ, 髙瀬久光

    第33回 日本医療薬学会年会, 仙台  2023.11 

  • 内田まやこ Invited

    エビデンス創出の軌跡

    第15回 日本緩和医療薬学会, 熊本, シンポジウム  2022.5 

  • 九州山口沖縄の薬剤師を対象とした教育プログラムがもたらす緩和ケアへの理解度向上と行動変化

    山田真裕, 内田まやこ, 葉田昌生, 因間大悟, 有吉俊二, 井上章治, 神村英利, 原口亨

    第17回 日本緩和医療薬学会年会  2024.5 

  • チーム医療の中で薬剤師が実践する臨床研究 Invited

    内田まやこ

    メディカルプロフェッショナルレクチャー, 京都  2023.11 

  • シンポジウム 緩和薬物療法認定薬剤師の介入の医療経済効果に関する多施設 共同後方視的観察研究(最終結果報告) Invited

    川尻雄大, 菅原英輝, 槙原克也, 大野凜太郎, 宮本義浩, 飛鷹範明, 内田まやこ, 髙瀬 久光

    第16回 日本緩和医療薬学会, 神戸  2023.5 

  • シンポジウム 緩和ケアにおける薬剤師の副作用への介入:多施設パイロット調査 Invited

    中川左理, 小瀬英司, 仁木一順, 橋詰淳哉, 川添哲嗣, 鈴木訓史, 内田まやこ, 高瀬久光

    第 16回 日本緩和医療薬学会, 神戸  2023.5 

  • シンポジウム 教育セミナー のこれまでとこれから Invited

    矢野琢也, 内田まやこ, 宮本康敬, 鳥越一宏, 中川貴之

    第16回 日本緩和医療薬学会, 神戸  2023.5 

  • シンポジウム 化学的着想に基づく有害事象報告データベースを用いた仮説生成と創薬研究への展望 Invited

    清水忠, 山岡健太, 藤原正規, 内田まやこ, 植沢芳広, 遠藤未来, 五島誠, 室井延之

    第25回日本医薬品情報学会総会・学術大会, 京都  2023.6 

  • シンポジウム pSMILEの立ち上げと今後の展望 Invited

    壁谷めぐみ, 天川雅彦, 笠原庸子, 石塚友一, 今村牧夫, 内田まやこ, 宮本康敬, 矢野琢也, 中川貴之

    第16回 日本緩和医 療薬学会, 神戸  2023.5 

  • シ ンポジウム 緩和薬物療法認定薬剤師による介入指導の実態調査および非認定薬剤師 との比較検討(最終報告) Invited

    田中怜, 菅幸生, 宮崎雅之, 佐藤由美, 中川隼一, 萩原諒一, 内田まやこ, 高瀬久光

    第16回 日本緩和医療薬学会, 神戸  2023.5 

  • アイトラッキング技術を用いた調剤業務の煩雑性に与える影響因子の検討 ~右脳を活用した薬剤師の思考プロセスの解析研究~

    湯北崇嗣, 伊丹稜, 森部凛音, 永田健一郎, 末次王卓, 廣田豪, 内田まやこ, 家入一郎, 田中雅幸, 辻敏和

    医療薬学フォーラム2024、熊本  2024.7 

  • アイトラッキング技術を用いた調剤業務の効率性/安全性に向けた検討 ~エラー誘発モデルを用いた薬剤師の思考プロセスの解析~

    西山優斗, 吉川奈菜, 永田健一郎, 末次王卓, 廣田豪, 内田まやこ, 家入一郎, 岩根, 詩織, 田中雅幸, 辻敏和

    医療薬学フ ォーラム2024、熊本  2024.7 

  • がん悪液質マウスモデルにおけるシスチン・テアニンの抑制効果

    久田松韻生, 川尻雄大, 峯圭佑, 森皓平, 石田晴多, 内田まやこ, 土屋誉, 小林大介, 島添隆雄

    日本医療薬学会第6回フレッシャーズ・カンファランス  2023.6 

  • いのちを支える専門職にあなたもなれる! Invited

    内田まやこ

    兵庫県立宝塚北高等学校, 兵庫, 職業人講話②  2023.3 

  • いのちを支える専門職にあなたもなれる! Invited

    内田まやこ

    兵庫県立宝塚北高等学校, 兵庫, 職業人講話①  2023.3 

  • JASPOブラッシュアップセミナー2020参加者アンケートから見えてくるCOVID-19流行下での薬剤師教育のあり方

    土屋雅美, 寺薗英之, 牧陽介, 吉川直樹, 河原陽, 西村佳子, 篠原佳祐, 小川大介, 森理保, 岩本義弘, 板垣文雄, 益子寛之, 米村雅人, 内田まやこ

    日本臨床腫瘍薬学会学術大会2022, 仙台  2022.3 

  • JASPOスタートアップセミ ナー2020参加者アンケートから見えてくるCOVID-19流行下での薬剤師教育のあり方

    寺薗 英之, 土屋雅美, 牧陽介, 吉川直樹, 河原陽介, 西村佳子, 篠原佳祐, 小川大介, 森理保, 岩本義弘, 板垣文雄, 益子寛之, 米村雅人, 内田まやこ

    日本臨床腫瘍薬学会学術大会2022, 仙台  2022.3 

  • がん化学療法における薬剤師の役割~九州大学病院での取り組み~

    内田まやこ

    日本臨床腫瘍薬学会ランチョンセミナー  2013 

     More details

    Language:Japanese  

  • 頭頸部がんに対するTS‐1との放射線同時併用療法における副作用管理

    末次王卓, 柳瀬悠子, 大串真理子, 内田まやこ, 池末裕明, 前山明香, 三嶋一登, 末安正典, 江頭伸昭, 大石了三

    日本薬学会年会要旨集  2010.3 

     More details

    Language:Japanese  

  • 頭頸部がんに対するTS-1との放射線同時併用療法における副作用管理

    末次 王卓, 柳瀬 悠子, 大串 真理子, 内田 まやこ, 池末 裕明, 前山 明香, 三嶋 一登, 末安 正典, 江頭 伸昭, 大石 了三

    日本薬学会年会要旨集  2010.3  (公社)日本薬学会

     More details

    Language:Japanese  

  • 連日化学療法と造血幹細胞移植におけるアプレピタントの制吐効果~キャンサーボードにおける腫瘍内科医と薬剤師の連携

    内田まやこ, 水元一博, 宮本敏浩, 池末裕明, 江頭伸昭, 大石了三

    日本臨床腫瘍学会学術集会(CD-ROM)  2013 

     More details

    Language:Japanese  

  • 造血幹細胞移植における大量化学療法時のアプレピタントの有用性検討

    内田まやこ, 一ノ瀬喜美子, 平岩ひろみ, 櫻井麻子, 加藤光次, 宮本敏浩, 池末裕明, 大石了三

    日本造血細胞移植学会総会プログラム・抄録集  2011 

     More details

    Language:Japanese  

  • 造血幹細胞移植におけるチーム医療

    内田まやこ

    Team Meloma Conference  2014 

     More details

    Language:Japanese  

  • 造血幹細胞移植におけるタクロリムス投与経路変更時の血中濃度変動要因の解析

    末次王卓, 内田まやこ, 槇原洋子, 池末裕明, 渡邊裕之, 矢野貴久, 大畠俊一, 宮本敏浩, 江頭伸昭, 増田智先

    日本医療薬学会年会講演要旨集  2014.8 

     More details

    Language:Japanese  

  • 造血器腫瘍患者におけるがん化学療法誘発悪心・嘔吐に関する前向き観察研究―医療スタッフの予測と実測の比較―

    内田まやこ, 中村任, 下川元継, 宮本敏浩, 赤司浩一

    第68回 日本薬学会近畿支部大会  2018.10 

     More details

    Language:Japanese  

  • 造血器腫瘍における包括的な患者サポートと次世代薬剤師へのメッセージ

    内田まやこ

    第28回 日本医療薬学会年会  2018 

     More details

    Presentation type:Symposium, workshop panel (public)  

  • 造血器腫瘍におけるアプレピタントの効果と安全性の検証

    内田まやこ, 一ノ瀬喜美子, 平岩ひろみ, 櫻井麻子, 加藤光次, 宮本敏浩, 池末裕明, 末安正典, 江頭伸昭, 大石了三

    日本医療薬学会年会講演要旨集  2011.9 

     More details

    Language:Japanese  

  • 造血器腫瘍におけるアプレピタントの効果と安全性の検討

    内田まやこ, 一ノ瀬喜美子, 平岩ひろみ, 櫻井麻子, 加藤光次, 宮本敏浩, 池末裕明, 末安正典, 江頭伸昭, 大石了三

    第21回 日本医療薬学会年会  2011 

     More details

    Language:Japanese  

  • 造血器悪性腫瘍領域における薬剤師の役割

    内田まやこ

    大阪薬科大学公開教育講座  2016 

     More details

    Language:Japanese  

  • 血液腫瘍疾患における薬学的管理

    内田まやこ

    沖縄県地域がん診療連携拠点病院 薬剤師教育セミナー  2016 

     More details

    Language:Japanese  

  • 血液内科領域での薬剤師の取り組み

    内田まやこ

    兵庫県病院薬剤師会オンコロジーセミナー  2016 

     More details

    Language:Japanese  

  • 血液内科病棟における薬剤師の役割~九州大学病院の取り組み~

    内田まやこ

    造血器腫瘍とチーム医療  2011 

     More details

    Language:Japanese  

  • 血液内科病棟における薬剤師の取り組み

    内田まやこ

    チーム医療で行うがん化学療法セミナーin久留米  2012 

     More details

    Language:Japanese  

  • 血液内科病棟での薬剤師の役割~同志の存在・横のつながりの必要性~

    内田まやこ, 池末裕明, 石丸隆之, 渡邊裕之, 三嶋一登, 大石了三

    日本医療薬学会年会講演要旨集  2011.9 

     More details

    Language:Japanese  

  • 血液がん領域におけるパロノセトロンの有用性と安全性の検討

    内田まやこ

    造血器悪性腫瘍支持療法学術講演会  2015 

     More details

    Language:Japanese  

  • 血液がん領域におけるアプレピタント使用の実際と薬剤師の役割

    内田まやこ

    熊本県薬剤師会オンコロジーセミナー  2012 

     More details

    Language:Japanese  

  • 血液がん領域におけるアプレピタントの有用性検討

    内田まやこ, 一ノ瀬喜美子, 平岩ひろみ, 櫻井麻子, 加藤光次, 宮本敏浩, 池末裕明, 江頭伸昭, 大石了三

    第4回 福岡県病院薬剤師会学術大会  2012 

     More details

    Language:Japanese  

  • 血液がん領域におけるアプレピタントの効果と安全性の検討

    内田まやこ

    血液腫瘍研究会  2012 

     More details

    Language:Japanese  

  • 血液がん標準薬物治療と薬学的介入の実際

    三嶋一登, 内田まやこ, 池末裕明, 大石了三

    日本医療薬学会年会講演要旨集  2010.10 

     More details

    Language:Japanese  

  • 血液がん患者への薬剤師の介入ポイント

    内田まやこ

    Pharmacist Seminar on Hematology  2015 

     More details

    Language:Japanese  

  • 血液がん患者への緩和ケア

    内田まやこ

    第7回 Phamacy Seminar  2017 

     More details

    Language:Japanese  

  • 血液がん化学療法の処方支援による副作用回避~チーム医療における薬剤師の貢献を示す~

    内田まやこ

    日本医療薬学会, 第1回 がん専門薬剤師全体会議,  2013 

     More details

    Language:Japanese  

  • 血液がん化学療法における医師と協働した薬剤師による後ろ向き臨床研究

    内田まやこ, 渡邊裕之, 池末裕明, 江頭伸昭, 増田智先

    医療薬学フォーラム講演要旨集  2014.6 

     More details

    Language:Japanese  

  • 薬局でのがん患者への緩和ケアに関する基礎知識

    内田まやこ

    がん・糖尿病関連研修会  2019.2 

  • 薬学的知見に基づく管理・指導に関する卒後研修会の有用性評価―ポリファーマシー状態の評価と処方提案―

    角山香織, 中村敏明, 中村任, 宮崎誠, 内田まやこ, 永井純也

    第3回 日本薬学教育学会年会  2018 

     More details

    Language:Japanese  

  • 薬剤管理指導業務の標準化を目的とした「指導の要点と記録のポイント集」の作成

    池末裕明, 児玉亜由美, 別城朋子, 内田まやこ, 渡邊裕之, 園田正信, 末安正典, 江頭伸昭, 大石了三

    日本医療薬学会年会講演要旨集  2011.9 

     More details

    Language:Japanese  

  • 薬剤師の症例検討会~議論を深めるために~

    内田まやこ

    第28回 日本医療薬学会年会  2018 

     More details

    Presentation type:Symposium, workshop panel (public)  

  • 薬剤師の仕事~がん薬物療法における安全性向上のための薬学的支援~ Invited

    内田まやこ

    職業講話②, 滋賀県立守山高等学校  2021.7 

  • 薬剤師の仕事~がん薬物療法における安全性向上のための薬学的支援~ Invited

    内田まやこ

    職業講話①, 滋賀県立守山中学校  2021.7 

  • 薬剤師のしごと~がん化学療法における副作用管理~

    内田まやこ

    基礎薬学講座, 高槻中学・高等学校  2019.10 

  • 薬剤師のしごと~

    内田まやこ

    府立牧野高等学校進学相談会  2019.10 

  • 薬剤師による緩和ケア推進を目的として看護師支援の試みとその効果

    内田まやこ, 水元一博, 長坂明日香, 辻敏和, 渡邊裕之, 末次王卓, 斉藤麻美, 池末裕明, 江頭伸昭, 大石了三

    第17回 日本緩和医療学会年会  2012 

     More details

    Language:Japanese  

  • 薬剤師による緩和ケア推進を目的とした看護師支援の試みとその効果

    内田 まやこ, 水元 一博, 長坂 明日香, 辻 敏和, 渡邊 裕之, 末次 王卓, 斉藤 麻美, 池末 裕明, 江頭 伸昭, 大石 了三

    日本緩和医療学会学術大会プログラム・抄録集  2012.6  (NPO)日本緩和医療学会

     More details

    Language:Japanese  

  • 薬剤師が関わる緩和ケア

    内田まやこ

    第7回 沖縄美ら島薬学ネットワーク  2014 

     More details

    Language:Japanese  

  • 薬剤師が知っておきたい末梢神経障害のエッセンス

    内田まやこ

    大阪薬科大学 サテライトセミナー  2019.10 

  • 薬剤師が知っておきたい慢性骨髄性白血病治療薬のエッセンス

    内田まやこ

    佐久市薬剤師会 東信がん薬物療法セミナー  2019.3 

  • 自家造血幹細胞移植前処置におけるアプレピタントの有用性および安全性の検討

    末次王卓, 内田まやこ, 池末裕明, 内田沙織, 加藤光次, 宮本敏浩, 渡邊裕之, 末安正典, 江頭伸昭, 大石了三

    日本医療薬学会年会講演要旨集  2012.10 

     More details

    Language:Japanese  

  • 膵臓がんの経過中に失明をきたした2症例

    清水 祐紀子, 嶋本 正弥, 山川 文子, 土谷 美智子, 内田 まやこ, 松尾 裕美, 水元 一博, 外 須美夫

    日本緩和医療学会学術大会プログラム・抄録集  2012.6  (NPO)日本緩和医療学会

     More details

    Language:Japanese  

  • 膵癌患者におけるFOLFIRINOX療法の副作用発現状況調査に基づいた服薬指導シートの作成とその評価

    南 晴奈, 福田 未音, 平野 めぐみ, 田島 壮一郎, 内田 まやこ, 渡邊 裕之, 池末 裕明, 江頭 伸昭, 増田 智先

    日本薬学会年会要旨集  2015.3  (公社)日本薬学会

     More details

    Language:Japanese  

  • 腎障害時の造血器腫瘍患者への薬学的介入ポイント

    内田まやこ

    第4回 日本臨床腫瘍薬学会学術大会  2015 

     More details

    Language:Japanese   Presentation type:Symposium, workshop panel (public)  

  • 腎機能に応じた抗がん剤治療~血液がん症例を中心に考察する!!~

    内田まやこ, 池末裕明, 渡邊裕之, 増田智先

    日本緩和医療薬学会年会プログラム・要旨集  2015 

     More details

    Language:Japanese  

  • 緩和医療領域におけるポリファーマシーに対する薬剤師の介入に関する全国実態調査

    内田まやこ, 鈴木真也, 菅幸生, 菅原英輝, 国分秀也, 植沢芳広, 中川貴之, 髙瀬久光

    第29回 日本医療薬学会年会シンポジウム  2019.11 

  • 緩和医療業務に関する看護師の現状把握‐緩和ケアの推進を目的としたアンケート調査-

    藤井明日香, 辻敏和, 渡邊裕之, 角田朋子, 内田まやこ, 末次王卓, 江頭伸昭, 大石了三

    第72回 九州山口薬学大会  2010 

     More details

    Language:Japanese  

  • 緩和医療を支える薬剤師の役割 Invited

    内田まやこ

    第140回大分県病院薬剤師会県内地区研修会, 大分  2021.11 

  • 緩和医療を担う薬剤師育成のための標準教育モデルの開発 Invited

    内田まやこ

    日本臨床腫瘍薬学会学術大会2021, 千葉, シンポジウム, オンデマンド配信  2021.3 

  • 緩和医療を担う薬剤師育成のための標準教育モデルの開発

    山田真裕, 内田まやこ, 葉田昌生, 因間大悟, 有吉俊二, 青木和子, 井上章治, 島添隆雄, 満生清士, 原口亨

    第28回 日本医療薬学会年会  2018 

     More details

    Language:Japanese  

  • 緩和医療におけるポリファーマシーに対する薬剤師の介入に関する多施設前向き観察研究

    内田まやこ, 鈴木真也, 菅幸生, 菅原英輝, 国分秀也, 植沢芳広, 中川貴之, 髙瀬久光

    第29回 日本臨床精神神経薬理学会年会シンポジウム  2019.10 

  • 緩和医療におけるポリファーマシーに対する薬剤師の介入に関する全国実態調査

    中川貴之, 内田まやこ, 鈴木真也, 菅幸生, 菅原英輝, 国分秀也, 植沢芳広, 髙瀬久光

    第29回 日本臨床精神神経薬理学会年会シンポジウム  2019.10 

  • 緩和ケアチームに依頼があったアカシジアの14例

    嶋本正弥, 清水祐紀子, 早水真理子, 早水真理子, 山川文子, 土谷美智子, 内田まやこ, 松尾裕美, 水元一博, 外須美夫, 須藤信行

    日本緩和医療学会学術大会プログラム・抄録集  2012 

     More details

    Language:Japanese  

  • 緩和ケアに関する医薬品情報の解析によるニーズ把握とその応用

    松下 尚弘, 末次 王卓, 池末 裕明, 内田 まやこ, 渡邊 裕之, 柳瀬 悠子, 山口 麻美, 三嶋 一登, 江頭 伸昭, 大石 了三

    日本薬学会年会要旨集  2010.3  (公社)日本薬学会

     More details

    Language:Japanese  

  • 看護師の適切な疼痛ケア実践を支援する薬剤師の取り組みとその評価

    内田まやこ, 今井智之, 辻敏和, 長坂明日香, 渡邊裕之, 池末裕明, 末安正典, 江頭伸昭, 水元一博, 大石了三

    日本緩和医療学会学術大会プログラム・抄録集  2013 

     More details

    Language:Japanese  

  • 疼痛時に失神発作を伴う頸部リンパ節転移患者の一症例

    早水 真理子, 清水 祐紀子, 土谷 美智子, 山川 文子, 嶋本 正弥, 松尾 裕美, 内田 まやこ, 水元 一博, 外 須美夫

    日本緩和医療学会学術大会プログラム・抄録集  2012.6  (NPO)日本緩和医療学会

     More details

    Language:Japanese  

  • 抗がん薬使用後の白血病および骨髄異形 成症候群の発現リスクに関する有害事象自発報告データベースを用いた解析

    川尻雄大, 小林大介, 内田まやこ, 島添隆雄

    日本薬学会第140年会, 京都  2020.3 

  • 妊娠中に胃がんが判明し、急速な経過をたどった一症例

    清水 祐紀子, 波多野 有美, 嶋本 正弥, 今野 里美, 土谷 美智子, 山川 文子, 村上 一徳, 内田 まやこ, 水元 一博, 外 須美夫

    日本緩和医療学会学術大会プログラム・抄録集  2013.6  (NPO)日本緩和医療学会

     More details

    Language:Japanese  

  • 同種造血幹細胞移植におけるアプレピタントの制吐効果と安全性の検討

    加藤光次, 内田まやこ, 池末裕明, 竹中克斗, 岩崎浩己, 宮本敏浩, 豊嶋崇徳, 大石了三, 赤司浩一

    日本内科学会  2012.2 

     More details

    Language:Japanese  

  • 医薬品副作用情報データベースに基づく薬物性尿細管間質性腎炎の報告件数と転帰分析

    尾山 早紀, 細畑 圭子, 稲田 文香, 内田 まやこ, 岩永 一範

    臨床薬理  2017.11  (一社)日本臨床薬理学会

     More details

    Language:Japanese  

  • 医薬品副作用データベースJADERを利用した抗凝固薬の安全性解析

    若林智仁, 細畑圭子, 新家都, 尾山早紀, 稲田文香, 内田まやこ, 岩永一範

    第3回 日本臨床薬理学会 近畿地方会  2018.10 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

  • 医薬品副作用データベ ースを用いたベンダムスチン関連の皮膚障害に関する評価

    内田まやこ, 川尻雄大, 前川奈美, 高野碧, 細畑圭子, 植沢芳広

    医療薬学フォーラム2021/ 第29回クリニカルファーマシーシンポジウム, 沖縄  2021.7 

  • 効率的な院外処方箋の疑義照会方法の確立を目的とした現状調査

    末次 王卓, 秦 晃二郎, 渡邊 裕之, 金谷 朗子, 池末 裕明, 内田 まやこ, 武智 秀明, 竹野 将行, 高木 淳一, 江頭 伸昭, 瀬尾 隆, 増田 智先

    日本薬学会年会要旨集  2015.3 

     More details

    Language:Japanese  

  • 再発卵巣がんに対するドキソルビシン塩酸塩リポソーム製剤治療における服薬指導シートの作成と活用

    石川瑠美佳, 渡邉裕之, 内田まやこ, 末次王卓, 山口麻美, 池末裕明, 江頭伸昭, 大石了三

    日本薬学会年会要旨集  2011.3 

     More details

    Language:Japanese  

  • 九州大学病院における小児緩和ケアチームの取り組み

    西本恭子, 阿部智慧子, 古賀友紀, 笹月桃子, 賀来典之, 落合正行, 木下義晶, 香月大輔, 山下洋, 山根謙一, 山座治義, 小笠原貴子, 山本千晴, 内田まやこ, 土井紗世, 高田英俊

    日本小児科学会学術集会  2016.5 

     More details

    Language:Japanese  

  • ベンダムスチン投与に伴う静脈炎軽減に向けた薬学的介入

    辻川 智子, 渡邊 裕之, 内田 まやこ, 末次 王卓, 池末 裕明, 江頭 伸昭, 大石 了三

    日本薬学会年会要旨集  2012.3  (公社)日本薬学会

     More details

    Language:Japanese  

  • 緩和医療におけるポリファーマシーに対する薬剤師の介入に関する全国実態調査

    鈴木真也, 内田まやこ, 菅幸生, 菅原英輝, 国分秀也, 中川貴之, 高瀬久光

    日本緩和医療薬学会年会プログラム・要旨集  2018 

     More details

    Language:Japanese  

  • 緩和ケア-薬剤師の立場から-

    内田まやこ

    九州大学医学部4年生, 医学総合講義(緩和ケア)  2013 

     More details

    Language:Japanese  

  • 緩和ケア-薬剤師の立場から-

    内田まやこ

    九州大学医学部4年生, 医学総合講義(緩和ケア)  2012 

     More details

    Language:Japanese  

  • 緩和ケア-薬剤師の立場から-

    内田まやこ

    九州大学医学部4年生 医学総合講義(緩和ケア)  2011 

     More details

    Language:Japanese  

  • 緩和ケア-薬剤師の立場から-

    内田まやこ

    九州大学医学部4年生, 医学総合講義(緩和ケア)  2009 

     More details

    Language:Japanese  

  • 緩和ケア-薬剤師の立場から-

    内田まやこ

    九州大学医学部4年生, 医学総合講義(緩和ケア)  2010 

     More details

    Language:Japanese  

  • 緩和ケア-薬剤師の立場から-

    内田まやこ

    九州大学医学部4年生, 医学総合講義(緩和ケア)  2014 

     More details

    Language:Japanese  

  • 緩和ケア-薬剤師の立場から-

    内田まやこ

    九州大学医学部4年生, 医学総合講義(緩和ケア)  2015 

     More details

    Language:Japanese  

  • 緩和ケア(疼痛コントロール)

    内田まやこ

    第2回薬剤師のための臨床腫瘍薬学セミナー  2018 

     More details

    Language:Japanese  

  • 緩和ケア分野での地域連携へ向けた取り組み〜病院薬剤 師・保険薬局薬剤師合同グループワークの開催〜

    竹野将行, 高木淳一, 内田まやこ, 池末裕明, 佐田裕子, 渡邊裕之, 末次王卓, 江頭 伸昭, 増田智先, 瀬尾隆

    第26回 日本医療薬学会年会  2016 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

  • 緩和ケアマニュアルの活用方法

    内田まやこ

    福岡市薬剤師会学術講演会  2015 

     More details

    Language:Japanese  

  • 緩和ケアチームの活動

    内田まやこ

    大鵬薬品社内勉強会  2015 

     More details

    Language:Japanese  

  • 緩和ケアチームに依頼があったアカシジアの14例

    嶋本 正弥, 清水 祐紀子, 早水 真理子, 山川 文子, 土谷 美智子, 内田 まやこ, 松尾 裕美, 水元 一博, 外 須美夫, 須藤 信行

    日本緩和医療学会学術大会プログラム・抄録集  2012.6  (NPO)日本緩和医療学会

     More details

    Language:Japanese  

  • 緩和ケアチームにおける薬剤師の役割

    内田まやこ

    別府市薬剤師会学術講演会  2012 

     More details

    Language:Japanese  

  • 緩和ケアに関する医薬品情報の解析によるニーズ把握とその応用

    松下尚弘, 末次王卓, 池末裕明, 内田まやこ, 渡邊裕之, 柳瀬悠子, 山口麻美, 三嶋一登, 江頭伸昭, 大石了三

    日本薬学会年会要旨集  2010.3 

     More details

    Language:Japanese  

  • 緩和ケアに関する医療従事者の意識調査ならびに携帯用緩和ケアマニュアルの作成

    内田まやこ, 渡邊ひろゆき, 野田祐紀子, 嶋本正弥, 坂本節子, 山川文子, 土谷美智子, 松尾裕美, 水元一博, 江頭伸昭, 大石了三

    日本緩和医療薬学会年会プログラム・要旨集  2009 

     More details

    Language:Japanese  

  • 緩和ケアにおける薬剤師の役割~薬薬連携の重要性~

    内田まやこ

    鳥栖三養基薬剤師会  2011 

     More details

    Language:Japanese  

  • 緩和ケアにおける薬剤師の役割~九州大学病院の取り組み~

    内田まやこ

    第4回 沖縄疼痛研究会  2013 

     More details

    Language:Japanese  

  • 緩和ケアにおける薬剤師の役割~九州大学病院の取り組み~

    内田まやこ

    第363回 医師会病院薬物療法研修会  2014 

     More details

    Language:Japanese  

  • 緩和ケアにおける薬剤師の役割と可能性

    内田まやこ

    Pharmacy Seminar in Odate  2018 

     More details

    Language:Japanese  

  • 緩和ケアにおける薬剤師の役割 Invited

    内田まやこ

    みやざきホスピス・緩和ケアネットワーク第20回 学術集会, 宮崎  2021.10 

  • 緩和ケアにおける薬剤師の役割

    内田まやこ

    福岡市薬剤師会 Basic Study  2013 

     More details

    Language:Japanese  

  • 緩和ケアにおける薬剤師の役割

    内田まやこ

    熊本県薬剤師会オンコロジーセミナー  2012 

     More details

    Language:Japanese  

  • 緩和ケアにおける薬剤師の役割

    内田まやこ

    平成20年度 第3回 福岡県コメディカルスタッフがん医療研修会  2008 

     More details

    Language:Japanese  

  • 緩和ケアにおける薬剤師の役割

    内田まやこ

    福岡県薬剤師会緩和ケアセミナー  2017 

     More details

    Language:Japanese  

  • 緩和ケアにおける薬剤師の役割

    内田まやこ

    佐世保市薬剤師会学術講演会  2014 

     More details

    Language:Japanese  

  • 緩和ケアにおける病院薬剤師の役割

    内田まやこ

    東区緩和ケア医師の会  2010 

     More details

    Language:Japanese  

  • 緩和ケアにおける病薬連携

    内田まやこ

    第5回 緩和医療薬薬連携セミナー in Hanshin  2018 

     More details

    Language:Japanese  

  • 緩和ケアでの医薬品情報の解析によるニーズ把握とその応用

    松下尚弘, 末次王卓, 池末裕明, 内田まやこ, 渡邊裕之, 柳瀬悠子, 山口麻美, 三嶋一登, 江頭伸昭, 大石了三

    日本薬学会第130年会  2010 

     More details

    Language:Japanese  

  • 緩和ケア (疼痛コントロール)

    内田まやこ

    第2回 福岡県薬剤師会・日本臨床腫瘍薬学会合同 薬剤師のための臨床腫瘍薬学セミナー  2018.11 

  • 糖尿病薬について

    内田まやこ

    九州大学病院 北11階病棟 看護師勉強会  2013 

     More details

    Language:Japanese  

  • 研究推進委員会報告~緩和医療におけるポリファーマシーに対する薬剤師の介入に関する前向き観察研究~

    鈴木真也, 内田まやこ, 菅幸生, 菅原英輝, 国分秀也, 植沢芳広, 中川貴之, 髙瀬久光

    第13回 日本緩和医療薬学会年会シンポジウム  2019.6 

  • 研究推進委員会報告~緩和医療におけるポリファーマシーに対する薬剤師の介入に関する全国実態調査~

    内田まやこ, 鈴木真也, 菅幸生, 菅原英輝, 国分秀也, 植沢芳広, 中川貴之, 髙瀬久光

    第13回 日本緩和医療薬学会年会シンポジウム  2019.6 

  • 研究推進委員会報告~がん患者のオピオイド関連呼吸抑制に関する国内有害事象自発報告データベース (JADER) を用いた解析~

    菅原英輝, 内田まやこ, 鈴木真也, 菅幸生, 植沢芳広, 中川貴之, 髙瀬久光

    第13回 日本緩和医療薬学会年会シンポジウム  2019.6 

  • 研究推進委員会報告~JADERを用いた医療用麻薬による有害事象報告件数の時代的変遷~

    菅幸生, 内田まやこ, 鈴木真也, 菅原英輝, 植沢芳広, 中川貴之, 髙瀬久光

    第13回 日本緩和医療薬学会年会シンポジウム  2019.6 

  • 看護師の適切な疼痛ケア実践を支援する薬剤師の取り組みとその評価

    内田 まやこ, 今井 智之, 辻 敏和, 長坂 明日香, 渡邊 裕之, 池末 裕明, 末安 正典, 江頭 伸昭, 水元 一博, 大石 了三

    日本緩和医療学会学術大会プログラム・抄録集  2013.6  (NPO)日本緩和医療学会

     More details

    Language:Japanese  

  • 看護師の疼痛ケア教育への薬学的介入とその効果

    今井智之, 辻敏和, 長坂明日香, 内田まやこ, 渡邊裕之, 平川良宏, 末安正典, 江頭伸明, 大石了三

    九州山口薬学大会  2011 

     More details

    Language:Japanese  

  • 癌化学療法における トータルアセスメント ~吐き気対策~

    内田まやこ

    Logical Support研究会  2017 

     More details

    Language:Japanese  

  • 痛みに対する薬剤の使い方-WHOを中心に-

    内田まやこ

    平成21年度 第4回 福岡県コメディカルスタッフがん医療研修会  2009 

     More details

    Language:Japanese  

  • 疼痛時に失神発作を伴う頸部リンパ節転移患者の一症例

    早水真理子, 清水祐紀子, 土谷美智子, 山川文子, 嶋本正弥, 松尾裕美, 内田まやこ, 水元一博, 外須美夫

    日本緩和医療学会学術大会プログラム・抄録集  2012 

     More details

    Language:Japanese  

  • 疼痛時に失明発作を伴う頸部リンパ説転移患者の一症例

    早水真理子, 清水祐紀子, 土谷美智子, 山川文子, 嶋本正弥, 松尾裕美, 内田まやこ, 水元一博, 外須美夫

    第17回 日本緩和医療学会学術大会  2012 

     More details

    Language:Japanese  

  • 理系女性の実体験に基づいたキャリアパス

    内田まやこ

    5大学連携講義, 理系女性のためのキャリアパス設計論  2018 

     More details

    Language:Japanese  

  • 現場の医師・薬剤師によるチーム医療

    内田まやこ

    九州大学医学部・薬学部4年生, チーム医療演習  2013 

     More details

    Language:Japanese  

  • 現場の医師・薬剤師によるチーム医療

    内田まやこ

    九州大学医学部・薬学部4年生, チーム医療演習  2014 

     More details

    Language:Japanese  

  • 現場の医師・薬剤師によるチーム医療

    内田まやこ

    九州大学医学部・薬学部4年生, チーム医療演習  2015 

     More details

    Language:Japanese  

  • 無菌調製実技セミナー

    内田まやこ

    大阪薬科大学 無菌調製実技セミナー  2019.9 

  • 無菌治療部における造血幹細胞移植患者の栄養サポートへの取り組み~無菌治療部栄養サポートチーム(無菌治療部NST)によるNST回診の導入~

    前田明希, 村井春菜, 船津奈緒美, 森崎初美, 安武奈美, 中屋純子, 猿渡嘉子, 塩谷千里, 宮下知子, 山下さきの, 山口貞子, 内田まやこ, 亀崎健次郎

    日本造血細胞移植学会総会プログラム・抄録集  2016.2 

     More details

    Language:Japanese  

  • 滋賀県の薬局に対するびわ湖メディカルネット(医療)と淡海あさがおネット(介護)の利用と在宅医療推進に関するアンケート調査

    天野富美夫, 粂明日香, 亀田紗希, 北村光祐紀, 小池敦資, 内田まやこ

    日本薬局学会学術総会  2018.11 

     More details

    Language:Japanese  

  • 添付文書の利活用状況ならびに学習ニーズに関する調査

    森山 真由, 角山 香織, 中村 任, 宮崎 誠, 内田 まやこ, 永井 純也, 中村 敏明

    社会薬学  2019.9  (一社)日本社会薬学会

     More details

    Language:Japanese  

  • 治療関連白血病・骨髄異形成症候群の発症リスクに関する大規模副作用データベースを用いた解析

    川尻 雄大, 小林 大介, 内田 まやこ, 廣本 詩織, 井上 将志, 池田 朔, 井上 瑞季, 島添 隆雄

    臨床薬理  2020.10  (一社)日本臨床薬理学会

     More details

    Language:Japanese  

  • 治療関連白血病・骨髄異形成症候群の発症リスクに関する大規模副作用データベースを用いた解析

    川尻雄大, 小林大介, 内田まやこ, 廣本詩織, 井上将志, 池田朔, 井上瑞季, 島添隆雄

    第41回 日本臨床薬理学会学術総会, 福岡  2020.12 

  • 服薬指導シートを用いた患者ケアの実際と情報共有化への活用

    内田まやこ

    がん化学療法実践セミナー  2012 

     More details

    Language:Japanese  

  • 服薬指導シートを用いた患者ケアと情報共有化への活用

    内田まやこ

    第1回 沖縄支持療法セミナー  2013 

     More details

    Language:Japanese  

  • 服薬指導シートを用いた患者ケアと情報の共有化への活用

    内田まやこ

    がん支持療法セミナー  2013 

     More details

    Language:Japanese  

  • 有害事象自発報告データベー スを用いた経口抗凝固薬の安全性解析

    飯田達也, 細畑圭子, 若林智仁, 内田まやこ, 岩永一範

    第15回次世代を担う若手のための医療薬科学 シンポジウム  2021.10 

  • 有害事象データベースを用いた抗てんかん薬による皮膚障害のシグナル評価 従来薬と新世代薬との違い

    稲田 文香, 細畑 圭子, 尾山 早紀, 内田 まやこ, 新家 郁, 森 康裕, 山口 裕規, 高野 碧, 前川 奈美, 若林 智仁, 岩永 一範

    臨床薬理  2018.5  (一社)日本臨床薬理学会

     More details

    Language:Japanese  

  • 有害事象データベースを用いた抗てんかん薬による皮膚障害のシグナル評価~従来薬と新世代薬との違い~

    稲田文香, 細畑圭子, 尾山早紀, 内田まやこ, 新家郁, 森康裕, 山口裕規, 高野碧, 前川奈美, 若林智仁, 岩永一範

    日本臨床薬理学会  2018.7 

     More details

    Language:Japanese  

  • 日本緩和医療薬学会研究推進委員会報告, 緩和医療におけるポリファーマシーに対する薬剤師の介入に関する全国実態調査

    鈴木真也, 内田まやこ, 菅幸生, 菅原英輝, 国分秀也, 中川貴之, 高瀬久光

    第12回 日本緩和医療薬学会年会  2018 

     More details

    Language:Japanese  

  • 新規制吐剤(アプレピタント)併用前後の制吐効果とQOLの改善について~副作用の評価方法の統一にむけて~

    一ノ瀬喜美子, 平岩ひろみ, 櫻井麻子, 内田まやこ, 加藤光治, 宮本敏浩

    日本造血細胞移植学会総会プログラム・抄録集  2011 

     More details

    Language:Japanese  

  • 支持療法

    内田まやこ

    平成31年度 がん専門薬剤師 集中教育講義  2019.12 

  • 支持療法

    内田まやこ

    平成30年度 がん専門薬剤師集中教育講義  2018 

     More details

    Language:Japanese  

  • 抗菌薬について

    内田まやこ

    九州大学病院 北11階病棟 看護師勉強会  2013 

     More details

    Language:Japanese  

  • 抗がん薬使用後の白血病および骨髄異形成症候群の発現リスクに関する有害事象自発報告データベースを用いた解析

    川尻 雄大, 小林 大介, 内田 まやこ, 島添 隆雄

    日本薬学会年会要旨集  2020.3  (公社)日本薬学会

     More details

    Language:Japanese  

  • 抗がん剤治療における体表面積算出に関する調査と算出式の統一

    岡田昌之, 成末まさみ, 松浦まなみ, 杉本悠花, 岩本英子, 池末裕明, 内田まやこ, 渡邊裕之, 末安正典, 大石了三

    日本医療薬学会年会講演要旨集  2009.9 

     More details

    Language:Japanese  

  • 抗がん剤による有害事象の早期発見・回避に向けた取り組み

    池末裕明, 三嶋一登, 内田まやこ, 渡邉裕之, 末安正典, 大石了三

    日本医療薬学会年会講演要旨集  2007.9 

     More details

    Language:Japanese  

  • 我が国の大規模医薬品副作用データベースJADERに基づくオピオイド関連有害事象の解析

    菅原英輝, 菅幸生, 内田まやこ, 鈴木真也, 植沢芳広, 中川貴之, 髙瀬久光

    第29回 日本臨床精神神経薬理学会年会シンポジウム  2019.10 

  • 我が国の大規模副作用データベースに基づくオピオイド使用がん患者における呼吸抑制の検討

    菅原英輝, 内田まやこ, 鈴木真也, 菅幸生, 植沢芳広, 中川貴之, 髙瀬久光

    第13回 日本緩和医療薬学会年会シンポジウム  2019.6 

  • 情報共有化ツールとしてのがん化学療法服薬指導シートの有用性評価

    貴島幸子, 辻川智子, 渡邊裕之, 内田まやこ, 池末裕明, 江頭 伸昭, 増田智先

    第76回 九州山口薬学大会  2014 

     More details

    Language:Japanese  

  • 急性骨髄性白血病患者への薬学的介入

    内田まやこ

    Oncology Pharmacist Academy  2012 

     More details

    Language:Japanese  

  • 心臓カテーテル検査実施患者における薬剤管理指導業務

    内田まやこ, 安芸敬生, 白水景子, 末安正典, 吉川学, 伊藤善規, 大石了三

    日本医療薬学会年会講演要旨集  2004.9 

     More details

    Language:Japanese  

  • 婦人科におけるがん化学療法ワークシートの有用性

    内田まやこ, 原田路子, 池末裕明, 小坪一哉, 伊藤善規, 大石了三

    日本医療薬学会年会講演要旨集  2003.9 

     More details

    Language:Japanese  

  • 妊娠中に胃がんが判明し,急速な経過をたどった一症例

    清水祐紀子, 波多野有美, 嶋本正弥, 今野里美, 土谷美智子, 山川文子, 村上一徳, 内田まやこ, 水元一博, 外須美夫

    日本緩和医療学会学術大会プログラム・抄録集  2013 

     More details

    Language:Japanese  

  • 地域における緩和医療推進のための取り組み~病院薬剤師・保険薬局薬剤師合同グループワークの実施~

    佐田裕子, 内田まやこ, 渡邊裕之, 池末裕明, 末次王卓, 江頭伸昭, 竹野将行, 高木淳一, 瀬尾隆, 増田智先

    日本緩和医療薬学会年会プログラム・要旨集  2015 

     More details

    Language:Japanese  

  • 同種造血幹細胞移植におけるアプレピタントの制吐効果と安全性の検討

    加藤 光次, 内田 まやこ, 池末 裕明, 竹中 克斗, 岩崎 浩己, 宮本 敏浩, 豊嶋 崇徳, 大石 了三, 赤司 浩一

    日本内科学会雑誌  2012.2  (一社)日本内科学会

     More details

    Language:Japanese  

  • 医薬品副作用情報データベースに基づく薬物性顎骨壊死の発現状況および背景因子に関する検討 デノスマブに着目した検討

    稲田 文香, 細畑 圭子, 尾山 早紀, 内田 まやこ, 岩永 一範

    臨床薬理  2017.11  (一社)日本臨床薬理学会

     More details

    Language:Japanese  

  • 医薬品副作用情報データベースに基づく薬物性顎骨壊死の発現状況および背景因子に関する検討~デノスマブに着目した検討~

    稲田文香, 細畑圭子, 尾山早紀, 内田まやこ, 岩永一範

    日本臨床薬理学会  2017.11 

     More details

    Language:Japanese  

  • 医薬品副作用情報データベースに基づく薬物性尿細管間質性腎炎の報告件数と転帰分析

    尾山早紀, 細畑圭子, 稲田文香, 内田まやこ, 岩永一範

    日本臨床薬理学会  2017.11 

     More details

    Language:Japanese  

  • 医薬品副作用データベースにお ける胃がんで使用される抗がん薬に関連する急性腎障害の評価

    内田まやこ, 髙野碧, 近藤悠希, 鈴木真也, 細畑圭子

    第31回日本医療薬学会年会, 熊本  2021.10 

  • 医薬品副作用データベース JADER を利用した抗凝固薬の安全性解析

    若林智仁, 細畑圭子, 新家郁, 尾山早紀, 稲田文香, 内田まやこ, 岩永一範

    第3回 日本臨床薬理学会近畿地方会  2018.10 

  • 医療チームにおけるがん化学療法の情報共有化ツールとしての服薬指導シートの有用性

    内田まやこ, 大畠俊一, 亀崎健次郎, 加藤光次, 宮本敏浩, 馬場英司, 池末裕明, 江頭伸昭, 赤司浩一, 増田智先

    日本臨床腫瘍学会学術集会(CD-ROM)  2014 

     More details

    Language:Japanese  

  • 効率的な院外処方箋の疑義照会方法の確立を目的とした現状調査

    末次 王卓, 秦 晃二郎, 渡邊 裕之, 金谷 朗子, 池末 裕明, 内田 まやこ, 武智 秀明, 竹野 将行, 高木 淳一, 江頭 伸昭, 瀬尾 隆, 増田 智先

    日本薬学会年会要旨集  2015.3  (公社)日本薬学会

     More details

    Language:Japanese  

  • 副作用の発現予測に基づく服薬指導シートを使用したがん化学療法への薬剤師の関わり

    内田まやこ, 池末裕明, 三島一登, 渡邊裕之, 江頭伸昭, 大石了三

    第2回 西日本ファーマシューティカルケア研究会  2010 

     More details

    Language:Japanese  

  • 再発卵巣がんに対するドキソルビシン塩酸塩リポソーム製剤治療における服薬指導シートの作成と活用

    石川 瑠美佳, 渡邉 裕之, 内田 まやこ, 末次 王卓, 山口 麻美, 池末 裕明, 江頭 伸昭, 大石 了三

    日本薬学会年会要旨集  2011.3  (公社)日本薬学会

     More details

    Language:Japanese  

  • 先進的がん薬物療法におけるがん専門薬剤師の役割と期待 がん薬物療法における支持療法の標準化への取り組み(The role and hope of board certificated oncology pharmacy specialist (BCOPS) in innovative chemotherapy Standardization of Supportive Care in Medication Oncology)

    池末 裕明, 渡邉 裕之, 三嶋 一登, 内田 まやこ, 末安 正典, 江頭 伸昭, 大石 了三

    日本癌学会総会記事  2009.8  (一社)日本癌学会

     More details

    Language:English  

  • 先読み臨床力を高めるためのがん医療コミュニケーション~薬剤師が取り組むシームレスな患者ケア~

    内田まやこ

    第28回 日本医療薬学会年会  2018 

     More details

    Presentation type:Symposium, workshop panel (public)  

  • 保険薬局薬剤師を対象とした無菌調製実技セミナーに関する有用性評価

    音窪麻衣, 内田まやこ, 井上薫, 金美恵子, 河合悦子, 中村敏明

    第30回日本医療薬学会年会, 名古屋  2020.9 

  • 九州大学病院血液内科病棟における薬剤師の取り組み

    内田まやこ

    日本病院薬剤師会東北ブロック, 第2回 学術大会ランチョンセミナー  2012 

     More details

    Language:Japanese  

  • 九州大学病院における薬学的管理の実際-抗悪性腫瘍薬-

    内田まやこ

    薬薬連携研修会  2011 

     More details

    Language:Japanese  

  • 九州大学病院における小児緩和ケアチームの取り組み

    西本 恭子, 阿部 智慧子, 古賀 友紀, 笹月 桃子, 賀来 典之, 落合 正行, 木下 義晶, 香月 大輔, 山下 洋, 山根 謙一, 山座 治義, 小笠原 貴子, 山本 千晴, 内田 まやこ, 土井 紗世, 高田 英俊, 九大小児緩和ケアチーム

    日本小児科学会雑誌  2016.5  (公社)日本小児科学会

     More details

    Language:Japanese  

  • 九州大学病院がん化学療法薬薬連携セミナー開催とその評価

    渡邊裕之, 内田まやこ, 池末裕明, 三嶋一登, 末次王卓, 児玉亜由美, 大林かよ, 山路寛子, 山口麻美, 斉藤麻美, 石川瑠美佳, 末安正典, 江頭伸昭, 水元一博, 大石了三

    第20回 日本医療薬学年会  2010 

     More details

    Language:Japanese  

  • 九大病院・産婦人科での入院患者におけるパクリタキセルによる過敏症状の発現とその対策

    原田路子, 内田まやこ, 八幡秀昭, 有吉和也, 平川俊夫, 中野仁雄, 千堂年昭, 川重誠, 伊藤善規, 大石了三

    第66回 九州山口薬学大会  2002 

     More details

    Language:Japanese  

  • レナリドミド・デキサメタゾン併用療法における好中球数減少症の発現状況と危険因子解析

    山下花南恵, 柴谷直樹, 池末裕明, 内田まやこ, 池村舞, 安藤基純, 橋田亨

    第7回 日本臨床腫瘍薬学会2018  2018 

     More details

    Language:Japanese  

  • レナリドミド・デキサメタゾン併用療法における好中球数減少の発現状況と危険因子解析

    山下花南恵, 柴谷直樹, 池末裕明, 内田まやこ, 池村舞, 安藤基純, 橋田亨

    日本臨床腫瘍薬学会学術大会講演要旨集  2018 

     More details

    Language:Japanese  

  • ポリファーマシーにおける薬剤師介入効果に関する前向き観察研究

    鈴木真也, 内田まやこ, 菅幸生, 菅原英輝, 国分秀也, 植沢芳広, 中川貴之, 高瀬久光

    第29回 日本医療薬学会年会シンポジウム  2019.11 

  • ポリファーマシーと医療安全 Invited

    内田まやこ

    第14回 日本緩和医療薬 学会 岡山, 緩和医療薬学会ワークショップ, ライブ配信  2021.5 

  • ベンダムスチン投与に伴う静脈炎軽減に向けた薬学的介入

    辻川智子, 渡邊裕之, 内田まやこ, 末次王卓, 池末裕明, 江頭伸昭, 大石了三

    日本薬学会年会要旨集  2012.3 

     More details

    Language:Japanese  

  • ベルケイド~薬剤師の立場から~

    内田まやこ

    第43回 福岡BMT研究会  2009 

     More details

    Language:Japanese  

  • バラクルード錠温湯懸濁時におけるエンテカビル安定性に及ぼす併用薬の影響

    花園 真緒, 飯田 紘生, 北尾 昂志, 中島 康太郎, 内田 まやこ, 岩永 一範, 中村 任

    日本薬学会年会要旨集  2019.3  (公社)日本薬学会

     More details

    Language:Japanese  

  • デノスマブによる低Ca血症発現に及ぼす腎機能の影響

    秦晃二郎, 池末裕明, 辻敏和, 渡邊裕之, 三嶋一登, 内田まやこ, 江頭伸昭, 増田智先

    医療薬学フォーラム講演要旨集  2014.6 

     More details

    Language:Japanese  

  • チーム医療のなかで薬剤師が行うがん患者・ご家族へのがん診療情報提供

    内田まやこ, 水元一博, 高山浩一, 渡邊裕之, 坂本節子, 池末裕明, 江頭伸昭, 大石了三

    日本臨床腫瘍学会学術集会プログラム・抄録集  2012 

     More details

    Language:Japanese  

  • チーム医療における薬剤師の新たな業務ーがん専門薬剤師外来の取り組みー

    内田まやこ

    福岡オンコロジー研究会  2016 

     More details

    Language:Japanese  

  • チーム医療における薬剤師が関わる緩和ケア

    内田まやこ

    八代薬薬連携セミナー  2014 

     More details

    Language:Japanese  

  • チーム医療で行うがん患者・ご家族への医療用麻薬に関する情報提供

    内田まやこ, 早水真理子, 清水祐紀子, 土谷美智子, 嶋本正弥, 山川文子, 渡邊裕之, 池末裕明, 水元一博, 江頭伸昭, 大石了三

    第6回 日本緩和医療薬学会年会  2012 

     More details

    Language:Japanese  

  • タキソール過敏症における前投薬:基礎ならびに臨床での効果

    高崎新也, 斉藤麻美, 五郎丸剛, 原田路子, 千堂年昭, 伊藤善規, 内田まやこ, 八幡秀昭, 平川俊夫, 中野仁雄

    日本薬学会123年会  2003 

     More details

    Language:Japanese  

  • ゼヴァリン療法のクリティカルパス作成

    内田まやこ, 山口麻美, 池末裕明, 松江祥子, 平岩ひろみ, 馬場眞吾, 原田直樹, 宮本敏浩, 豊嶋崇徳, 江頭伸昭, 大石了三

    日本医療薬学会年会講演要旨集  2010.10 

     More details

    Language:Japanese  

  • クリニカルクエスチョンを臨床研究に繋げて論文化しよう

    内田まやこ

    近畿ブロック Oncology Pharmacist Community Forum 2019  2019.12 

  • オピオイド鎮痛薬適正使用のための緩下薬予防投与の推進

    末次王卓, 池末裕明, 内田まやこ, 白水景子, 尾川理恵, 峯昌敏, 渡邊裕之, 三嶋一登, 末安正典, 江頭伸昭, 大石了三

    日本医療薬学会年会講演要旨集  2007.9 

     More details

    Language:Japanese  

  • オピオイド適正使用に向けた薬剤師の取り組み 緩和医療におけるポリファーマシーに対する薬剤師の介入に関する多施設前向き観察研究

    内田 まやこ, 鈴木 真也, 菅 幸生, 菅原 英輝, 国分 秀也, 植沢 芳広, 中川 貴之, 高瀬 久光

    日本臨床精神神経薬理学会・日本神経精神薬理学会合同年会プログラム・抄録集  2019.10  日本臨床精神神経薬理学会・日本神経精神薬理学会

     More details

    Language:Japanese  

  • オピオイド適正使用に向けた薬剤師の取り組み 緩和ケア領域におけるポリファーマシーの現状と病院/薬局薬剤師の介入実態に関する全国アンケート調査

    中川 貴之, 鈴木 真也, 内田 まやこ, 菅原 英輝, 菅 幸生, 国分 秀也, 植沢 芳広, 高瀬 久光

    日本臨床精神神経薬理学会・日本神経精神薬理学会合同年会プログラム・抄録集  2019.10  日本臨床精神神経薬理学会・日本神経精神薬理学会

     More details

    Language:Japanese  

  • オピオイド適正使用に向けた薬剤師の取り組み 我が国の大規模医薬品副作用データベースJADERに基づくオピオイド関連有害事象の解析

    菅原 英輝, 菅 幸生, 内田 まやこ, 鈴木 真也, 植沢 芳広, 中川 貴之, 高瀬 久光

    日本臨床精神神経薬理学会・日本神経精神薬理学会合同年会プログラム・抄録集  2019.10  日本臨床精神神経薬理学会・日本神経精神薬理学会

     More details

    Language:Japanese  

  • オピオイドの副作用について

    内田まやこ

    九州大学病院緩和ケア担当看護師定例会  2009 

     More details

    Language:Japanese  

  • オピオイドの副作用について

    内田まやこ

    九州大学病院 北7階1病棟 看護師勉強会  2010 

     More details

    Language:Japanese  

  • その人らしさに繋がる語りから患者を支える心理的サポート

    村上 一徳, 嶋本 正弥, 清水 祐紀子, 山川 文子, 今野 里美, 土谷 美智子, 内田 まやこ, 水元 一博, 外 須美夫

    日本緩和医療学会学術大会プログラム・抄録集  2014.6  (NPO)日本緩和医療学会

     More details

    Language:Japanese  

  • その人らしさに繋がる語りから患者を支える心理的サポート

    村上一徳, 嶋本正弥, 清水祐紀子, 山川文子, 今野里美, 土谷美智子, 内田まやこ, 水元一博, 外須美夫

    日本緩和医療学会学術大会プログラム・抄録集  2014 

     More details

    Language:Japanese  

  • そこが知りたい!血液がん化学療法を看護ケアする上でのポイント

    内田まやこ

    日本緩和医療薬学会年会プログラム・要旨集  2016 

     More details

    Language:Japanese  

  • がん薬物療法における皮膚障害について考える

    内田まやこ

    大阪薬科大学サテライトセミナー  2018 

     More details

    Language:Japanese  

  • がん薬物療法における支持療法の標準化への取り組み

    池末裕明, 渡邊裕之, 三嶋一登, 内田まやこ, 末安正典, 江頭伸昭, 大石了三

    第68回 日本癌学会学術総会  2009 

     More details

    Language:Japanese  

  • がん薬物療法における支持療法の標準化の取り組み

    池末裕明, 渡邊裕之, 三嶋一登, 内田まやこ, 末安正典, 江頭伸昭, 大石了三

    第19回 日本医療薬学会年会  2009 

     More details

    Language:Japanese   Presentation type:Symposium, workshop panel (public)  

  • がん薬物療法における口腔粘膜障害について考える

    内田まやこ

    大阪薬科大学 サテライトセミナー  2018.11 

  • がん緩和 医療における薬剤師育成のための卒後研修2年後の受講者の行動変化調査

    葉田昌生, 山田真裕, 内田まやこ, 因間大悟, 有吉俊二, 神村英利, 原口亨

    第30回日 本医療薬学会年会, 名古屋  2020.9 

  • がん疼痛治療薬について

    内田まやこ

    院内緩和ケア担当看護師向け勉強会  2011 

     More details

    Language:Japanese  

  • がん患者を対象とした薬剤師育成のための卒後研修会の有用性評価 Invited

    内田まやこ

    第14回 日本緩和医療薬学会 岡山, シンポジウム, オンデマンド配信  2021.5 

  • がん患者のライフステージに応じた薬物療法から緩和医療まで

    内田まやこ

    第14回 大阪薬科大学 公開シンポジウム, がん専門医療人材養成プラン事業  2017 

     More details

    Language:Japanese  

  • がん患者に対する緩和ケアを担う薬剤師育成のための体系的な教育プログラムの構築

    内田まやこ, 山田真裕, 葉田昌生, 因間大悟, 有吉俊二, 青木和子, 井上章治, 島添隆雄, 満生清士, 原口亨

    第13回 日本緩和医療薬学会年会  2019.6 

  • がん性疼痛治療に関する薬薬連携セミナーの開催と評価

    内田まやこ, 渡邊裕之, 池末裕明, 三嶋一登, 大林かよ, 山路寛子, 水元一博, 江頭伸昭, 小野伸昭, 大石了三

    日本緩和医療薬学会年会プログラム・要旨集  2010 

     More details

    Language:Japanese  

  • がん性疼痛に必要な薬物療法

    内田まやこ

    がんプロ看護師養成講義研修会  2012 

     More details

    Language:Japanese  

  • がん専門薬剤師外来の取り組み

    内田まやこ

    福岡大学筑紫病院 緩和ケアセミナー  2016 

     More details

    Language:Japanese  

  • がん化学療法薬薬連携セミナー~がん診療連携拠点病院と薬局薬剤師との連携強化を目指して~

    内田まやこ, 水元一博, 渡邊裕之, 池末裕明, 大石了三

    日本医療マネジメント学会九州・山口連合大会プログラム・抄録集  2010 

     More details

    Language:Japanese  

  • がん化学療法ワークシートを活用した支持療法

    内田まやこ

    日本臨床腫瘍薬学会  2013 

     More details

    Presentation type:Symposium, workshop panel (nominated)  

  • がん化学療法レジメン管理における評価支援ツールおよび教育システムの構築とその評価

    大林かよ, 渡邊裕之, 佐藤由紀子, 山内結衣, 了戒百合子, 内田まやこ, 平川良宏, 末安正典, 江頭伸昭, 大石了三

    第71回 九州山口薬学大会  2009 

     More details

    Language:Japanese  

  • がん化学療法を受ける患者と家族に対する抗がん剤の副作用に関する情報提供のための冊子作成とその評価

    内田 まやこ, 草場 仁志, 高山 浩一, 坂本 節子, 江藤 清子, 水元 一博, 渡邊 裕之, 池末 裕明, 江頭 伸昭, 増田 智先

    日本緩和医療学会学術大会プログラム・抄録集  2014.6  (NPO)日本緩和医療学会

     More details

    Language:Japanese  

  • がん化学療法を受ける患者と家族に対する抗がん剤の副作用に関する情報提供のための冊子作成とその評価

    内田 まやこ, 草場 仁志, 高山 浩一, 坂本 節子, 江藤 清子, 水元 一博, 渡邊 裕之, 池末 裕明, 江頭 伸昭, 増田 智先

    日本緩和医療学会学術大会プログラム・抄録集  2014.6 

     More details

    Language:Japanese  

  • がん化学療法による口腔粘膜炎をどう予防し、どう対処する?

    内田まやこ

    サンスター・大阪薬科大学合同セミナー ~オーラルフレイルと口腔ケア指導~  2019.11 

  • がん化学療法における薬薬連携強化を目的とした保険調剤薬局へのアンケート調査

    了戒百合子, 渡邊裕之, 池末裕明, 内田まやこ, 三嶋一登, 末安正典, 江頭伸昭, 高木淳一, 小野信昭, 大石了三

    第72回 九州山口薬学大会  2010 

     More details

    Language:Japanese  

  • がん化学療法における薬剤管理指導:処方チェックおよび副作用モニタリングの効率化

    内田まやこ, 池末裕明, 三嶋一登, 末安正典, 伊藤善規, 大石了三

    医療薬学フォーラム講演要旨集  2005.7 

     More details

    Language:Japanese  

  • がん化学療法における薬剤師の役割~九州大学病院血液内科病棟での取り組み~

    内田まやこ

    福岡がん化学療法セミナー  2013 

     More details

    Language:Japanese  

▼display all

MISC

  • 糖尿病患者への新規服薬フォローアップ支援シートに対する薬局薬剤師の評価

    矢原 恵美[堀田], 一丸 智司, 井上 良祐, 津田 賢蔵, 清水 忠, 内田 まやこ, 木下 淳

    医療薬学   50 ( 5 )   248 - 257   2024.5   ISSN:1346-342X eISSN:1882-1499

     More details

    Language:Japanese   Publisher:(一社)日本医療薬学会  

  • 【「副作用が生じていないこと」を確認するための副作用の機序とモニタリング】副作用症状がないことを確認するモニタリング 間質性肺炎

    内田 まやこ

    調剤と情報   29 ( 15 )   2687 - 2692   2023.11   ISSN:1341-5212

     More details

    Language:Japanese   Publisher:(株)じほう  

    間質性肺炎は,致死的になる場合もあり,早期発見,早期対応が極めて重要となる。薬剤投与中に,空咳や,息切れ・呼吸困難などを訴えた場合は,間質性肺炎の発症を疑う。一部の患者では,風邪様症状後に急性増悪し,短期間のうちに生命に関わることがある。本稿では,『重篤副作用疾患マニュアル;間質性肺炎』にそって主要なポイントを解説する。(著者抄録)

  • 間質性肺炎 Invited

    内田まやこ

    調剤と情報   29 ( 15 )   2687 - 2692   2023.11

  • がん患者の体系的な緩和ケア教育プログラムの構築と評価

    内田まやこ

    薬事新報   ( 3282 )   1227 - 1234   2022.12

     More details

    Authorship:Lead author  

  • ポリファーマシーに対する保険薬局薬剤師の介入に関する多施設共同前向き観察研究

    内田 まやこ

    薬事新報   ( 3281 )   7 - 13   2022.11   ISSN:0289-3290

     More details

    Language:Japanese   Publisher:(株)薬事新報社  

  • ポリファーマシーに対する保険薬局薬剤師の介入に関する多施設共同前向き観察研究

    内田まやこ

    薬事新報   ( 3281 )   1202 - 1208   2022.11

     More details

    Authorship:Lead author  

  • がん化学療法施行患者への服薬指導の充実を目指して(2)

    内田 まやこ

    薬事新報   ( 3277 )   7 - 15   2022.10   ISSN:0289-3290

     More details

    Language:Japanese   Publisher:(株)薬事新報社  

  • がん化学療法施行患者への服薬指導の充実を目指して(2)

    内田 まやこ

    薬事新報   ( 3277 )   7 - 15   2022.10   ISSN:0289-3290

     More details

    Authorship:Lead author   Language:Japanese   Publisher:(株)薬事新報社  

  • がん化学療法施行患者への服薬指導の充実を目指して(1)

    内田まやこ

    薬事新報   (3272)   968 - 974   2022.9

     More details

    Authorship:Lead author  

  • 医療データベースを用いた医薬品の副作用の発現時期評価

    内田 まやこ

    薬事新報   ( 3268 )   7 - 13   2022.8   ISSN:0289-3290

     More details

    Language:Japanese   Publisher:(株)薬事新報社  

  • 医療データベースを用いた医薬品の副作用の発現時期評価

    内田 まやこ

    薬事新報   ( 3268 )   7 - 13   2022.8   ISSN:0289-3290

     More details

    Authorship:Lead author   Language:Japanese   Publisher:(株)薬事新報社  

  • 薬局薬剤師を対象とした無菌調製実技セミナーに関する生涯教育の有用性

    音窪 麻衣, 内田 まやこ, 井上 薫, 金 美惠子, 河合 悦子, 中村 敏明

    大阪医科薬科大学薬学部雑誌   1   119 - 125   2022.3

     More details

    Language:Japanese   Publisher:大阪医科薬科大学薬学部  

    無菌調製実技セミナーの受講者を対象に、受講前、セミナー第1部受講後(座学講義および基礎実技)、第2部受講後(応用実技等)に質問紙調査を実施し、セミナーの有用性について評価、検討した。受講者は11名(勤務年数10年以上7名、5年以上10年未満2名、1年から5年未満1名、無回答1名)であり、調査用紙は全員から回収された。セミナーの満足度は無菌調製に必要な基本的な知識や基礎実技に対しての満足度は、「満足」5名、「やや満足」2名であった。クリーンベンチを使用した無菌操作を伴った実技での満足度は「満足」8名、「やや満足」との回答はなかった。セミナーの難易度は第1部、第2部ともに「難しい」と回答した受講者が半数以上となった。セミナーの活用度については「非常に役に立つ」7名、「役に立つ」4名との回答で、「役に立たない」との回答はなかった。実施したセミナーの意義は高く、有用であったと考えられた。

  • 緩和ケアに関する薬剤師を対象とした卒後教育の有用性

    内田 まやこ

    薬局   72 ( 11 )   3307 - 3311   2021.10   ISSN:0044-0035

     More details

    Language:Japanese   Publisher:(株)南山堂  

  • 緩和ケアに関する薬剤師を対象とした卒後教育の有用性

    内田まやこ

    薬局2021年72巻11月号   72 ( 11 )   129 - 133   2021.10

     More details

    Authorship:Lead author  

  • 体系的な教育プログラム受講後の薬剤師の行動変容

    内田まやこ

    薬事新報   276 - 284   2021.3

     More details

    Authorship:Lead author  

  • 医療データベースを用いた医薬品の安全性評価

    内田まやこ

    薬事新報   197 - 204   2021.2

     More details

    Authorship:Lead author  

  • 服薬指導の充実とチーム医療推進に向けた実践例

    内田 まやこ

    薬局   71 ( 12 )   3514 - 3518   2020.11   ISSN:0044-0035

     More details

    Language:Japanese   Publisher:(株)南山堂  

  • 皮膚障害の予測因子に関する後ろ向き観察研究

    内田 まやこ

    薬事新報   ( 3174 )   1155 - 1163   2020.11   ISSN:0289-3290

     More details

    Authorship:Lead author   Language:Japanese   Publisher:(株)薬事新報社  

  • 服薬指導の充実とチーム医療推進に向けた実践例

    内田 まやこ

    薬局   71 ( 12 )   3514 - 3518   2020.11   ISSN:0044-0035

     More details

    Authorship:Lead author   Language:Japanese   Publisher:(株)南山堂  

  • 皮膚障害の予測因子に関する後ろ向き観察研究

    内田 まやこ

    薬事新報   ( 3174 )   1155 - 1163   2020.11   ISSN:0289-3290

     More details

    Language:Japanese   Publisher:(株)薬事新報社  

  • がん治療の有効性と安全性の評価基準

    内田 まやこ

    薬局   71 ( 11 )   3408 - 3412   2020.10   ISSN:0044-0035

     More details

    Authorship:Lead author   Language:Japanese   Publisher:(株)南山堂  

  • がん治療の有効性と安全性の評価基準

    内田 まやこ

    薬局   71 ( 11 )   3408 - 3412   2020.10   ISSN:0044-0035

     More details

    Language:Japanese   Publisher:(株)南山堂  

  • がん化学療法誘発悪心・嘔吐の予防と治療(3)

    内田 まやこ

    薬局   71 ( 10 )   3210 - 3212   2020.9   ISSN:0044-0035

     More details

    Language:Japanese   Publisher:(株)南山堂  

  • がん化学療法誘発悪心・嘔吐の予防と治療③

    内田 まやこ

    薬局   71 ( 10 )   3210 - 3212   2020.9   ISSN:0044-0035

     More details

    Authorship:Lead author   Language:Japanese   Publisher:(株)南山堂  

  • がん化学療法誘発悪心・嘔吐の予防と治療(2)

    内田 まやこ

    薬局   71 ( 9 )   3055 - 3059   2020.8   ISSN:0044-0035

     More details

    Language:Japanese   Publisher:(株)南山堂  

  • がん化学療法誘発悪心・嘔吐の予防と治療②

    内田まやこ

    薬局 2020年8月 Vol.71 No.9   2020.8

     More details

    Authorship:Lead author  

  • がん化学療法誘発悪心・嘔吐の予防と治療(1)

    内田 まやこ

    薬局   71 ( 8 )   2842 - 2845   2020.7   ISSN:0044-0035

     More details

    Language:Japanese   Publisher:(株)南山堂  

  • がん化学療法誘発悪心・嘔吐の予防と治療①

    内田まやこ

    薬局 2020年7月 Vol.71 No.8   2020.7

     More details

    Authorship:Lead author  

  • 自粛生活で感じたこと

    内田まやこ

    薬事新報   2020.7

     More details

    Authorship:Lead author  

  • 発熱性好中球減少症の予測因子に関する後ろ向き観察研究

    内田 まやこ

    薬事新報   ( 3154 )   11 - 18   2020.6   ISSN:0289-3290

     More details

    Language:Japanese   Publisher:(株)薬事新報社  

    当院でドセタキセル療法を行った進行または再発非小細胞肺癌(NSCLC)81例(男性51例、女性30例)を対象に、発熱性好中球減少症(FN)の発現状況と予測因子について検討した。その結果、FNの発現率は22%で、ドセタキセル単剤群では19.7%、ドセタキセルとベバシズマブ併用群では40.0%であった。また、多変量ロジスティック回帰分析では、治療開始前のPS 1-2、血小板数18.8×10^4/μL以下が、ドセタキセル療法を受けているNSCLC患者におけるFNの重要な予測因子であることが明らかになった。

  • 緩和ケア領域のポリファーマシーに対する病院薬剤師の積極的な介入実態

    内田まやこ

    薬事新報   2020.6

     More details

    Authorship:Lead author  

  • 発熱性好中球減少症の予測因子に関する後ろ向き観察研究

    内田まやこ

    薬事新報   641 - 648   2020.6

     More details

    Authorship:Lead author  

  • 緩和ケア領域のポリファーマシーに対する病院薬剤師の積極的な介入実態

    内田 まやこ

    薬事新報   ( 3152 )   7 - 19   2020.6   ISSN:0289-3290

     More details

    Language:Japanese   Publisher:(株)薬事新報社  

  • 本邦における医療リアルワールドデータ利活用の実例

    内田 まやこ

    薬事新報   ( 3148 )   7 - 13   2020.5   ISSN:0289-3290

     More details

    Language:Japanese   Publisher:(株)薬事新報社  

  • 薬剤師ふたばの症例検討奮闘記 症例検討会本番 議論を深めるために

    内田まやこ, 矢野良一

    薬局 2020年5月 Vol.71 No.6   2020.5

     More details

    Authorship:Lead author  

  • 本邦における医療リアルワールドデータ利活用の実例

    内田まやこ

    薬事新報   2020.5

     More details

    Authorship:Lead author  

  • 【おさらい!「がん」の基本 がん関連処方に備える、患者さんを支える】患者さんの生活&療養サポート!副作用と支持療法 ポリファーマシー、薬剤師の一歩前進に期待!

    内田 まやこ, 高瀬 久光

    Rp.+   19 ( 1 )   119 - 119   2020.1

     More details

    Language:Japanese   Publisher:(株)南山堂  

  • おさらい!がんの基本

    内田まやこ

    レシピプラス 2020年冬号 Vol.19 No.1   2020.1

     More details

    Authorship:Lead author  

  • チーム医療におけるがん化学療法の情報共有化 ツールとしての服薬指導シートの有用性

    内田 まやこ

    薬事新報   ( 3127 )   7 - 11   2019.12   ISSN:0289-3290

     More details

    Language:Japanese   Publisher:(株)薬事新報社  

  • チーム医療におけるがん化学療法の情報共有化ツールとしての服薬指導シ-トの有用性

    内田まやこ

    薬事新報   2019.12

     More details

    Authorship:Lead author  

  • がん患者に対する緩和ケアを担う薬剤師育成のための体系的な教育プログラムの構築

    内田まやこ

    薬事新報   2019.11

     More details

    Authorship:Lead author  

  • がん患者に対する緩和ケアを担う薬剤師育成のための体系的な教育プログラムの構築

    内田 まやこ

    薬事新報   ( 3123 )   7 - 16   2019.11   ISSN:0289-3290

     More details

    Language:Japanese   Publisher:(株)薬事新報社  

  • がん化学療法誘発悪心・嘔吐対策に関する多施設共同研究のサブグループ解析

    内田まやこ

    薬事新報   2019.10

     More details

    Authorship:Lead author  

  • がん化学療法誘発悪心・嘔吐対策に関する多施設共同研究のサブグループ解析

    内田 まやこ

    薬事新報   ( 3118 )   15 - 23   2019.10   ISSN:0289-3290

     More details

    Language:Japanese   Publisher:(株)薬事新報社  

  • 医師・薬剤師協働で行うがん化学療法誘発悪心・嘔吐対策に関する前向き観察研究

    内田 まやこ

    薬事新報   ( 3114 )   13 - 19   2019.9   ISSN:0289-3290

     More details

    Language:Japanese   Publisher:(株)薬事新報社  

  • 医師・薬剤師協働で行うがん化学療法誘発悪心・嘔吐対策に関する前向き観察研究

    内田まやこ

    薬事新報   2019.9

     More details

    Authorship:Lead author  

  • 薬剤師が行う悪心・嘔吐対策に関する臨床研究~九州大学病院血液腫瘍内科病棟での取り組み~③ベンダムスチン療法編

    内田まやこ

    薬事新報   2019.8

     More details

    Authorship:Lead author  

  • 薬剤師が行う悪心・嘔吐対策に関する臨床研究~九州大学病院血液腫瘍内科病棟での取り組み~②ABVD療法編

    内田まやこ

    薬事新報   2019.7

     More details

    Authorship:Lead author  

  • 第2回病院薬剤師が実践するリバーストランスレーショナルリサーチの最前線~分子標的探索と個別化医療への挑戦~ がん薬物療法の適正化推進に向けた臨床薬学的研究

    渡邊 裕之, 内田 まやこ, 増田 智先

    薬学雑誌   139 ( 6 )   901 - 909   2019.6   ISSN:0031-6903

     More details

    Language:Japanese   Publisher:(公社)日本薬学会  

    抗癌剤投与における副作用は患者のQOLを低下させる。薬剤師は、副作用の情報を収集、解析し抗癌薬の適正使用、医療安全に貢献するとともに、予防法、対策を確立させることが重要である。癌薬物療法の適正化推進に向け、1)ベンダムスチン投与による血管障害に関する臨床観察研究、2)造血幹細胞移植の前処置としての大量化学療法における制吐療法に関する臨床観察研究、について概説した。

  • 薬剤師が行う悪心・嘔吐対策に関する臨床研究~九州大学病院血液腫瘍内科病棟での取り組み~①R-CHOP療法編

    内田まやこ

    薬事新報   2019.6

     More details

    Authorship:Lead author  

  • 【薬物療法問題集 コモンな50疾患・150題で実力がつく!】悪性腫瘍 多発性骨髄腫

    内田 まやこ

    薬事   60 ( 14 )   2762 - 2765   2018.10   ISSN:0016-5980

     More details

    Language:Japanese   Publisher:(株)じほう  

  • 薬物療法問題集

    内田まやこ

    月刊薬事 2018年10月臨時増刊号 Vol.60 No.14   2018.10

     More details

    Authorship:Lead author  

  • 医薬品リスク管理計画(RMP)の利活用に関する卒後研修会の有用性評価

    角山 香織, 中村 敏明, 中村 任, 内田 まやこ, 芝野 真喜雄, 宮崎 誠, 永井 純也

    日本医薬品情報学会総会・学術大会講演要旨集   21回   157 - 157   2018.6

     More details

    Language:Japanese   Publisher:(一社)日本医薬品情報学会  

  • 多発性骨髄腫

    内田まやこ

    月刊薬事, 臨時増刊号   2762 - 2765   2018

     More details

    Authorship:Lead author   Language:Japanese  

  • 新薬展望2017 第III部 治療における最近の新薬の位置付け〈薬効別〉~新薬の広場~癌治療補助薬

    内田まやこ

    医薬ジャーナル   53   360‐372   2017.1   ISSN:0287-4741

     More details

    Authorship:Lead author   Language:Japanese  

    J-GLOBAL

  • 【新薬展望2017】(第III部)治療における最近の新薬の位置付け<薬効別> 新薬の広場 癌治療補助薬

    内田 まやこ

    医薬ジャーナル   53 ( 増刊 )   360 - 372   2017.1   ISSN:0287-4741

     More details

    Language:Japanese   Publisher:(株)医薬ジャーナル社  

    2016年に承認された癌治療補助薬は,新有効成分を有する薬剤が存在しないものの,新効能,小児用量追加といった,既存の薬剤を有効活用したものが複数ある。フェブキソスタット(フェブリク錠)は,癌化学療法に伴う高尿酸血症に対する新効能・用量,アミトリプチリン塩酸塩(トリプタノール錠)は,末梢性神経障害性疼痛に対する新効能・用量,ホスアプレピタントメグルミン(プロイメンド注)は,抗悪性腫瘍薬投与に伴う消化器症状(悪心,嘔吐)への小児用量追加として承認されている。また,癌性疼痛に対するHydromorphoneやオピオイド系鎮痛薬による便秘に対する症状緩和薬として,Naldemedineの臨床試験が進行中であり,結果が期待される。(著者抄録)

  • SGLT2阻害薬の皮膚障害関連事象発現状況に関する市販後調査報告とJADERとの比較からみたJADERの特徴

    角山 香織, 多門 啓子, 細畑 圭子, 内田 まやこ, 中村 任, 岩永 一範, 中村 敏明

    日本薬剤疫学会学術総会抄録集   22回   98 - 99   2016.11

     More details

    Language:Japanese   Publisher:(一社)日本薬剤疫学会  

  • がん専門薬剤師外来~適切かつ継続的な経口抗がん薬治療を支援~

    内田まやこ

    Hospha 2016 No.3 Hot Field 26   2016.4

     More details

    Authorship:Lead author  

  • 専門薬剤師リレーエッセイ 私の宝物-患者さんとの出会い-

    内田まやこ

    医療薬学   42   550 - 550   2016

     More details

    Authorship:Lead author   Language:Japanese  

  • 人と人 私の宝物-彼女との出会い-

    内田まやこ

    薬事新報   2900   38 - 38   2015

     More details

    Authorship:Lead author   Language:Japanese  

  • 平成26年度 日本医療薬学会がん薬物療法海外派遣研修に参加して

    内田まやこ

    医療薬学   41   286 - 287   2015

     More details

    Authorship:Lead author   Language:Japanese  

  • 28-P4PM-068 造血幹細胞移植におけるタクロリムス投与経路変更時の血中濃度変動要因の解析(TDM・投与設計2,一般演題(ポスター),新時代を拓く医療薬学フロンティア)

    末次 王卓, 内田 まやこ, 愼原 洋子, 池末 裕明, 渡邊 裕之, 矢野 貴久, 大畠 俊一, 宮本 敏浩, 江頭 伸昭, 増田 智先

    日本医療薬学会年会講演要旨集   24   438 - 438   2014.8

     More details

    Language:Japanese   Publisher:日本医療薬学会  

    CiNii Books

  • 土-P3-382 VTD療法における薬剤管理指導業務への展開(がん薬物療法(服薬指導・情報提供),ポスター発表,一般演題,再興、再考、創ろう最高の医療の未来)

    近森 綾子, 内田 まやこ, 末次 王卓, 渡邊 裕之, 池末 裕明, 國分 千代, 金谷 朗子, 末安 正典, 江頭 伸昭

    日本医療薬学会年会講演要旨集   23   315 - 315   2013.8

     More details

    Language:Japanese   Publisher:日本医療薬学会  

    CiNii Books

  • 症状と対処の仕方がわかる!抗がん薬副作用とマネジメント 第7回 悪性リンパ腫 R‐CHOP療法

    池末裕明, 内田まやこ

    月刊薬事   55 ( 5 )   840 - 850   2013.5   ISSN:0016-5980

     More details

    Language:Japanese  

    CiNii Books

    J-GLOBAL

  • 症状と対処の仕方がわかる!抗がん薬副作用とマネジメント(第7回) 悪性リンパ腫 R-CHOP療法

    池末 裕明, 内田 まやこ

    薬事   55 ( 5 )   840 - 850   2013.5   ISSN:0016-5980

     More details

    Language:Japanese   Publisher:(株)じほう  

  • P1-159 自家造血幹細胞移植前処置におけるアプレピタントの有用性および安全性の検討(がん薬物療法(制吐支持療法),ポスター,一般演題,岐路に立つ医療〜千年紀の目覚め〜よみがえれ!ニッポン!薬の改革は我らが手で!)

    末次 王卓, 内田 まやこ, 池末 裕明, 内田 沙織, 加藤 光次, 宮本 敏浩, 渡邊 裕之, 末安 正典, 江頭 伸昭, 大石 了三

    日本医療薬学会年会講演要旨集   22   293 - 293   2012.10

     More details

    Language:Japanese   Publisher:日本医療薬学会  

    CiNii Books

  • 服薬指導シートを活用した患者支援と情報共有化の重要性

    内田まやこ

    臨床薬剤師支援ツール エスタブリッシュファーマシスト, 病院版 3   2012.4

     More details

    Authorship:Lead author  

  • P-0078 造血器腫瘍におけるアプレピタントの効果と安全性の検討(一般演題 ポスター発表,がん薬物療法(副作用対策),Enjoy Pharmacists' Lifestyles)

    内田 まやこ, 一ノ瀬 喜美子, 平岩 ひろみ, 櫻井 麻子, 加藤 光次, 宮本 敏浩, 池末 裕明, 末安 正典, 江頭 伸昭, 大石 了三

    日本医療薬学会年会講演要旨集   21   194 - 194   2011.9

     More details

    Language:Japanese   Publisher:日本医療薬学会  

    CiNii Books

  • P-0537 薬剤管理指導業務の標準化を目的とした「指導の要点と記録のポイント集」の作成(一般演題 ポスター発表,品質管理,Enjoy Pharmacists' Lifestyles)

    池末 裕明, 児玉 亜由美, 別城 朋子, 内田 まやこ, 渡邊 裕之, 園田 正信, 末安 正典, 江頭 伸昭, 大石 了三

    日本医療薬学会年会講演要旨集   21   271 - 271   2011.9

     More details

    Language:Japanese   Publisher:日本医療薬学会  

    CiNii Books

  • 血液内科病棟での薬剤師の役割 : 同志の存在・横のつながりの必要性(シンポジウム21 血液腫瘍の世界へ飛び込め〜HematologyとOncologyの壁を越えよう〜,Enjoy Pharmacists' Lifestyles)

    内田 まやこ, 池末 裕明, 石丸 隆之, 渡邊 裕之, 三嶋 一登, 大石 了三

    日本医療薬学会年会講演要旨集   21   87 - 87   2011.9

     More details

    Language:Japanese   Publisher:日本医療薬学会  

    CiNii Books

  • P1-533 九州大学病院がん化学療法薬薬連携セミナー開催とその評価(一般演題 ポスター発表,地域・在宅医療・薬薬連携,臨床から学び臨床へと還元する医療薬学)

    渡邊 裕之, 内田 まやこ, 池末 裕明, 三嶋 一登, 末次 王卓, 児玉 亜由美, 大林 かよ, 山路 寛子, 山口 麻美, 斎藤 麻美, 石川 瑠美佳, 末安 正典, 江頭 伸昭, 水元 一博, 大石 了三

    日本医療薬学会年会講演要旨集   20   376 - 376   2010.10

     More details

    Language:Japanese   Publisher:日本医療薬学会  

    CiNii Books

  • S7-6 血液がん標準薬物治療と薬学的介入の実際(シンポジウムS7 がん治療における薬学的介入・薬剤管理指導の実際(がん専門薬剤師教育セミナー),臨床から学び臨床へと還元する医療薬学)

    三嶋 一登, 内田 まやこ, 池末 裕明, 大石 了三

    日本医療薬学会年会講演要旨集   20   210 - 210   2010.10

     More details

    Language:Japanese   Publisher:日本医療薬学会  

    CiNii Books

  • P2-288 ゼヴァリン療法のクリティカルパス作成(一般演題 ポスター発表,癌薬物療法(入院化学療法),臨床から学び臨床へと還元する医療薬学)

    内田 まやこ, 山口 麻美, 池末 裕明, 松江 祥子, 平岩 ひろみ, 馬場 眞吾, 原田 直樹, 宮本 敏浩, 豊嶋 崇徳, 江頭 伸昭, 大石 了三

    日本医療薬学会年会講演要旨集   20   437 - 437   2010.10

     More details

    Authorship:Lead author   Language:Japanese   Publisher:日本医療薬学会  

    CiNii Books

  • 【そこが知りたい! 緩和ケアにおける服薬指導】取り入れたい、服薬指導のさまざまな実践 服薬指導のための院内ツール 医療従事者のための緩和ケアマニュアル

    内田 まやこ, 渡邊 裕之, 大石 了三

    緩和ケア   20 ( 10月増刊 )   181 - 185   2010.10   ISSN:1349-7138

     More details

    Language:Japanese   Publisher:(株)青海社  

  • 医療従事者のための緩和ケアマニュアル

    内田まやこ, 渡邊裕之, 大石了三

    緩和ケア   20   181 - 185   2010.10   ISSN:1349-7138

     More details

    Authorship:Lead author   Language:Japanese  

    J-GLOBAL

  • O14-007 抗がん剤治療における体表面積算出に関する調査と算出式の統一(一般演題 口頭発表,がん薬物療法,医療薬学の創る未来 科学と臨床の融合)

    岡田 昌之, 成末 まさみ, 松浦 まなみ, 杉本 悠花, 岩本 英子, 池末 裕明, 内田 まやこ, 渡邊 裕之, 末安 正典, 大石 了三

    日本医療薬学会年会講演要旨集   19   284 - 284   2009.9

     More details

    Language:Japanese   Publisher:日本医療薬学会  

    CiNii Books

  • S15-4 がん化学療法における副作用への対応(シンポジウムS15 がん治療に貢献する専門薬剤師,医療薬学の創る未来 科学と臨床の融合)

    池末 裕明, 末次 王卓, 渡邉 裕之, 内田 まやこ, 三嶋 一登, 末安 正典, 江頭 伸昭, 大石 了三

    日本医療薬学会年会講演要旨集   19   227 - 227   2009.9

     More details

    Language:Japanese   Publisher:日本医療薬学会  

    CiNii Books

  • 29-S4-4 抗がん剤による有害事象の早期発見・回避に向けた取り組み(シンポジウム29-S4 一歩進んだ「がん薬物業務」,社会の期待に応える医療薬学を)

    池末 裕明, 三嶋 一登, 内田 まやこ, 渡邉 裕之, 末安 正典, 大石 了三

    日本医療薬学会年会講演要旨集   17   152 - 152   2007.9

     More details

    Language:Japanese   Publisher:日本医療薬学会  

    CiNii Books

  • 30-P1-125 オピオイド鎮痛薬適正使用のための緩下薬予防投与の推進(がん薬物療法,社会の期待に応える医療薬学を)

    末次 王卓, 池末 裕明, 内田 まやこ, 白水 景子, 尾川 理恵, 峯 昌敏, 渡邊 裕之, 三嶋 一登, 末安 正典, 江頭 伸昭, 大石 了三

    日本医療薬学会年会講演要旨集   17   313 - 313   2007.9

     More details

    Language:Japanese   Publisher:日本医療薬学会  

    CiNii Books

  • For the safety management of on admission bringing medicine. Drug control guidance business and bringing medicine management.

    内田まやこ, 三嶋一登, 末安正典, 大石了三

    月刊薬事   48 ( 6 )   827 - 832   2006.6   ISSN:0016-5980

     More details

    Authorship:Lead author   Language:Japanese  

    CiNii Books

    J-GLOBAL

  • 【入院時持参薬の安全管理に向けて】薬剤管理指導業務と持参薬管理

    内田 まやこ, 三嶋 一登, 末安 正典, 大石 了三

    薬事   48 ( 6 )   827 - 832   2006.6   ISSN:0016-5980

     More details

    Language:Japanese   Publisher:(株)じほう  

  • New point of view on paclitaxel hypersensitivity.

    伊藤善規, 内田まやこ, 大石了三

    薬局   57 ( 3 )   456 - 463   2006.3   ISSN:0044-0035

     More details

    Language:Japanese  

    J-GLOBAL

  • パクリタキセル過敏症に対する新しい考え方

    伊藤 善規, 内田 まやこ, 大石 了三

    薬局   57 ( 3 )   456 - 463   2006.3   ISSN:0044-0035

     More details

    Language:Japanese   Publisher:(株)南山堂  

  • P-123 心臓カテーテル検査実施患者における薬剤管理指導業務(5.薬剤服用歴管理・服薬指導(入院患者服薬指導),"薬剤師がつくる薬物治療"-薬・薬・学の連携-)

    内田 まやこ, 安藝 敬生, 白水 景子, 末安 正典, 吉川 学, 伊藤 善規, 大石 了三

    日本医療薬学会年会講演要旨集   14   247 - 247   2004.9

     More details

    Authorship:Lead author   Language:Japanese   Publisher:日本医療薬学会  

    CiNii Books

  • P-298 婦人科におけるがん化学療法ワークシートの有用性

    内田 まやこ, 原田 路子, 池末 裕明, 小坪 一哉, 伊藤 善規, 大石 了三

    日本医療薬学会年会講演要旨集   13   233 - 233   2003.9

     More details

    Authorship:Lead author   Language:Japanese   Publisher:日本医療薬学会  

    CiNii Books

▼display all

Committee Memberships

  • 九州山口薬学会   運営委員会, 理事  

    2024.10 - Present   

  • 日本癌治療学会   代議員  

    2023.8 - Present   

  • 日本医療薬学会   学術大会小委員会 委員  

    2023.8 - Present   

  • 日本緩和医療薬学会   先端学術緩和医療薬学タスクフォース 副委員長  

    2023.5 - Present   

  • 日本緩和医療薬学会   関連学会連携委員会 委員  

    2023.5 - Present   

  • 日本緩和医療薬学会   認定薬剤師制度委員会 アドバイザー  

    2023.5 - Present   

  • 日本緩和医療薬学会   理事  

    2023.5 - Present   

  • 日本緩和医療薬学会   教育研修委員会 委員長  

    2023.5 - Present   

  • 日本緩和医療薬学会   専門薬剤師制度委員会 アドバイザー  

    2023.5 - Present   

  • 神戸大学   認定臨床研究審査委員会 委員  

    2023.4 - Present   

  • 日本臨床腫瘍薬学会   メーリングリスト運営委員会 委員長  

    2022.6 - Present   

  • 日本医療薬学会 フレッシャーズ活性化委員会 委員  

    2022.4 - Present   

  • 近畿地区調整機構 大学小委員会 委員  

    2022.1 - Present   

  • 近畿地区調整機構 運営委員会 委員  

    2022.1 - Present   

  • 日本緩和医療薬学会   書籍:緩和医療薬学査読委員会 委員  

    2021.12 - 2023.4   

  • 日本臨床腫瘍薬学会 免疫チェックポイント阻害薬マネージメント教育プログラム開発ワーキンググループ 副委員長  

    2021.9 - Present   

  • 日本緩和医療薬学会   教育研修委員会 副委員長  

    2021.7 - 2023.5   

  • 日本緩和医療薬学会   臨床研究委員会 副委員長  

    2021.7 - 2023.5   

  • 日本薬学会   関西支部 委員  

    2021.5 - Present   

  • 日本病院薬剤師会   国際交流委員会 委員  

    2020.7 - Present   

  • 日本臨床腫瘍薬学会   理事  

    2020.5 - Present   

  • 日本臨床腫瘍薬学会   書籍「臨床腫瘍薬学 第2版」編集委員会 副委員長  

    2020.5 - 2022.9   

  • 日本臨床腫瘍薬学会   教育研修委員会 委員長  

    2020.5 - 2022.5   

  • 日本臨床腫瘍薬学会   代議員  

    2020.1 - Present   

  • 日本臨床腫瘍薬学会   教育研修委会 委員  

    2018.7 - 2020.5   

      More details

    Committee type:Academic society

  • 日本医療薬学会   医療薬学編集委員会 委員  

    2018.4 - Present   

      More details

    Committee type:Academic society

  • 日本医療薬学会   国際交流委員会 委員  

    2018.4 - Present   

      More details

    Committee type:Academic society

  • 日本臨床腫瘍薬学会   書籍「臨床腫瘍薬学」編集委員会 委員  

    2017.7 - 2019.3   

  • 日本緩和医療薬学会   試験委員会 委員  

    2017.6 - 2021.6   

      More details

    Committee type:Academic society

  • 日本医療薬学会   代議員  

    2016.12 - Present   

      More details

    Committee type:Academic society

  • 日本医療薬学会   がん専門薬剤師症例サマリー書面審査員  

    2016.8   

      More details

    Committee type:Academic society

  • 日本緩和医療薬学会   研究推進委員会 委員  

    2016.6 - 2018.6   

      More details

    Committee type:Academic society

  • 日本医療薬学会   がん専門薬剤師症例サマリー書面審査員  

    2014.8   

      More details

    Committee type:Academic society

  • 日本緩和医療薬学会   教育研修委員会 委員  

    2014.6 - Present   

      More details

    Committee type:Academic society

  • がん診療拠点病院の緩和ケアチームの基準 (2015年度版) 作成協力委員  

    2014.5 - 2015.5   

  • 日本緩和医療薬学会   試験問題作成 委員  

    2013.9 - 2016.10   

      More details

    Committee type:Academic society

  • 日本緩和医療薬学会   評議員  

    2012.6 - Present   

      More details

    Committee type:Academic society

▼display all

Social Activities

  • 医療薬学フォーラム2024(熊本), ⼀般発表, 一般発表優秀ポスター賞選考委員

    Role(s): Organizing member

    日本医療薬学会  2024.4 - 2024.7

  • 「がん患者における気持ちのつらさ」ガイドラインレビュー委員

    日本サイコオンコロジー学会・日本がんサポーティブケア学会  2023.10 - Present

  • 日本医療薬学会 第7回フレッシャーズ・カンファランス, 実行委員

    Role(s): Presenter, Organizing member

    日本医療薬学会  2023.8 - 2024.6

  • 医療薬学フォーラム2023(山形), ⼀般発表, 一般発表優秀ポスター賞選考委員

    Role(s): Organizing member

    日本医療薬学会  2023.7

  • 第17回 日本緩和医療薬学会 (東京) 2024 組織委員

    Role(s): Organizing member

    2023.7 - Present

  • Asia Pacific Oncology Pharmacy Conress2024, 実行委員

    Role(s): Organizing member

    2023.4 - Present

  • 日本薬学会第143年会(北海道), 口頭発表学生優秀発表賞審査員, 2023

    Role(s): Organizing member

    2023.3

  • 日本薬学会第143年会(北海道), 口頭発表座長, 2023

    Role(s): Presenter

    日本薬学会  2023.3

  • 日本医療薬学会 第6回フレッシャーズ・カンファランス, 実行委員長

    Role(s): Chief editor, Planner, Organizing member

    2022.6

  • 第16回 日本緩和医療薬学会 (神戸) 2023 プログラム委員

    Role(s): Organizing member

    2022.6 - 2024.5

  • 患者さんひとりひとりの治療に薬剤師としてできることは

    Role(s): Appearance

    京田辺市教育委員会・同志社大学, 京たなべ・同志社ヒューマンカレッジ 市民講座  2022.6

  • 日本医療薬学フォーラム2022(金沢), ⼀般発表, 一般発表優秀ポスター賞選考委員

    Role(s): Organizing member

    2022

  • 日本薬学会第142年会(名古屋), 口頭発表座長, 2022

    Role(s): Presenter

    2022

  • 日本薬学会第142年会(名古屋), 口頭発表学生優秀発表賞審査員, 2022

    Role(s): Organizing member

    2022

  • 日本臨床腫瘍薬学会学術大会2022(仙台), 一般演題(口頭発表), 座長

    Role(s): Presenter

    2022

  • 日本医療薬学フォーラム2021(沖縄), ⼀般発表, 一般発表優秀ポスター賞選考委員

    Role(s): Organizing member

    2021

  • 日本薬学会第141年会(広島), 口頭発表座長, 2021

    Role(s): Presenter

    2021

  • 日本薬学会第141年会(広島), 口頭発表学生優秀発表賞審査員, 2021

    Role(s): Organizing member

    2021

  • 日本医療薬学会第4回フレッシャーズ・カンファランス, 一般演題(口頭発表) , 座長, 2021

    Role(s): Organizing member

    2021

  • 日本医療薬学会第4回フレッシャーズ・カンファランス, 一般演題(口頭発表) , 優秀発表 審査員, 2021

    Role(s): Organizing member

    2021

  • 第15回 日本緩和医療薬学会 (熊本) 2022 プログラム委員

    Role(s): Organizing member

    2020.1 - 2022.5

  • 日本緩和医療薬学会 専門薬剤師ワーキンググループ委員

    Role(s): Investigater

    2020

  • 日本臨床腫瘍薬学会学術大会2020(福岡), 一般演題(口頭発表), 座長

    Role(s): Presenter

    2020

  • 第14回 日本緩和医療薬学会(岡山) 2021 プログラム委員

    Role(s): Organizing member

    2019.8 - 2021.5

  • 第28回 日本医療薬学会(神戸) 2018 実行委員

    Role(s): Organizing member

    2018.6 - 2018.11

  • 患者さんひとりひとりの治療に薬剤師ができることは

    Role(s): Panelist, Lecturer

    九州大学病院血液腫瘍内科  第10回 血液疾患医療講演会(患者・家族対象勉強会)  2017

  • 患者さんひとりひとりの治療に薬剤師としてできることは・・・

    Role(s): Appearance, Informant

    第77回 日本血液学会学術集会, 市民講座  内田まやこ  2015

  • 第8回 日本緩和医療薬学会(愛媛) 2014 プログラム委員

    Role(s): Organizing member

    2014.5 - 2014.11

  • 薬剤師の役割

    Role(s): Panelist

    九州大学病院血液腫瘍内科 第7回 血液疾患医療講演会(患者・家族対象勉強会)  2014

  • 抗がん剤治療を受けるために~副作用を知ろう~

    Role(s): Lecturer, Informant, Organizing member

    九州大学病院がんセンター  第6回クローバー会から第15回クローバ会まで(患者・家族対象勉強会)  2011 - 2015

▼display all

Media Coverage

  • がん緩和ケア投薬過多 Newspaper, magazine

    毎日新聞  内田まやこ, 鈴木真也, 菅幸生, 菅原英輝, 国分秀也, 植沢芳広, 中川貴之, 髙瀬久光  2019.9

  • 医療費の抑制 ターゲットは… TV or radio program

    NHKニュースウォッチナイン  内田まやこ, 鈴木真也, 菅幸生, 菅原英輝, 国分秀也, 植沢芳広, 中川貴之, 髙瀬久光  2019.9

     More details

    Author:Myself 

  • 8割がポリファーマシー経験 病院薬剤師の介入で不適切処方削減に貢献 Promotional material

    m3.com(ミクスOnline)  内田まやこ, 鈴木真也, 菅幸生, 菅原英輝, 国分秀也, 植沢芳広, 中川貴之, 髙瀬久光  2019.7

     More details

    Author:Myself 

  • 日本緩和医療薬学会が実態調査, 緩和ケアでのポリファーマシー解消に貢献 Promotional material

    日経ドラッグインフォーメーション(DIオンライン)  内田まやこ, 鈴木真也, 菅幸生, 菅原英輝, 国分秀也, 植沢芳広, 中川貴之, 髙瀬久光  2019.7

     More details

    Author:Myself 

  • ポリファーマシー介入 実態と効果が明らかに Promotional material

    週刊 薬事新報  内田まやこ, 鈴木真也, 菅幸生, 菅原英輝, 国分秀也, 植沢芳広, 中川貴之, 髙瀬久光  2019.7

  • がん専門薬剤師外来~適切かつ継続的な経口抗がん薬治療を支援~ Promotional material

    Hospha 2016 No.3 Hot Field 26, エーザイ株式会社  内田まやこ  2016.4

     More details

    Author:Myself 

  • 「服薬指導シートを活用した患者支援と情報共有化の重要性」臨床薬剤師支援ツール Promotional material

    エスタブリッシュファーマシスト病院版 3, ファイザー株式会社  内田まやこ  2012.4

     More details

    Author:Myself 

▼display all